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Summary
This project investigates sterol and oxysterol content of murine brain and 
macrophages. Oxysterols are oxidised forms of cholesterol implicated in a wide array 
of biological functions.
The compounds were analysed with LC-MS LTQ-Orbitrap high resolution 
system, which provides a highly sensitive and accurate tool for analysis of 
metabolites.
We profiled a sterol content of newborn murine brain and identified a broad 
spectrum of oxysterols. Some of these compounds are implicated in neurogenesis, a 
number of other oxysterols derived from desmosterol were identified in brain tissue 
for the first time.
We analysed murine model of human disease arising from reduced ability to 
produce cholesterol (SLOS). The sterol profile showed an altered level of cholesterol 
precursors and generally lowered concentration of oxysterols.
Next, we moved to analysis of brain lipidome from animals with disrupted 
mechanisms of cholesterol metabolism. Cholesterol hydroxylase Cyp46al provides 
the mechanism of cholesterol removal from the brain. The study of the knock out 
mice did not reveal the existence of any compensatory mechanisms. The results 
showed mainly the reduction in cholesterol synthesis.
We profiled a sterol content of Cyp27al-/- mouse brain. Cyp27al participates 
in bile acid synthesis. The steroid profile revealed changed pattern of mono- and 
polihydroxylated sterols suggesting an upregulation of an alternative pathway of bile 
acid synthesis. We also analysed the consequence of deficiency of another enzyme 
involved in bile acids synthesis Cyp7bl. In brain of Cyp7bl-/- mouse we found 
elevated levels of known Cyp7bl substrates, and increased concentration of other, 
putative substrates for this enzyme.
The last experimental chapter concentrates on analysis of murine macrophages 
treated with interferon p and y. The treatment induced an increased production of 25- 
hydroxycholesterol. This links sterol metabolism with mechanisms of immune 
defence.
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Gene and protein nomenclature
Human protein abbreviations are written with al the letters in uppercase, mice protein 
abbreviations are written with only the first letter in uppercase and the remaining 
letters in lower case.
Gene abbreviations are italicised, with uppercase and lowercase letters following the 
pattern for proteins.
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1 Introduction
1.1 Origins of oxysterols
Cholesterol is present at various degrees in all animal cells where it plays 
vital physiological functions. As a constituent of cell membranes cholesterol 
modulates fluidity of the lipid bilayer [1] [2] [3] [4] while its metabolically active 
pool serves as precursors of oxysterols, bile acids and steroid hormones.
The cholesterol molecule is based on a cyclopentanoperhydrophentanthrene 
core with a hydroxyl group attached to one side and a isooctyl chain bound to the 
other end (Figure 1.1). Such a “design” of cholesterol provides a unique feature: the 
cyclic frame with the hydroxyl group is more polar than the non-polar hydrocarbon 
tail. However, this property can by altered by addition of hydrophilic groups either to 
the ring structures or to the chain. The gradation of polarity within steroid molecules 
as well as the possibility of alteration their hydrophilic properties have profound 
physiological consequences, such as translocation through biological membranes or 
interactions with regulatory proteins, just to name a few.
Cholesterol derivatives which share its tetracyclic nucleus, are known as steroids; to 
this group belong oxysterols, bile acids and steroid hormones. On the contrary, 
opening of any of the ring structures gives an origin to compounds known as seco- 
sterols, exemplified by vitamin D3 .
Nonpolar side chain 
(  ^
Polar Tetracyclic core
hydroxyl group
Figure 1.1 Structure of cholesterol
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In the animal body cholesterol originates either from the diet or can be 
biosynthesised. Dietary cholesterol is absorbed from the intestine, and then is 
distributed to tissues via the circulation. Steroids have a very low solubility in 
aqueous solutions, so in order to be transported in the blood they need to be coupled 
to proteins, forming complexes known as lipoproteins. The transport of cholesterol 
and its derivatives from the intestine is carried out in Low Density Lipoproteins 
(LDL), while an excess of sterols is removed from the tissues in High Density 
Lipoproteins (HDL) which transfer the sterols to the liver. These two classes of 
lipoproteins are different in steroid composition and the proteins involved in their 
transport.
Although cholesterol can be obtained from a diet, all cells can biosynthesise 
sterols de novo. High intake of cholesterol from the diet suppresses the rate of its de 
novo synthesis by the body, hence the homeostasis relays on both dietary and 
indigenous pools of cholesterol. For humans the level of dietary cholesterol absorbed 
per day ranges between 300-700 mg compared to approximately 800 mg synthesised 
in the liver [5].
In humans the liver is responsible for biosynthesis of the majority of body 
cholesterol, which is later distributed across tissues, with the exception of the brain. 
Brain is separated from the peripheral circulation by blood brain barrier which is 
formed by tight connections of endothelial cells. BBB prevents the entry of 
microorganisms and compounds such as endotoxins from entering the CNS. This 
structure is selectively permeable allowing the passage of small molecules such as 
water by means of passive diffusion, while active transport is needed for compounds 
such as glucose and amino acids. The blood brain barrier prevents larger lipophilic 
molecules such as cholesterol from entering the nervous tissue, therefore all 
cholesterol in the brain must be produced in situ.
Cholesterol is de novo biosynthesised in the mevalonate pathway. In 
general, the pathway can by divided into four main blocks. In the first one acetyl-CoA 
is transformed into 3-hydroxy-3-methylglutarl-CoA (HMG-CoA). In the next stage 
HMG-CoA is reduced to form mevalonic acid. This is a rate-limiting step in the 
mevalonate pathway and is catalysed by the enzyme HMG-CoA reductase. HMG- 
CoA reductase is controlled by a negative feedback mechanism with the final product 
of the pathway, cholesterol. Mevalonate is then transformed into isopentenyl
pyrophosphate. The condensation of six molecules of isopentenyl pyrophosphate 
leads to the formation of squalene. In the final part of the pathway linear squalene is 
transformed into a tetracyclic structure, lanosterol, which is later modified to form 
cholesterol. The transition from lanosterol to cholesterol can by achieved in two 
separate pathways utilising either 7-dehydrocholesterol or desmosterol (24- 
dehydrocholesterol) as the intermediates. 7-Dehydrocholesterol and desmosterol are 
reduced by actions of specific reductases to form cholesterol. Oxysterols, for 
example 25-hydroxycholesterol, can be produced from hydroxylation of cholesterol 
and also have a regulatory role on the mevalonate pathway. The scheme of 
mevalonate pathway is presented in Figure 1.2 [6 ]. The control loop of HMG-CoA 
reductase is disturbed in cells of patients suffering from defects of cholesterol 
synthesis such as Smith-Lemli-Opitz Syndrome (SLOS). SLOS arises from the 
malfunction of 7-dehydrocholesterol reductase, which leads to accumulation of 7- and 
its isomer, 8 -dehydrocholesterol, accompanied by reduced levels of cholesterol.
The general pathway of cholesterol removal from the body proceeds via the 
formation of bile acids. Bile acids are polar derivatives of cholesterol, the 
transformation of cholesterol into bile is carried out via oxysterols as intermediate 
metabolites. The main role of bile is to serve as detergents aiding the emulsification, 
digestion and adsorption of lipids and fat soluble vitamins from food. Recently a new 
function of bile acids emerged when these compounds were found to be ligands to 
nuclear receptors.
In humans the main pool of bile acids is generated in the liver, where they are 
conjugated with either taurine or glycine. Then bile acids are transported to and 
enriched in the gall bladder, from where they are excreted into the duodenal part of 
the intestine. In the intestine bile can be either re-absorbed via the enterohepatic 
circulation or removed from the body with the faeces.
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1.2 Characteristics of oxysterols
Oxysterols are mono- or polyoxygenated derivatives of cholesterol or its 
precursors. These compounds are precursors to bile acids, steroid hormones and 
vitamin D3 , they serve as transport routes for cholesterol and have also biological 
activity as ligands to receptors. The oxygen-containing group can be attached to the 
sterol molecule in form of a hydroxyl (hydroxycholesterol), a ketone (keto- o 
oxocholesterol) or carboxylate group (acid derivatives of cholesterol). Hydroxylation 
or generation of a ketone group is possible on either the steroid core or on the alkyl 
chain, while the carboxylate function applies only to the side-chain.
Cholesterol derivatives possessing an additional oxygen-containing group are 
less hydrophobic, which has multiple consequences for their physical and 
physiological properties. Oxygenated forms of cholesterol can pass more readily 
through biological membranes, therefore increasing the rate of transportation in cells.
Oxysterols can be generated by either enzymatic or non-enzymatic 
mechanisms. An overview of oxysterols found in human and rodent brain is presented 
in Figure 1.4 and Figure 1.5.
Non-enzymatic reactions include autoxidation or reaction with ozone. 
Autoxidation preferably occurs at the allylic C7 carbon and tertiary C25 carbon. This 
generates 7a-hydroxy-, 7p-hydroxy-, 7-keto- and 25-hydroxycholesterol, 
respectively. Generation of ozone by antibody-catalysed reactions was reported by 
Wentworth et al [7]. This reaction is likely to occur in sites affected by inflammation. 
Exposure to ozone causes opening of oxysterol ring structures leading to formation of 
seco-sterols.
Enzymes involved in the metabolism of cholesterol predominantly belong to 
the family of cytochrome P450 (Cyp monoxygenases, with the exception to 
cholesterol 25-hydroxylase [8 ]. The Cyp enzymes are an ancient family of proteins 
involved in sterol metabolism in animals, plants, yeast and some classes of bacteria. 
Most of bacteria do not have Cyp proteins, however the strains that express these 
enzymes includes bacteria employed in synthesis of therapeutical agents such as 
streptomycin (Streptomce)s and anti-cancer drugs (Myxobacteria) [9, 10]. On the 
contrary, Cyp can be targeted in patogens such as Mycobacteria r i l l  and fungi [12]. 
Azoles-based fungicides inhibit Cyp51, preventing from conversion of lanosterol to
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fungal sterol -  ergosterol. This class of anti-fungal drugs is used to treat a wide range 
of pathogent in medical in agricultural use IT3-151. Many Cyp enzymes are 
responsible for metabolism of xenobiotics. Cholesterol 25-hydroxylase, which is not a 
Cyp enzyme, is expressed in various tissues including heart, lung and kidney and its 
activity can be upregulated during the immune response. Its cellular localisation is 
limited to endoplasmatic reticulum and Golgi apparatus.
Cyp7al and Cyp27al initiate the two main metabolic pathways of bile acid 
biosynthesis: the “classical” also known as the “neutral” and the “alternative”, which 
can be also referred to as “acetic” pathways. The main, “classical”, route is initiated 
by hydroxylation of cholesterol at the 7a  position catalysed by the endoplasmatic 
reticulum enzyme Cyp7al. This reaction is a major regulator and rate limiting step in 
the bile acid biosynthesis. Cyp7al is a hepatic enzyme, hence this reaction is limited 
to the liver.
In the “alternative” pathway the formation of bile acids starts from 
hydroxylation the alkyl chain at the 27 position. It worth noting that this 
nomenclature is not equivocal due to 25R stereochemistry introduced by 
hydroxylation of the terminal C-26 carbon. Hence a molecule previously named 27- 
hydroxycholesterol possessing (25R)26-hydroxyl group is re-named into 26- 
hydroxycholesterol [16], however many authors still use the name 27- 
hydroxycholesterol. This reaction of 26-hydroxylation is performed by the 
mitochondrial enzyme Cyp27al, ubiquitously expressed by various cells IT 71. 
including neurons and glia f 18-201.
Cyp7al is a cytochrome P450 microsomal hepatic enzyme that converts 
cholesterol to 7a-hydroxycholesterol. Cyp27al is a ubiquitously expressed enzyme 
confined to mitochondria. It not only metabolizes cholesterol to 27- 
hydroxycholesterol, but also transforms resulting oxysterol into 27-carboxylic acid. 
Deficiency of CYP27A1 in humans is linked to metabolic disorder Cerebrotendinous 
Xantomatosis [2JJ.
la -  and 27-hydroxylation are initial steps of bile acid formation. 27- 
hydroxylated cholesterol and 27-carboxlic acid can be further hydroxylated by 
CYP7B1, an enzyme specifically catalysing 7a-hydroxylation of oxysterols. Two 
human disorders are associated with malfunction of CYP7B1: liver failure in children
23
HOHO' lung epithelial cells ,
7 0xoycholesterol 
C5-3b-ol-7-one Cholesterol 5 6-epoxide 
C-3biOl 6,6-epoxide
OH
HO'
HO’ O H 3b- Hydroxycholest- 5-en-27 oic acid 
Cs-3b.7b-diol
7b-Hydroxyc.holesterol
C^-SbJb-diol
OH
H O ' H O ' HO v
2 7-Hydroxychotesterol 
C5-3b,27-diol
cholesterol25-hydroxy1ase (also CYP27A1, 
CYP46A1)
3b-Hydroxy-5-oxo-5 6secocholestan-6-al
HOHO' Hepatic, Hepatic,
OH
3,5-Dihyaroxy-B-norcholestane 
6 - ca rbo xya Ideh yd e h o '
25-Hydroxycholesterol
C5-3b.25-diol
H O '
24S Hydroxycholesterol
OH
HO' HO' OH
HO
7a Hydroxycholesterol (astrocyte)4b- H ydr oxycholesterol
OHOH OH
H O ' OH
HO'
25.27-Dihydroxycholesterol
OH (astrocyte)
'o hho'
OH
7a.25-Dihydroxycho!esterol
Cs-3b.7a.25-triol
ho'
h o '
24S, 25-Di hydroxycholesterol 
C* 3b 24S 25-tnol 24S . 2 7-Dihydroxycholesterol
ho' OH
7a.27-Dihydroxycholesterol 
C -3b7a.27 triol
Figure 1.4 Oxysterols identified in human and rat brain. Enzymes indicated in red, 
subcellular locations abbreviated as follows: Endoplasmatic reticulum (ER), 
Mitochondria (Mit), Peroxisome (Pos), Cytosol (Cyt). Reproduced from ref. [22].

HO
CYP27A1
Alcohol
dehydroge
most tissues
27-Hydroxycholeslerol 3|i-hydroxycholesi-5-en-27-oic Acid
CYP27A1/
Alcohol
dehydroge
7n.27-Dihydroxycholesterol 3|V7u-Dihydroxycholesl-5-en-27-oic Acid
ER/Mit 3(J-Hydroxy-A5-C27 ER/Mit 3(FHydroxy-A5-C27 ER/Mit
steroid dehydrogenase/ steroid dehydrogenase/
J isomerase 1j isomerase u
OH
7tt.27 Dihydroxycholest-4-en- 3-one
3|J- Hydro xy-A5-C2, 
steroid dehydrogenase/ 
isomerase
o '  ^  ^  'OH
7u-Hydroxy-3-oxocholest-4-en-27-oic Acid
7u Hydroxy- 3-oxochol-4-en -27 oic Acid
Chenor.eoxyr.holic Acid
3-Oxo-A4 5|3 reductase 
<u-hydroxysteroid dehydrogenase
u
ihydroxycholestane 7u 12«» Dihydroxy- 3-oxocholest-4-en 27-oic Acid
3<i 7u-Dihydroxycholestan-27 oic Acid
HO
OH
'OH
Cyt/Pos
Figure 1.6 Simplified bile acid biosynthesis pathways in man. Endoplasmatic 
reticuclum (ER),Mitochondria (Mit), Peroxisome (Pos), Cytosol (Cyt). Reproduced 
from ref. [22].
7u-Hydroxycholeslerol
7c i - Hydrox ycholest-4 - en • 3-one
26
and spastic paraplegia f23-251. The schematic view presenting bile acid 
biosynthesis pathways is shown in Figure 1.6.
CYP11A1 resides in mitochondria and is expressed mainly in steroidogenic 
tissues, where it catalyzes the conversion of cholesterol to pregnenolone. This is 
obtained by double hydroxylation at positions C20 and C22, followed by a cleavage 
of the side chain.
CYP46A1 is detected specifically in nervous tissue where is found in 
microsomes. This monoxygenase converts cholesterol to 24<S-hydroxycholesterol, and 
to much lesser degree 27- and 25-hydroxycholesterol. Cyp3a4, similarly to CYP7A1, 
is expressed in hepatic microsomes, and converts cholesterol to 4p-hydroxylation 
and, to in minor degree, 25-hydroxycholesterol.
Some cytochrome CYP450 based cholesterol/oxysterol hydroxylases can 
target other compounds apart from cholesterol, CYP3A provides 4 f- and 25- 
hydroxylation of cholesterol f261 and 6|3-hydroxylation of testosterone [27]. On the 
contrary, the catalytic activity of other enzymes such as CYP11A1 is limited to 
cholesterol as the substrate [28]. Moreover, the products generated by these enzymes, 
are rarely limited to one oxysterol, as an example is a CYP46A1 hydroxylating 27-, 
25- and 24S-positions of cholesterol [29, 301.
1.3 Oxysterols as pleiotropic modulators of cell physiology
Initially oxysterols were recognised for their role in cholesterol homeostasis 
[3JJ, however more recent studies show that their control reaches far beyond sterol 
synthesis [32]. Oxygenated derivatives of cholesterol exert a wide range of functions 
affecting cell survival and apoptosis f33-371 viability of cancer cells [38, 39] 
embryogenesis f401 and immune response f411 (more details in chapter 1.5 Roles of 
oxysterols in immunity).
The hypothesis of oxysterols acting as suppressors of cholesterol biosynthesis 
was proposed by Kandutch [421 in the 1970’s. According to this, oxysterols, rather 
than abundant cholesterol, modulate the mevalonate pathway via negative feed back 
loop. Later findings confirmed that oxysterols are acute governors of cholesterol 
production and furthermore, disposal. This control is executed either on the 
enzymatic level by accelerating the degradation of a mevalonate pathway enzyme
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HMG-CoA reductase or on a transcriptional level by altering the expression of genes 
involved in catabolism and anabolism of cholesterol.
Oxysterols were proven to accelerate an ubiquitin-dependant degradation of 
HMG-CoA reductase, which is the rate-limiting enzyme required for synthesis of 
cholesterol. A number of oxysterols can increase the rate of ubiquitination of the 
reductase, which leads to quicker proteolysis of the protein [43].
In addition to removal of the biosynthetic enzyme, oxysterols alter the level of 
cholesterol by controlling the expression of genes involved in sterol 
biosynthesis/metabolism. In the mevalonate pathway the expression of a number of 
enzymes is suppressed by increased concentration of oxysterols, the down regulated 
enzymes include squalene synthase, HMG-CoA synthase, and as mentioned before 
HMG-CoA reductase [44].
The control over expression of genes can be mediated by transcription factors 
that respond to changing levels of sterols in the environment such as Liver X 
Receptors (LXRs) and Sterol Regulatory Element Binding Protein (SREBP).
While SREBP induces cholesterol production and uptake, LXR is responsible 
for its increased disposal from the cell. Further studies on these two transcription 
factors proved that cross talk between SREBP and LXR affects a wide range of cell 
functions not only directly related to lipid homeostasis [45].
LXRa and p belong to the class of nuclear receptors, which after 
heterodimerisation with the Retinoid X Receptor (RXR) act as transcription factors 
regulating expression of genes. LXRa is mainly expressed in adipose tissue, the liver 
and the intestine and controls cholesterol homeostasis. LXRp is ubiquitously 
expressed across the body and is important in functioning of brain [46] and the 
immune system [471. Natural ligands for LXR are oxysterols such as 22R-, 25-, 27-, 
24S-hydroxycholesterol, 24S,25-epoxycholesterol and the cholesterol precursor - 
desmosterol. Recent study also showed that LXR can be induced by 25- and 26- 
hydroxy-7-dehydrocholesterol, which are metabolites of 7-dehydrocholesterol 
generated by CYP27A1 [48].
Upon activation, LXR-RXR heterodimers binds to the LXR-response element 
of the regulated genes, which can result in either stimulation and inhibition of 
transcription. Non-active dimers binds to complexes containing corepressors and in 
this form LXR can suppress the expression of genes.
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LXRs up-regulates genes involved in cholesterol homeostasis such as Cyp7al 
(in mouse) catalyse hydroxylation of cholesterol [49], ABCA1 and ABCD1 
responsible for removal of cholesterol from the cells [50, 51] and Apolipoprotein E 
which mediates cholesterol transport [52]. LXR is also a main governor of expression 
of Niemann-Pick type Cl protein, which is involved in intracellular cholesterol 
trafficking [531.
In brain LXR ligands stimulate neurogenesis of murine midbrain as well as 
development of dopaminergic neurons [461. This finding is of special importance as 
loss of dopaminergic neurons is the characteristic feature of Parkinson’s disease [541. 
LXR is involved in alleviation of inflammatory response by promoting expression of 
genes expressing anti-inflammatory proteins TYRO-3, AXL and MER [36. 551 or 
polyunsaturated fatty acids F56. 57]. In macrophages LXR activated by desmosterol 
suppresses the inflammatory response provoked by Toll Like Receptors (TLR) 
activation [35, 58]. LXR ligands are also reported to alleviate symptoms of 
neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease in 
murine models. Inflammatory processes are believed to contribute to the etiology of 
these disorders [59, 601.
As opposed to LXRs, low concentration of cholesterol “activate” SREBP. The 
inactive form of SREBP is coupled to the escort protein SCAP which interacts with 
an ER protein anchored to membrane -  Insig [611.
SREBPs are present in three main isoforms SREBPla, SREBPlc and 
SREBP2. SREBP Is primarily control lipogenesis with SREBPla highly expressed in 
immune cells and SREBPlc is abundant in various organs, especially liver and 
adipose [61, 62]. SREBP2 is responsible for biosynthesis and uptake of cholesterol 
[35, 56, 63].
SREBP binds to SCAP which responds to the changes in cholesterol 
concentration. SCAP contains a sterol-sensing domain, which is activated by 
cholesterol, but not by side-chain hydroxylated oxysterols such as 25- 
hydroxycholesterol [641. Interestingly, similar domains were also identified in HMG- 
CoA reductase, Patched and Nieman-Pick Cl protein which are believed to interact 
with sterols [65]. At high concentration of cellular cholesterol, cholesterol binds to 
SCAP which, in turn, changes its conformation in order to bind to the ER resident 
protein Insig [66]. When cholesterol is scarce SCAP can detach from Insig and the
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SCAP-SREBP complex can be transported to Golgi where SREBP is transformed to 
its active form.
Insig is expressed in two isoforms INSIG 1 and INSIG2, which directly retain 
the complex with SREBP and SCAP by the ER membrane [35, 67]. INSIG, unlike 
SCAP, can bind oxysterols possessing a hydroxyl group in the side-chain, such as 
24S-, 25- or 27-hydroxycholesterol. Binding of oxysterols by Insig augments binding 
with SCAP, as well as decreases the rate of Insig degradation [68].
The HMG-CoA reductase gene is a target for SREBP regulation, as the key 
enzyme in the mevalonate pathway and is subjected to control from both cholesterol 
and oxysterol levels. SREBP also stimulates expression of the LDL receptor, which 
uptakes cholesterol-lipoprotein complexes leading its to decreased concentration in 
the circulation[69].
As mentioned before SREBP is not the only protein which respond to cellular 
cholesterol. NPC1 protein contains a sterol-sensing domain highly homologous to 
SREBP. Mutations in NPC1 gene are found in patient suffering from Niemann-Pick 
type C 1 disease. This is a neurovisceral disorder characterised by an accumulation of 
lipids, which in brain leads to neurodegeneration. NPC1 protein binds cholesterol by 
binding its 3p-hydroxyl group together with the cyclic core inside a structural pocket 
[70]. NCP1 participates in transport of cholesterol from late endosome/lyzosomes to 
the endoplasmatic reticulum, where it can be estrified, or transferred across the 
membrane to the extracellular matrix [71]. Defect in NPC1 causes malfunction of 
SREBP and LXR action, what leads to an accumulation of intracellular cholesterol. In 
macrophages these disturbance of the sterol homeostasis contributes to development 
of atherosclerosis [72].
Patch (PTCH1), protein implicated in embryonic morphogenesis and 
suppression of carcinogenesis, also capable to bind cholesterol, however the binding 
domain differs from that of SREBP and NPC1. PTCH1 belongs to Hedgehog 
signalling pathway. Disruptions in this pathway during embryogenesis result in 
teratogenic malformation of the foetus, such as holoprosencephaly [73], while 
malfunction in an adulthood leads to development of cancer [741. PTCH1 is a 
membrane receptor which upon binding cholesterol activates next protein - 
Smoothened (Smo) [75]. Activated Smo triggers a cascade of reactions which alter 
expression of transcription factors, such as glioma-related oncogenes. This leads to
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activation or suppression of the target genes including the ones belonging to 
Hedgehog pathway, thus creating negative and positive feedback control [76, 771. 
What is interesting, not only cholesterol affects Hedgehog pathway, oxysterols were 
also characterised as potent ligands for Smo protein [74, 78, 791.
As exemplified by Niemann-Pick type Cl protein and Sonic Hedgehog 
pathway, sterols can exert function of secondary messengers in signal transduction 
cascades, finely tuning wide range of processes. However, this dependencies are still 
not fully understood and require further study to in order to evaluate their possible 
therapeutic importance.
1.4 Cholesterol and oxysterols in the brain
Brain is the most cholesterol-rich organ, and contains 2-3% of the total body 
weight. In an adult, healthy animal blood brain barrier (BBB) is impermeable for 
cholesterol therefore its entire pool is synthesised in situ. Peripherally generated 
cholesterol can be used by central nervous system during embryogenesis and in 
newly bom animals before the full formation of BBB. In adult mammals BBB can be 
compromised in a pathological states such as multiple sclerosis [80], epilepsy [81], 
Alzheimer Disease [82], meningitis [83] or infection with parasite Trypanosoma [84]-
In a normal physiological state of an adult mammalian brain entire cholesterol 
is created in an autonomic mevalonate. BBB is formed by tight junctions of 
endothelial cells of the capillary vessels surrounding the CNS which impede diffusion 
of cholesterol [85]. As opposed to that, more hydrophilic forms of cholesterol - 
oxysterols can freely migrate through the barrier, therefore hydroxylation of 
cholesterol can be used as an exit route for brain-generated sterols. In addition to 
that, it was showed that some steroids of plant origin such as sitosterol and 
campesterol can be accumulated in the brain, which suggests some sort of flux 
mechanism of these sterols [86, 871.
Cholesterol is present predominantly in unesterified form in CNS; only in 
young animals small quantities of cholesteryl and desmosterol esters were detected 
[881. The increased amount of esterified cholesterol is associated with 
neurodegenerative disorders such as multiple sclerosis [891.
Cholesterol in the brain tissue is generally divided into two polls: 
metabolically inactive which is “locked” inside myelin sheets and metabolically
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accessible cholesterol present in cellular membranes of neurons and astrocytes. 
Myelination of neuronal axons by oligodendrocytes is carried out from later stages of 
embryonic development, accelerates in postnatal period and lasts until adolescence 
f90-951. In adult rodent brain cholesterol confined to myelin sheets accounts for 70% 
of the total pool. The highest rate of cholesterol synthesis occurs during intense 
myelination, which in mice occurs at the 3 weeks age [94], and decreases in elder 
animals. Cholesterol in human brain is characterised by an unusually long half-life 
time, [88, 96-991. which reflect its relatively inert position within myelin envelope.
The remaining 30% of cholesterol is metabolically active and present in 
various aspects of brain development. It appears that formations of synapses depends 
on the supply of cholesterol not only provided by neurons but also additionally 
biosynthesised by glia IT 00-1021.
Cholesterol can not leave the brain through BBB per se, however its 24S- 
hydroxylated analogue can freely cross the barrier and by peripheral circulation be 
transported to the liver. Further metabolism is initiated by hydroxylation at 7a  
position catalysed by microsomal, hepatical enzyme Cyp39Al IT031. in subsequent 
steps 7a,24S-dihydroxycholesterol is transformed into bile acids.
24S-Hydroxylation is the main exit route for cholesterol, however 
hydroxylations at C25 and C27 are also present in brain but to much lesser degree 
IT 041. It is estimated that around 60% of cholesterol efflux from CNS is performed 
via 24S-hydroxylation IT 051. This transformation is provided by brain-specific, ER 
enzyme Cyp46al, which is expressed in neurones, however its expression in the 
whole brain vary between anatomical regions 147. 491. The deletion of this gene 
surprisingly does not cause the increase in the level of cholesterol, but instead it 
reduces the rate of its synthesis IT 061.
Although the majority of 24S-hydroxycholesterol is metabolised exogenously, 
25-hydroxylation of this oxysterol was reported in cultured astrocytes yielding
24S,25-dihydroxycholesterol. Also 27-hydroxycholesterol was metabolised in the 
same manner by astrocytes [56]. For some of these transformation can be responsible 
Cyp46al which was reported to have 25- or 27-hydroxylase activity towards 24S- 
hydroxycholesterol. The generation of 24S,25-dihydroxycholesterol and 24S,27- 
dihydroxycholesterol by CYP46A1 was shown in CYP46A1 transfected HEK cells 
and in vitro by an isolated enzyme IT 071.
32
Furthermore, 7a-hydroxylation activity was detected in brain derived
microsomes for 25- and 27-hydroxycholesterol, but not 24S-hydroxycholesterol. The 
7a-hydroxylation was followed by conversion of 3p-hydroxo-5-ene group into 3-oxo- 
4-ene conformation [108].
27-hydroxycholesterol is produced by ubiquitously expressed enzyme
Cyp27al, which was found also in neurons and glia [19]. The defection of CYP27A1 
is associated with a metabolic disorder with neurological impairment
Cerebrotendinous Xanthomatosis [2JJ. 27-Hydroxycholesterol is also LXR ligand, 
although less potent than 24S-hydroxycholesterol [109].
Recently, also another side chain-oxidised sterol: 25-hydroxycholesterol has 
been demonstrated to be produced by brain cells astrocytes IT 101. This oxysterol is 
produced as a part of humoral response to pathogens, its role in the brain remains 
unknown.
Brain is an endocrine organ involved in production of steroid hormones such 
as pregnenolone. The biosynthesis of this involves 20S- and 22R-hydroxylation of 
cholesterol followed by a cleavage of the side chain. 20S-hydroxycholesterol was 
detected in rat brain IT 111 while 22R-hydroxycholesterol was found in human CNS. 
Pregnenolone is synthesised from cholesterol by mitochondrial enzyme CYP11A1, 
also known as P450scc (Cytochrome P450 side chain cleavage) which is expressed in 
rodent brain IT 12-1141.
24S,25-Epoxycholesterol, as opposed to other oxysterols, does not originate 
from the modification of cholesterol, but is produced in a shunt of a mevalonate 
pathway leading to synthesis of cholesterol. Synthesis of 24,25EC is from the activity 
of the 2,3-oxidosqualene cyclase (OSC) fl 15-1171. OSC catalysis the transformation 
of 2,3(*S)-monooxidosqualene (MOS) to lanosterol or the 24,25EC precursor 
2,3(»S):22(1S),23-dioxidosqualene (DOS) to 24(S),25-epoxylanosterol. This is followed 
by conversion of lanosterol and 24(5),25-epoxylanosterol into cholesterol and 
24,25EC, respectively.
Under physiological conditions the synthesis of cholesterol dominates U181. 
The presence of 24S,25-Epoxycholesterol was shown in developing and new bom 
brain, which is not surprising, considering high rate of cholesterol synthesis in this 
organ U19. 1201. Recently, this oxysterol was shown to promote neurogenesis via 
LXR in foetal murine brain [121]. 24S,25-Epoxycholesterol is synthesised by various
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cells in vitro including, neuronal cell line SN4741 (AM unpublished observations), 
ovarian cells l~681 and fibroblasts (AM unpublished observations). 24S,25- 
Epoxycholesterol is a potent ligand of LXR ri091 and SREBP inhibitor, which 
enables this oxysterol to participate in the control of cholesterol biosynthesis. As this 
oxysterol is synthesised in parallel to cholesterol it can serve as an early warning 
signal against its over-production [122].
In work of Mcdonald and colleagues IT231 were also identified ring- 
hydroxylated derivatives such as 4P-hydroxycholesterol and 5,6-epoxycholesterol. In 
humans 4P-hydroxycholesterol is biosynthesised by 4p-hydroxylation of cholesterol 
catalysed by ER enzyme CYP3A4 [124], predominantly expressed in the liver and, to 
much lesser degree, in the brain [125]. 5p,6P-Epoxycholesterol is considered as a 
product of cholesterol autooxidation and lipid peroxidation [1261 showing cytotoxic 
properties in in vitro systems H27. 1281.
1.5 Roles of oxysterols in immunity
The first evidences that alteration of lipid metabolism can be a part of the 
immune system emerged relatively recently when in 2009 Diczfalusky and colleagues 
reported upregulated production of 25-hydroxycholesterol by macrophages treated 
with LPS and type I and II interferons in vitro. Moreover, increased levels of 25- 
hydroxycholesterol were also detected in blood of mice and volunteers who were 
administered LPS intravenously IT 291. Since then the cross talk between immune 
response and sterol metabolism has been a subject of intense research. Sterols and 
cholesterol intermediates play a role in both innate IT30. 1311 and adaptive immunity 
ri30. 1321. they are involved in the antiviral response [133], differentiation of 
lymphocytes IT341 and immunoglobulin production [1301.
Treatment of macrophages with interferon y or murine cytomegalovirus 
(MCMV) activates cholesterol 25-hydroxylase, the activation is mediated by 
signalling the protein Statl [1351. Interferon y, by binding to IFN y receptor activates 
Statl protein, which binds to the promoter of cholesterol 25-hydroxylase, enhancing 
its expression. Also incubation of macrophages with virus increased expression of 
cholesterol 25-hydroxylase. Macrophages infected with virus alter their lipid 
metabolism by suppression of the mevalonate pathway [1331. therefore it is feasible,
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that increased concentration of 25-hydroxycholesterol can inhibit cholesterol 
synthesis via SREBP.
Moreover, 25-hydroxycholesterol produced as a part of the antiviral response 
has antiviral properties. In vitro it inhibits the internalisation of a broad number of 
coated viral species into the host cell [136], by altering the cellular membrane. 
Increased concentration of 25-hydroxycholesterol prevents viral-cellular membrane 
fusion which is required for vims entry. The antiviral properties were shown for 
pathogens responsible for chronic infections such as human immunodeficiency vims, 
vesicular stomatitis vims, herpes simplex vims 1 and murine gammaherpex vims 
[1361. as well as for acutely infectious species such as Ebola vims, Nipah vims, 
Russian Spring-Summer Encephalitis and Rift Valley fever vims.
The antiviral activity of 25-hydroxycholesterol was also assessed in vivo. 
Humanised mice which received injection with 25-hydroxycholesterol prior to HIV 
infection had 80% less HIV mRNA than controls. Furthermore, mice with a knockout 
of cholesterol 25-hydroxylase were more susceptible for murine gammaherpex vims 
infection.
The mechanisms of antiviral properties may involve alteration of membrane 
properties as well as the inhibition of geranylgeranylation of protein, however they 
were not fully elucidated [1331.
25-Hydroxycholesterol can be further hydroxylated by the action of CYP7B1 
yielding 7a,25-dihydroxycholesterol, which was found to be a chemotropic agent 
recognised by the receptor EBI2 in B cells f!32. 1371. B cells belong to lymphocytes 
and are involved in humoral adaptive immunity. The pivotal function of B cells is 
production of antibodies in response to pathogenic antigens. B cells also present 
antigens to other cells involved in humoral response, furthermore they can become 
memory B cells important in response to repeated exposure to the antigen. In 
mammals B cells are produced in bone marrow but maturation and differentiation is 
performed in secondary lymphoid tissues such as spleen.
Differentiating B cells migrate within this tissue directed by the gradient of 
7a,25-dihydroxycholesterol sensed by the G-protein coupled receptor EBI2. 
Migration of B cells from and to follicular areas of the spleen is essential for 
specialisation of these cells into the one recognising antibodies presented by T-cells
[138]-
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7a,25-Dihydroxycholesterol is further metabolised by 3p-HSD into 7a,25- 
dihydroxycholest-4-ene-3-one, which is lacking the biological activity of its 
hydrogenated analogue.
CH25H and CYP7B1 are expressed in lymphoid stromal cells, while in 
dendritic cells the expression of CH25H is inhibited [139].
The second main class of lymphocytes are T cells which, as opposed to B- 
cells, are involved in the cellular part of the immune response. Liver X Receptor 
activation inhibits differentiation of T cells into Thl7 subpopulations, this 
suppression of T cell transition is linked to mitigation of inflammatory symptoms of 
encephalomyelitis [140].
1.6 Metabolomics of sterols
Metabolomics is an emerging branch of “omic” studies concentrating on the 
analysis of small molecule metabolites present in biological matrices. Unlike 
genomics, transcriptomics or proteomics, metabolomics focuses on final products of 
cellular biochemistry. Genomics analyses structure and function of the genome of an 
organism (genomics), however, genes are transcribed under tight control and the 
entire genome is not actively transcribed. Transcriptomics concentrates on mRNA 
transcripts, though under posttranscriptional control these may not be translated into 
active proteins. Proteomics measures the levels of proteins expressed by the organism 
H411 including the proteins that are in a metabolically inert form. As the activity of 
proteins can be inhibited by the environment, their presence may not translate into 
production of a final metabolite. Hence metabolomics is an ultimate tool in assessing 
a current biological condition of the organism.
Metabolomics is the analyses of small molecules (molecular weight <1,000 
Da) which can be either products of cellular anabolism or catabolism. Molecules that 
are generated in non-enzymatic processes such as autoxidation can also contribute to 
the metabolome. This generates a great number of structurally and functionally 
diverse compounds. Such a quantity of potential analytes can be embraced with two 
approaches, i.e. global or targeted metabolomics IT421.
The global methodology applies when the analytes of interest are not well 
characterised, and the aim is to qualify and quantify the highest possible number of 
compounds. This methodology can be used for an analysis of sample derived from a
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patient suffering from unknown disease when the obtained data is compared to data 
from healthy individual in order to characterise metabolites unique for the disorder.
The targeted approach (metabolite profiling) is used when analysed molecules 
are defined to some extent prior to experiment, thus enabling optimisation of the 
analytical methodology for the detection of compounds of interest. This methodology 
was adopted by research bodies such as Lipid Metabolites and Pathways Strategies 
(LIPID MAPS) in USA, and The European Lipidomics Initiative and European 
Network for Oxysterol Research.
Although the class of analytes is defined, the actual analysis provides two 
main challenges. Firstly, the compounds can be present at very different levels 
making the detection of low-abundance molecules difficult, and secondly, structural 
similarity of compounds may make them difficult to separate.
These challenges can be addressed by using multiple separation methods 
during sample preparation/analysis and employing a detector capable of identifying 
closely related molecules. This can be achieved by using a solid phase extraction 
(SPE) technique followed by liquid chromatography (LC) coupled to a mass 
spectrometry (MS) detector. While SPE and LC will provide the separation based on 
polarity of analytes, MS will separate them further according to their mass to charge 
ratio (m/z).
Mass spectrometry provides a sensitive and specific analysis of molecules, 
hence its popularity in metabolite profiling studies. The principle of mass 
spectrometry is separation of ionised molecules in electric or magnetic field 
according to their mass to charge ratio. Furthermore, ions can be fragmented which 
provides additional information regarding structure. These features allow 
measurement of known analytes as well as putatively identify the structures of novel 
compounds. A schematic diagram of the methodology used in the analysis of 
oxysterols is presented in Figure 1.7.
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Extraction of sterols
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column
Separation of oxysterols 
from cholesterol
Figure 1.7 Schematic sequence of events for the analysis of oxysterols extracted from 
biological material
1.7 Extraction of sterols from biological matrices
The biochemical composition of cells, tissues and other biological matrices is 
extremely complex. This means that the compounds of interest are surrounded by a 
high number of other compounds, which may interfere with analysis. To reduce the 
impact of the matrix, the chosen technique should favour the predetermined analytes 
such as sterols. The ultimate extraction method provides a high yield of analyte while 
simultaneously reducing the amount of other, unwanted substances.
The performance of the extraction can be assessed by the addition of an 
internal standard. This should be done at the start of the extraction protocol, so the 
potential loss of standard during the procedure mirrors the loss of the target lipids.
The most common extraction method for lipids is a liquid extraction with 
organic solvents. During the extraction only the analytes which are soluble can be 
transferred to the solvent; non soluble substances, such as proteins, carbohydrates will 
precipitate. The efficiency of extraction depends on polarity of solvents compared 
against the polarity of analytes, therefore the selection of solvents affects the type of
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isolated lipids, for example cholesteryl esters will be extracted with high efficiency 
by hexane, while non esterified cholesterol can be isolated by ethanol.
Two most traditionally used methods for lipid extraction are Folch IT431 and 
Bligh-Dyer IT 441 methods. Folch protocol was originally developed for the isolation 
of brain lipids. According to this procedure tissue is homogenised with mixture of 
chloroform and methanol (2:l;v/v), then water or saline is added. The final 
volumetric ratio of chloroform, methanol and water (saline) is 8:4:3. The solvents 
then separate into two layers: lower, containing mainly chloroform and methanol and 
upper -  predominantly aqueous. Lipids are present in chloroform rich-phase while 
water-soluble contaminants are transferred into water-rich solution. Bligh and Dyer 
modified the previous method to accommodate for an extraction of tissues containing 
higher proportion of water. McDonald has optimised the method for an extraction of 
oxysterols, by replacing methanol with ethanol [123]. In this method tissue is initially 
homogenised in ethanol, with subsequent addition of chloroform and saline solution. 
Also pure ethanol was used as solvent for extraction of hepatic lipids with satisfactory 
results r 1451. An ultimate method for lipid extraction has not been developed, the 
efficiency of each method depends on the nature of lipids as well as the nature of used 
tissues accounting for varied results produced by different laboratories.
1.8 SPE for fractionation and enrichment of lipids
Solid phase extraction (SPE) is a technique used for the separation, purification 
and enrichment of compounds present in analysed material. In regards to oxysterols, 
there is a requirement to separate these from much more abundant lipids. Lipid 
extract contains mainly phospholipids, triacylglycerols, esters of cholesterol and 
cholesterol. Presence of these molecules in the solution would have detrimental effect 
on further analytical processing, for instance lipids present at high concentrations are 
prone to precipitation in more aqueous solutions.
In the SPE technique the mixture of analytes is passed through solid, porous 
material (stationary phase), aided by the flow of a solvent (mobile phase). Depending 
on the affinity of the analyte to the mobile and solid phases the analyte can be either 
flushed out by the mobile phase or retained by the solid phase. In general, 
classification of SPE is based on the type of affinity used; it can be polarity of
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molecules (reverse and normal phase SPE) or ionic interactions (cation and anion 
exchange SPE).
Ion exchange SPE is rarely used in lipidomics as many lipids are electrically 
neutral. The most commonly used SPE is a reversed phase. In this type of SPE, the 
stationary phase is made of non-polar material which interacts with lipids while the 
mobile phase consists of polar solvents. For this type of SPE van der Waals forces 
provide weak, reversible binding of analyte to stationary phase. The stationary phase 
material is usually silica with attached hydrophobic hydrocarbon chains (ODS or 18) 
with a high affinity to hydrophobic analytes, the stationary phase is packed inside a 
cartridge. The retention of the compound is determined by its polarity, the non-polar 
stationary phase will interact stronger with non-polar analytes, while more polar 
molecules will be eluted. A gradient of mobile phases of decreasing polarity will 
gradually elute less polar compounds. This allows for subsequent isolation of separate 
classes of lipids IT461.
The flow of the mobile phase can be aided either by applying a positive pressure 
to the top of the cartridge or by applying the negative pressure at the bottom. To 
improve efficiency of the work flow, SPE cartridges can be mounted on a manifold 
providing a negative pressure to the cartridges via vacuum manifold.
Reversed phase SPE is widely used for isolation of oxysterols. Oxysterols are 
present at levels three orders of magnitude lower than cholesterol, therefore 
simultaneous detection of these compounds is difficult due to the limited dynamic 
range of instruments. Cholesterol is also susceptible to autoxidation and oxysterols 
generated in this process would interfere with endogenous compounds. Oxysterols are 
more polar than cholesterol therefore are easier to elute with polar solvent than 
cholesterol which requires a more non-polar mobile phase.
In our methodology sterols in solid tissues are extracted by ethanol, which is 
subsequently diluted to 70% ethanol with water. Media retained after cell culture is 
added to ethanol to form a 70% solution. This is applied onto a reversed phase SPE 
cartridge. More polar oxysterols are eluted from the column while cholesterol and 
more hydrophobic compounds such as cholesteryl esters and triacylglicerydes are 
bound to the stationery phase. Cholesterol can be eluted from the column by ethanol. 
This method was used for extraction of oxysterols from plasma IT471 and brain [148].
For the separation of mixtures containing high concentration of compounds of 
varied polarity “recycling” SPE can be used. In this method the mixture of analytes is
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initially dissolved in high organic content solvent. This is passed through the SPE 
column, allowing non-polar compounds to be retained by the column. The resulting 
effluent is diluted with polar solvent, such as water and re-applied onto the SPE 
column, in this cycle more polar compounds will be bound by the solid phase. In 
following cycles the polarity of the eluent is increased, allowing more polar 
compounds to be captured by the solid phase. The step-wise increase in the polarity 
of solution is required for retaining molecules of diverse polarity, as the dilution of 
the solvent at the initial stage with water would cause non-polar analytes to 
precipitate. The original method was described by Liere and colleagues IT491 for the 
separation of brain steroids. Griffiths has adapted this system for the analysis of 
oxysterols.
1.9 Mass spectrometry
The analysis of the lipidome presents distinct challenges; the analytes are often 
present at a trace-level, furthermore the compounds may be structurally closely 
related which complicates identification. For these reasons, mass spectrometry, with 
high sensitivity and specificity, is a commonly chosen tool in the study of lipids.
In general, the mass spectrometer can be divided into following parts: (1) an 
inlet, releasing the sample, (2) a source, where the analyte is ionised, (3) a mass 
analyser, that provides the means to discriminate the molecules according to their m/z 
ratio, (4) a detector that detects separated ions and (5) a data collection and analysis 
systems which facilitates further processing of obtained information. A diagram of 
the mass spectrometer used in this work is presented in Figure 1.10.
1.9.1 Inlet
The sample is injected into an ion source from an inlet. This device can be as 
simple as a syringe containing a mixture of analytes, when all compounds are 
introduced to the ion source simultaneously; this approach is commonly used in shot­
gun metabolomics. Alternatively the syringe may contain material separated prior to 
injection, for example with SPE techniques.
More commonly analytes are separated before applying them into the source 
either by High Pressure Liquid Chromatography (HPLC) or Gas Chromatography 
(GC) systems, which provide separation of compounds in a real time, just before 
entering the mass spectrometer.
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1.9.2 Ion sources
Ionisation of the sample can be achieved in a number of ways, where charge is 
transferred onto electrically neutral molecules. Most ionisation techniques for GC-MS 
are based on the formation of a molecular cation caused the loss of an electron from 
an exited molecule, however charge can be also acquired by a chemical reaction with 
an ion that is already electrically charged.
The choice of ionisation technique must consider the physical state of the 
analysed material and its chemical stability. With liquid samples, the fluid is 
electrically charged and ions sprayed into the source. This mechanism is exploited in 
electrospray ionisation. Solid samples can be ionised by matrix-assisted laser 
desorption/ionisation where the matrix provides a support for the sample, and is 
bombarded with a light beam able to ionised molecules. Some ionisation techniques 
are gently producing only a molecular or pseudomolecular ions, others, cause 
generation of fragment ions. The profile of these fragments can provide additional 
information regarding the structure of the original molecule [146].
The electrospray ionisation (ESI) technique is commonly used in 
metabolomics studies and was also used in our work. The electrospray is generated 
when the liquid is passed through a metal capillary in a strong electric field. The ESI 
source contains the spray capillary, which serves as one electrode. A counter 
electrode (sample orifice) is separated from the capillary by 0.3-1 cm. The liquid 
containing the analyte is passed through the metal capillary and sprayed into the 
space between the capillary and the orifice. Charged droplets are generated and as 
they travel in the electric field they loose solvent resulting in a spray of ions of 
analytes (
Figure 1.8 and Figure 1.9).
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Figure 1.8 Schematic figure o f ESI process. A positive potential is applied to the 
capillary, which becomes an anode. An electric potential o f the anode forces 
positively charged ions to the surface o f the meniscus. Upon the destabilisation o f the 
meniscus are released positively charged droplets which are transformed into ions. 
Reproduced from ref. [22],
The liquid used for delivery o f the sample to the electrospray capillary is usually an 
aqueous mixture o f volatile solvents. To increase conductivity o f an otherwise 
electrically neutral mixture, formic acid is often added. The presence o f organic 
solvents aids evaporation, which may be assisted by a nebulising gas, often applied to 
the electrospray capillary. A stream of gas can be also used to direct the spray into the 
orifice. The nebulising gases is usually an inert gas, for example nitrogen.
Electrospray is generated when a potential difference is applied between the 
two electrodes. The optimum voltage is determined by the geometry o f the source, 
dimensions and position o f the sprayer, sample flow rate and composition o f the 
solvent. Positive potential on the capillary will force anions to deposit on the walls of 
the tube, while cations are ejected with the solvents. When the repulsion forces 
between ions on the liquid surface are stronger than the surface tension, the surface of 
the liquid changes its properties allowing for formation o f the Taylor cone. With 
sufficiently high electric field the Taylor cone forms a je t which is later dispersed into 
the spray. Rayleigh limit defines the amount o f charge that liquid can accumulate 
before forming the Taylor cone. Ejected droplets travel in the direction o f the counter 
electrode gradually loosing the solvents. The charge density on the surface o f the 
droplets increases and, upon reaching the Rayleigh limit, the droplet decomposes 
generating a je t o f small droplets.
43
BFigure 1.9 The image o f ESI process acquired by a high-powered microscope. In 
panel A is shown the spray generated from a needle tip. Electric potential applied to 
the needle forces the liquid to become charged and to form a structure known as a 
Taylor cone. Panel B presents a droplet released form the capillary. Upon loosing the 
solvent the density o f the charge contained by the droplet increases, this leads to the 
formation o f smaller droplets and gas-phase ions. Reproduced from ref. [22].
The “daughter” droplets continue to travel, and to facilitate the loss o f the solvent at 
this stage the spray can be passed through heated capillary e.g. on instruments 
manufactured by Thermo Scientific, or through a number o f skimmers e.g. on 
instruments from Waters. As the droplets further shrink, ionised molecules are 
desorbed form the surface and continue to travel to the mass analyser.
1.9.3 Mass analysers
Ionised molecules are transferred into the mass analyzer, where they are 
separated according to their mass to charge ratio. This can be achieved either in a 
magnetic or in electric field, or in a combination o f both. Mass analysers can be also 
characterised by the duration o f segregation, where either a continuous stream o f ions
is analysed (scanning analysers) or, alternatively, a portion of ions is released and the 
analysis is performed in pulsed-like mechanism (trap analysers).
In magnetic analysers ions travelling from the source are subjected to 
magnetic field, which alters the trajectory of ions accordingly to their momentum, 
which in turn is a consequence of their m/z ratios. Only ions of predefined m/z values 
will be passed through an exit slit and reach the detector. The magnetic field is 
scanned to generate a mass spectrum.
Quadrupole analyzers consists of four parallel rods. The rods generate an oscillating 
electric field by altering their Radio Frequency (RF) and Direct Current (DC) 
voltages. These voltages are arranged so that only selected ions can pass through this 
system, while other particles will collide on the quadrupole. The voltages are scanned 
to generate a mass spectrum.
Time of Flight (TOF) analysers measure the time required for ions to pass through a 
drift tube. In order to precisely measure the time ions spend flying in the tube, they 
need to be released simultaneously at a precise time point. This require either the 
source to produce the ions in a pulsating manner or ions generated continuously are 
gated and released in intervals.
The last group of instruments is based on the ion trap principles: ions are confined in 
the trap where the manipulation of RF and DC potentials allows for a precise 
separation of particles. Commonly used traps include: quadrupole ion trap, ion 
cyclotron resonance and, the most recently developed, Orbitrap.
The above mentioned analysers can be used either as a stand-alone instruments or can 
be interfaced to form hybrid machines. One of the coupled analyzers is Linear ion 
Trap-Orbitrap (LTQ-Orbitrap) which was used in this work.
LTQ-Orbitrap
The general principles of LTQ-Orbitrap operations are as follow: (1) ions 
from the source are loaded into the linear ion trap, (2) the linear ion trap axially 
injects the ions into the C-trap, (3) the C-trap focuses the ions, and a smaller cloud, of 
ions are (4) injected into the Orbitrap, where (5) axial oscillations of ions in an 
electric field allows for separation. Schematic representation is shown in Figure 1.9.
The ions from the source are focused into a precise stream which flows into 
the ion trap. In an older model, the LTQ-Orbitrap XL, ions are directed by a tube 
lens/skimmer. In a newer version, LTQ-Orbitrap Velos, this was substituted with S- 
lenses. The S-Lens consists of a stack of metal ring plates (apertures) under RF
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frequency. Changing electric field applied to the apertures controls the movement of 
ions so the molecules are focused into a precise stream f 1501.
The first analyser, the Linear ion Trap, provides for ion storage, isolation and 
fragmentation. Ions from the S-lens are loaded into the trap and upon reaching a 
predefined number, the trap can start further processing of the ions. This sequence of 
loading the trap followed by the analysis is referred to as a scan. Alternatively the 
linear ion trap can only serve as storage device for ions that are transferred into the 
Orbitrap for analysis.
The linear ion trap in the LTQ-Orbitrap Velos is a dual cell analyser, which 
means that it contains two consecutive linear traps, each enclosed in a separate cell. In 
the first, high pressure, cell ions are trapped, isolated and can be subjected to 
fragmentation. The second cell, low pressure, provides efficient ejection of separated 
ions.
Ions in the linear trap can be analysed intact, in this mode the analyser gives the mass 
of intact ions. The second mode involves fragmentation of ions. In this mode 
precursor (parent) ions are subjected to collision with inert gas eg. helium, which 
produces fragment (daughter) ions that are subjected to analysis. This fragmentation 
method is called Collision Induced Dissociation (CID). Obtained fragment ions can 
be isolated and subjected to another cycle of fragmentation, this process is named a 
multi-stage fragmentation. In the nomenclature the number of fragmentations is 
characterised by the power of MS. One cycle of mass selection and fragmentation 
would be annotated by MS2, while MSn stands for a general multi-stage 
fragmentation. A disadvantage of CID fragmentation is a poor trapping capacity of 
the trap for lower mass ions. This results in detection only of ions with masses higher 
than 1/3 mass of its precursor. This limitation does not apply to Pulsed Q Dissociation 
(PQD) method which allows for the detection of low mass fragment ions (ref).
Alternative to CID and PQD methods, ions from the source can be simply 
stored in the LTQ from where they are passed into the C-Trap which focuses the 
cloud of ions and injects them into Higher Energy Collisional Dissociation (HCD) 
collision cell. In the HCD cell ions are fragmented and product ions are transported 
back via the C-Tap to the Orbitrap analyser. HCD method allows for detection of low 
mass fragment ions, unlike CID where only fragment ions with mass larger that 30% 
of parent ion are detected. Moreover, detection in the Orbitrap provides a benefit of
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high mass accuracy. The HCD method, however, provides lower chromatographic 
resolution, as the scanning rate is lower due to the Orbitrap’s longer duty cycle.
Scans performed by the LTQ-Orbitrap can be also subdivided accordingly to 
scan method: (1) full scan, (2) selected ion monitoring (SIM), (3) selected reaction 
monitoring (SRM) and (4) consecutive reaction monitoring (CRM). Full scan 
produces a plain spectrum of a sample, within a defined m/z range. Although it gives 
general information regarding the analyte, it may be not very discriminative, as ions 
present at low level would be dominated by other components such as impurities at 
higher levels. SIM, however, is a tailored method when only a defined mass will be 
scanned. SRM is similar, where only fragment ions generated in a unique reaction are 
monitored, such as for a characteristic neutral loss. In the CRM method two or more 
consecutive collision cycles occur and in each cycle only a selected ion is subjected to 
further fragmentation. The following cycle only occurs if the predefined ions are 
detected. (5) The final scan is the product ion scan where all the fragment ions (above 
the 1/3 cut off) are detected after fragmentation of a parent ion.
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1.9.4 Detectors
Ions released by the analyser are passed into the detector. In general, ions hitting the 
walls of the detector produce a stream of secondary particles such as electrons or photons 
which can be quantified. Ions are released from the analyser accordingly to their m/z ratio, 
which limits the number of particles simultaneously interacting with the detector. Signal 
generated in this process is low and to allow for a precise measurement needs to be enhanced. 
For this reason detector are often coupled with amplifiers, which are responsible for signal 
enhancement.
The main types of detectors used are Faraday cup and secondary electron multipliers 
(SEM). The Faraday cup ion collector is on older type of instruments and is used for a 
detection of relatively abundant streams of ions. SEM instruments are more modem and 
provide a much higher sensitivity of measurement. In SEM detector contains metal surfaces 
emitting secondary electrons following contact with ions. Positively charged ions hit the 
metal surface of the first dynode which releases electrons (for negatively charged ions there is 
a conversion dynode), the electrons are directed into a system of multiplying dynodes. 
Multiplication (gain) of the electron beam can be obtained either in a discrete (step-wise) or 
continuous method. In a discrete multiplier electrons hit a sequence of metal plates, on each 
stage emitting an increased number of particles. In a continuous multiplier, the electrons are 
interacting with a continuous surface capable of emitting an amplified number of electrons. 
The latter type of detector was used in the linear ion trap detection system of the LTQ- 
Orbitrap Velos system H51. 1521. The in the Orbitrap detection is through an image current 
generated by ions oscillating around a central spindle.
1.10 High Pressure Liquid Chromatography
The separation of compound with High Pressure/Performance Liquid 
Chromatography (HPLC) utilises the difference in the affinity of analytes to the stationary 
phase and the mobile phase of the system. The mobile phase consists of a mixture of organic 
solvents and buffer, which under high pressure flows through the stationery phase, which is a 
porous material tightly packed in a supporting tube (column). The time of the travel of 
analytes through the stationary phase is called the retention time. Different compounds have 
different retention times, which allows for the separation of analytes. In general, HPLC types 
can be distinguished depending on the mechanism of interaction that determines the 
separation of compounds by the chromatographic system. HPLC can be divided into: 
partition, adsorption, ion and exchange.
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Partition chromatography is the most popular method of separation. In this method 
the analytes are partitioned as the sample moves across the stationary phase propelled by the 
movement of the mobile phase. The polarity of the analyte versus polarity of the phases 
controls the velocity of separated molecules. This chromatography can be divided into 
normal and reversed phase chromatography. Normal phase chromatography utilises a polar 
stationary phase which can be made of bare silica. Separation is achieved by the movement of 
non-polar solvent such as chloroform as the mobile phase. Separated analytes must be readily 
soluble in non-polar solutions.
In reversed phase chromatography the stationary phase is nonpolar. The most popular 
material is silica with bond tetra (C4), octa (C8) or octadecyl (C l8) carbon chains. Shorter 
chains are more efficient in separation of large molecules possessing many hydrophobic 
groups such as proteins, longer alkyl chains are used in analysis of small molecules, for 
example lipids. The mobile phase used is a combination of polar organic and inorganic 
solvents. HPLC is the commonly coupled to the MS detector as mobile phase can easily form 
electrospray. To increase ionisation efficiency the solvents can be enriched with components 
such as formic acid or ammonia.
Components of the HPLC system
A high and stable pressure of flowing mobile phase is needed for efficient separation 
and this is provided by a specialised instrument -  HPLC system. It consists of a number of 
modules controlling sample delivery as well as the flow and temperature of the mobile phase 
during the separation. The Dionex Ultimate 3000 HPLC system, used in the present work, is 
divided into an autosampler, pump module with reservoir of the mobile phase and 
temperature control compartment where the column (stationary phase) is housed. A 
schematic representation of the HPLC system is presented in Figure 1.10.
MP1 J  Injection Auto­
samplerPump valve j
MP2
\  J
N. y \
Detector HPLC Column
Sample loop
Figure 1.10 Schematic representation of HPLC instrument (MP -  mobile phase).
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The flow of mobile phases is propelled by a system of pumps and pump valves. This 
maintains a steady flow of defined composition of mobile phases. The Ultimate 3000 system 
can combine solvents from up to four different reservoirs, however, the most common is a 
composition of two mobile phases. The alteration of the ratios of different solutions enables a 
change in the polarity of a final mobile phase, which accelerates and improves separation of 
analytes.
The autosampler (injector) injects the sample into a continuously flowing stream of 
the mobile phase. Sample is withdrawn from a cooled vial by a needle and fills the sample 
loop. The flow of the solvent through the sample loop is controlled by a six-port injection 
valve. The stator switches the ports allowing for removal of the sample from the loop and 
injecting it to the mobile phase system with a minimum in disruption of the flow.
Depending on the use of multiple mobile phases the elution can be divided into 
isocratic or gradient. In an isocratic flow the composition of mobile phases remains constant 
throughout the entire analysis. This method is commonly used for analysis of well-defined 
compounds, such as quantification of an active ingredient during the pharmaceutical quality 
control. Gradient elution is obtained when the proportion of solvents in the mobile phase is 
changed in a programmed manner. This can be either continuous or step-wise, while the 
speed of transition between the solvents and can be proportional to time (linear gradient) or 
can be increased/decreased with time of the analysis (curved gradient). In this way it is 
possible to slow down the elution of the least retained compounds and accelerate migration of 
the analytes with the highest column affinity. Gradient flow is therefore used for separation 
of a complex compositions of analytes, such as in metabolomics studies.
The mobile phase is pumped through the column where the sample is fractionated into 
the different analytes. The column is kept in a temperature-controlled chamber, as the 
fluctuations of temperature affect the viscosity and pressure of solvents. Variations of these 
affect the retention time of eluted compounds as well as the resolution of peaks. Higher 
temperature decreases the viscosity of mobile phase allowing faster analysis, however, this 
solution is not appropriate for thermally labile compounds. These can be separated at an 
ambient temperature equal to the temperature of the room where the instrument is housed, 
usually maintained constant by an air-condition system.
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1.11 Analysis of sterols with LC-MS
The analysis of steroid compounds can be challenging due to their chemical and 
physical properties. Sterols are lacking a strong chromophore which makes them unsuitable 
for high sensitivity UV-based analysis, mass spectral detection can be difficult due low 
volatility (important in GC-MS) and low ionisation efficiency (in LC-MS). Low solubility in 
aqueous solutions affects the selection of solvents used in LC-MS. Moreover, oxysterols are 
present at very low levels compared to a high excess of cholesterol. Cholesterol is also 
susceptible for autoxidation, producing non-endogenous oxysterols.
These issues can be mitigated by separating oxysterols from cholesterol at an early 
stage of sample preparation and by providing a chemical derivatisation of sterols. For LC-MS 
derivatisation can improve ionisation of compounds as well as increase their solubility. 
Ionisation efficiency is particularly important as it increases the sensitivity of mass 
spectroscopic detection for compounds present at trace level in biological material f88, 153. 
1541. During chemical derivatisation for LC-MS a molecule of interest is coupled to a readily 
ionisable compound.
Derivatisation of oxysterols followed by LC-MS analysis was used in the work of 
Honda and colleagueslT551. In their study sterols present in human plasma were derivatised 
with picolinic acid; the resulting material was purified with a Cis SPE cartridge. The material 
was further fractionated with HPLC using a Hypersil GOLD column with a gradient mobile 
phase. The composition of mobile phase at the beginning of the separation was more polar 
(acetonitrile:methanol:water, 40:40:20, v/v), reducing the water content with the duration of 
the run (acetonitrile:methanol:water, 45:45:10, v/v), to the solvents was added 0.1% formic 
acid. The detection limit of derivatised sterols were established at the picogram level on the 
column. Piconyl ester of cholesterol were detected on the level of O.lpg, which was almost 
4000 times higher than in the analysis of cholesterol in its native state.
Other derivatisation method used in the studies of sterol by LC-MS employs a 
precharged quaternary nitrogen moiety present in reagents: Girard T
((Hydrazinocarbonylmethyl)trimethylammonium chloride) and Girard P reagent (1- 
(Carboxymethyl)pyridinium chloride hydrazide). The ability of Girard T reagent to form 
hydrazones with steroids possessing an oxo group was described in work of Wheeler and 
Rosado-Lojo [156]. Girard reagents are hydrophilic and increase solubility of derivatised 
sterols in water-based solutions, this feature was utilised for the separation of ketosteroids 
from other sterols [157]. With the development of LC-MS technology Girard reagents were 
recognised as a steroid derivatisation agent, providing an easily ionisable moiety f 158-1601.
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As Girard reagents form hydrazones only with sterols possessing an oxo function, Griffiths’ 
group developed a methodology allowing the use of this application for a wider group of 
steroids [148]. Sterols possessing 3P-hydoxy-5-ene or 3 P-hydoxy-5a-hydrogen functions can 
be transformed into 3-oxo-4-ene or 3-oxo groups by action of a bacterial enzyme cholesterol 
oxidase as described by Brooks et al. fl61~|. The resulting compounds can be subjected to 
derivatisation with Girard P reagent and analysed on MS instrument. Obtained analytes can 
be separated prior to MS detection with capillary 0621 or reverse phase HPLC [148]. This 
approach was also evaluated for MALDI-MS [158. 163. 1641. The MS signal intensity was 
improved by Girard P derivatisation by a factor of 1000 [1621. This methodology was used in 
LC-MS analysis of brain [120. 148. 165. 1661. cerebrospinal fluid [1671 and plasma f 1681.
1.12 Aims of the project
LC-MS methodology has been employed for the analysis of sterols present in various 
biological matrices including nervous tissue. This work was focused on detailed profiling of a 
sterol content of murine brain. The study included a number of brain samples derived from 
animals at various stages of development as well as nervous tissue from animal models of 
human metabolic disorders. The second part of the project concentrated on the alteration of 
the lipidome as part of the immune response to pathogens.
The main objectives of this work:
1. Modification of an existing LC method for detailed analysis of murine brain 
tissue.
2. Analysis of new bom mouse brain with regard to neurosterols promoting 
neurogenesis.
3. Investigation of oxysterol biomarkers present in brain of murine model of human 
disease Smith-Lemli-Opitz.
4. Study of nervous tissue derived from Cyp46al deficient mice in order to establish 
a possible alternative metabolic pathways of cholesterol removal from the brain.
5. Analysis of lipid profile of brain from mice with disrupted synthesis of bile acids, 
representing models of human disorders Spastic Paraplegia type 5 and 
Cerebrotendinous Xanthomathosis.
6 . Investigation of sterol content of murine macrophages as apart of the immune 
response.
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Chapter 2
2 Materials and methods
2.1 Materials
2.1.1 Reagents and solvents
Solvents were from Fisher-Scientific (Loughborough, Leicestershire, UK). Water, 
acetonitrile, methanol and propan-2-ol were HPLC grade while ethanol was analytical grade. 
Acetic acid 100% was from VWR International Ltd (Poole, Dorset, UK) and formic acid 
98/100% from VWR International S.A.S. (Briare, France). Potassium phosphate buffer made 
from potassium dihydrogen phosphate (KH2P04) was from Sigma-Aldrich (Japan). 
Sterol/oxysterol standards were purchased from Avanti Polar Lipids (Alabaster, AL, USA). 
Cholesterol oxidase from Streptomyces sp. was obtained from Sigma-Aldrich (Saint Louis, 
MO, USA) and GP reagent [l-(carboxymethyl)pyridinium chloride hydrazide] from TCI 
Europe (Zwijndrecht, Belgium). SPE cartridges, Certified Sep-Pak C l 8 , 3cm3, 200 mg, were 
from Waters Inc (Elstree, UK).
2.1.2 Reference standards
The list of reference standards is presented in Table 2.1.
2.1.3 Preparation of standard solutions
Stock solutions of standard compounds were prepared by dissolving 1 mg of 24(R/S)- 
[26,26,26,27,27,27-2H6]hydroxycholesterol, 1 mg of 7-[25,26,26,26,27,27,27-
2 H7]oxocholesterol and 10 mg of [25,26,26,26,27,27,27-2H7]cholesterol in 10 mL of propan- 
2-ol. Working solutions were made by diluting of 10 pL of the 1 ng/pL oxysterol stock 
solutions with 990 pL of 99.9% ethanol.
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Table 2.1 Reference standards used for the work.
No Steroid/Sterol/Oxysterol 
Common and
Steroid/Sterol/Oxysterol 
Systematic name
Supplier
1. 22(R)-hydroxycholesterol cholest-5-en-3p,22(R)-diol Avanti Polar 
Lipids
(Alabaster, AL,2. 24(R)-hydroxycholesterol cholest-5-en-3p,24(R)-diol
3. 24(S)-hydroxycholesterol cholest-5-en-3P,24(S)-diol USA)
4. 25-hydroxycholesterol cholest-5-en-3p,25-diol
5. 7 a,26-dihydroxycholesterol cholest-(25R)-5 -en-3 p,7 a,26-triol
6. 7 P,26-dihydroxycholesterol cholest-(25R)-5 -en-3 P,7 P,26-triol
7. 7a,25-dihydroxycholesterol cholest-5-en-3p,7a,25-triol
8. 7 P,25-dihydroxycholesterol cholest-5-en-3p,7P,25-triol
9. 24(R),25-epoxycholesterol cholest-5-en-24(R),25-epoxy-3P-ol
10. desmosterol cholest-5,24-dien-3p-ol
11. 6 -dehydrocholesterol cholest-5,6-dien-3p-ol
12. 7-dehydrocholesterol cholest-5,7-dien-3P-ol
13. 8(9)-dehydrocholesterol cholest-5,8(9)-dien-3P-ol
14. 8 ( 14)-dehydrocholesterol cholest-5,8(14)-dien-3P-ol
15. 24(R/S)-[26,26,26,27,27,27-2 H6 ]hydroxycholesterol
16. 7-[25,26,26,26,27,27,27-^H7]oxocholesterol
17. [25^6^6,26,27 ^ ^ l - ^ c h o l e s t e t o ]
18. 19-hydroxycholesterol cholest-5-en-3P, 19-diol Steroloids
19. 26-hydroxycholesterol cholest-(25R)-5-en-3p,26-diol
20. 27-hydroxycholesterol cholest-(25S)-5-ene-3p,27-diol Technische
Universitat
Dresden21. (24Z)27-
hydroxydesmosterol
cholest-(24Z)-5,24-diene-3p,27-diol
22. (24E)27-
hydroxydesmosterol
cholest-(24E)-5,24-diene-3p,27-diol
23. 20R,22R-
dihydroxycholesterol
cholest-5-en-3p,20R,22R-triol previous 
studies in
24. 2 2 -oxocholesterol cholest-5-en-22-oxo-3p-ol Swansea
University
25. 24-oxocholesterol cholest-5-en-20-oxo-3p-ol
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2.1.4 Isolation of sterols/oxysterols from mouse brains
Newborn wild type and SLOS
Lipid extracts of neonatal mouse brains were a gift from Dr. C.H. Shackleton, 
Oakland Children’s Hospital, California. Newborn mouse brain was homogenised and 
initially extracted in methanol:chloroform (1:1, v/v), and re-extracted in methanol. The 
combined extracts were taken to dryness and shipped to Swansea.
The lipid extracts of newborn mouse brain, equivalent of 100 mg of wet tissue, were 
solubilised in 1.05 mL of 99.9% ethanol containing 50 ng of 24(R/S)- 
[2 H6 ]hydroxycholesterol, 50 pg of [2 H7 ]cholesterol and ultrasonicated for 15 min at room 
temperature. Then 0.45 mL of water was added and the mixture was sonicated for another 15 
min. The mixture was centrifuged at 14,000 g at 4 °C for 60 min and the supernatant was 
collected. The extraction procedure was repeated on the lipid residue (with a second 1.05 mL 
ethanol containing reference standards and addition of 0.45 mL of water) and the 
supernatants combined (final volume 3 mL).
Adult Cyp46al deficient mice
Lipid extracts of brains from Cyp46al deficient mice were a gift from Dr. D.W. 
Russell, University of Texas Southwestern Medical Center at Dallas, Dallas. Lipids were 
extracted from brains of four 15 week old female mice, two Cyp46al-/~ animals and two wild 
type (wt, Cyp46al+/+) controls. Brain tissue (0.4 -  0.5 g, wet weight) was homogenised in 
phosphate buffer solution (1.2 mL), then was added 6  mL of chloroform and methanol (1:2, 
v/v, 6  mL) mixture. After further homogenisation the sample was centrifuged (1,360 g) for 10 
min at 4 °C. Resulting supernatant was transferred to a fresh tube where again chloroform (2 
mL) and phosphate buffer (2 mL) were added. Following further centrifugation the organic 
phase was removed and solvents evaporated. The dried lipid residue was shipped to 
Swansea.
Lipids extract corresponding to 100 mg of brain wet weight were dissolved in 1.05 mL of 
ethanol containing 50 ng of 24R/S-[2H6]hydroxycholesterol and 50 pg of [2 H7]cholesterol and 
ultrasonicated for 15 min at room temperature. Water (0.45 mL) was added to the mixture 
and the extract was sonicated for another 15 min. The mixture was centrifuged at 14,000 g at
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4 °C for 60 min and the supernatant was retained. The residue was extracted again and the 
supernatants were combined.
Adult Cyp27al and Cyp7bl deficient mice
Brain samples disinfected from mice carrying mutations in Cyp7bl were generated at 
Edinburgh University. In the experimental procedure were used samples obtained from 13 
and 23 month old male mice. Brain samples from mice with disrupted Cyp27al were 
purchased from Jackson Laboratory (US).
A single chemosphere of the brain (approximately 200 mg) was weighted and the 
tissue was transferred into a glass/teflon homogeniser. To the tissue was added 2.10 mL of 
ethanol enriched with 100 ng of 24R/S-[2H6]hydroxycholesterol and 100 pg of 
[ H7 ]cholesterol. The mixture was homogenised by 30 passes of the pestle followed by 
sonication for 15 minutes. To the extract was added 0.9 ml of water was and the homogenate 
was sonicated for another 15 min. The liquid content of the homogeniser was transferred into 
a separate tube, while the remaining tissue residue in the homogeniser was extracted for the 
second time. The extract were brought together and centrifuged at 14,000 g at 4 °C for 60 
min. The supernatant was collected and divided in two aliquots. One aliquot (corresponding 
to 1 0 0  mg of the biological material) was used in further work.
2.1.5 Isolation of oxysterol/sterols from macrophages
Isolation and treatment o f macrophages
Lipid extracts of bone marrow derived macrophages (BMDM) and media were 
supplied by Dr. M. Blanc from Edinburgh University, UK. Macrophages were extracted 
form mice and treated in Edinburgh, while lipid extraction and MS analysis was performed in 
Swansea.
The procedure of isolation of the macrophages and the detail of the treatment are 
detailed in publication of Blanc et al. f 1351. Macrophages were isolated from mice femur and 
tibia. Extracted cells were flushed with Dulbeco Modified Eagle Medium (DMEM) 
supplemented with 1% penicillin-streptomycin solution and centrifugated for 5 minutes. The 
cell pellet was retained and resuspended in DMEM/F12 + GlutaMAX enriched with 10% 
Fetal Bovine Serum (FCS), 10% L929 conditioned medium (containing Colony-stimulating 
factor Csfl) and Penicillin/Streptomycin.
58
For the interferon challenge murine recombinant Interferon gamma (IFNy) and 
Interferon Beta 1 (IFNP) were diluted in complete medium. These were added to cells at a 
final concentration of 10 U/ml or 25 U/ml respectively.
The construction of the GFP-encoding Murine Cytomegalovirus (MCMV-GFP, 
originally named: pSM3fr-rev) used in this study was described in the publication of Angulo 
et al. [169]. The virus was propagated in mouse NIH-3T3 fibrobasts. The amount of 
infectious MCMV/MHV- 6 8  present in the viral stock was quantified by plaque assay on p53 
-/- MEF monolayers in 48-well plates.
Extraction o f  Oxysterols and Sterols.
Treated cells (106) were separated from medium (retained for subsequent extraction) and 
washed twice with 3mL of ice cold phosphate phosphate buffer. A further 1.6 ml of ice cold 
PBS was added to each plate and cells scraped into a 2mL microcentrifuge tube. The cells 
were centrifuged at 600g (4° C) for 5 min, the supernatant discarded, and 1ml of 99.9% 
ethanol added to the cell sediment. To the cell sediment in 1ml of 99.9% ethanol, 1.1ml of 
99.9% ethanol containing 20ng of [2H6]24(R/S)-hydroxycholesterol and lpg  of 
[2 H7 ]cholesterol (both Avanti Polar Lipids) was added, with sonication in an ultrasonic bath 
(5 min). Following centrifugation at 14,000g (4° C) for 60 min, 0.9ml of water was added
drop-wise to the supernatant to give a solution of 3ml of 70% ethanol.
To extract secreted oxysterols, incubation medium (2ml) was added drop-wise, with 
sonication in an ultrasonic bath (5 min), to 4.7ml of 99.9% ethanol containing 20 ng of 
[2H6]24(R/S)-hydroxycholesterol and lpg of [2 H7 ]cholesterol to give a solution of 6.7ml of 
70% ethanol.
2.1.6 Separation of oxysterols from sterols with SPE
During the sample preparation cholesterol can become autooxidised. Oxysterols generated in
this process alter an indigenous oxysterol profile of analysed material; therefore it is crucial 
to separate oxysterols from cholesterol in an initial SPE procedure. A Certified Sep-Pak C l 8  
(200 mg, Waters) cartridge were rinsed with 4 mL of 99.9% ethanol followed by an wash 
with 6  mL of 70% ethanol to equilibrate the solid phase. The solutions of extracted sterols 
and the internal standards in 70% ethanol were applied onto the cartridge and allowed to flow 
at a rate of 0.25 mL/min. The flow of the solvents through the cartridge was enhanced by a
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negative pressure applied to the outlet of the cartridge via a vacuum manifold (Vacuum 
Processing Station, Agilent). Resulting flow-through was collected.. A wash with 4 mL 70% 
ethanol was similarly collected and combined with the flow-through to give fraction SPE1- 
FR1 (
Figure 2.2). This fraction is expected to contain oxysterols [167]The column was washed 
further with 4 mL of 70% ethanol (SPE1-Fr2) and cholesterol eluted from the cartridge with 
2 mL of 99.9% ethanol (SPE1-Fr3). A final 2 mL of 99.9% ethanol was applied to the 
column to elute more hydrophobic sterols from the cartridge (SPE1-Fr4). Each fraction was 
divided into two equal volumes i.e. (SPE1-FR1A) and (SPE1-FR1B) and all fractions were 
dried under vacuum with Scanspeed concentrator (Scanvac) and reconstituted in 100 pL of 
propan-2 -ol.
2.1.7 Oxidation of sterols/oxysterols with cholesterol oxidase
Sterols/oxysterols with a 3P-hydroxy-5-ene or 3p-hydroxy-5a-hydrogen functions 
were transformed to 3-oxo-4-ene and 3-oxo analogues with cholesterol oxidase from 
Streptomyces sp. (Figure 2) f 1611. To the fractions “A” from above was added solution of 1 
mL 50 mM phosphate buffer (pH7) containing 3.0 pL of cholesterol oxidase (2 mg/mL in 
H2 O, 44 units/mg of protein). The mixtures were incubated for 1 h at 37 °C, and the reactions 
were terminated with 2 mL of methanol. The (B) fractions were treated in an identical 
manner but in the absence of cholesterol oxidase and with the 2 mL of added methanol 
containing 50 ng of 7-[ H7 ]oxocholesterol.
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Internal standardsLipid Extract
C18 SPE-1
70% EtOH
Dry, reconstitute in iPrOH
Cholesterol oxidase in 
phosphate buffer
70% MeOH70% MeOH
GP hydrazine (in 70% 
MeOH,5%HOAc)
Recycling
70% MeOH, 5% HOAc
MeOH
Cie SPE-2
3 x 1 ML MeOH
LC- MS"
Figure 2.1 Analytical protocol for the analysis of sterols and oxysterols extracted from 
biological material (brain tissue, cells, media). Extract was split into two portions, one is 
directly subjected to GP derivatisation (A), while the second one is incubated for 1 h with 
cholesterol oxidase (B) and then derivatised with GP reagent. In fraction A only sterols 
naturally possessing 3-oxo moiety are derivatised, in fraction B sterols with 3P-hydroxy-4- 
ene and 3p-hydroxy-5a-hydrogen will be converted to is 3-oxo analogues, which allows the 
derivatisation reaction. Recycling procedure for SPE2 was applied in order to separate and 
remove the excess of GP reagent.
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2.1.8 Derivatisation sterols/oxysterols with Girard P reagent
Neutral sterols/oxysterols are electrically inert and, therefore, poorly ionised in the API 
process. To overcome this issue we applied a derivatisation method to enhance their analysis. 
Sterols/oxysterols possessing an oxo group (either naturally or via treatment with cholesterol 
oxidase (Figure 2.1) were derivatised with the GP reagent which contains a pre-ionised 
quaternary nitrogen (Figure 2.2) IT 601. To each of the fractions from above was added 1 mL 
of phosphate buffer, 150 pL of glacial acetic acid and 150 mg of GP hydrazine (Figure 2.1). 
Glacial acetic acid added to the mixture increases the rate of hydrazone formation [156]. The 
mixture was incubated at room temperature overnight in the dark. We call the combined 
process of oxidation with cholesterol oxidase and derivatisation with GP reagent as a 
“charge-tagging”.
OH OH
26
Cholesterol Oxidase
HO' C27H44O2 
Exact Mass: 400.3341
GP HydrazineExact Mass: 402.3498
OH
NH,i *
HN
Exact Mass: 534.4054
GP Hydrazine HN.
Figure 2.2 The process of charge-tagging by derivatisation with Girard P reagent. Oxysterol 
possessing 3-oxo group forms positively charged hydrazones with GP hydrazine.
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2.1.9 Purification of sterols/oxysterols with SPE
Derivatised sterols/oxysterols were separated from the excess of GP hydrazine by a 
recycling method [148]. Sterol/oxysterol molecules, even when derivatised to the GP 
hydrazones, are still prone to precipitation in highly aqueous solutions. To tackle this 
problem a recycling method was used, where initially analytes were dissolved in 70% 
methanol, and recycled on a second 200 mg certified Sep-Pak C l 8  cartridge (SPE2). Prior to 
application of sample the column was washed with 6  mL of 100% methanol and 6  mL of 
10% methanol before conditioning with 4 mL of 70% methanol. The flow of solvent through 
the column was aided by a negative pressure applied to the column outlet by a vacuum 
manifold. The derivatisation mixtures from above (-3 mL -70% methanol) were applied to 
the column and effluent retained. The sample tube was then washed with 1 mL of 70% 
methanol and applied to the column followed by a column wash of 1 mL 35% methanol. The 
effluents were pooled (now -  5 mL) and diluted with 4 mL of water to give 9 mL of 35% 
methanol. This solution was then applied to the column and the flow-through collected, 
followed by a wash with 1 mL of 17% methanol. The flow-through and wash were diluted 
with 9 mL of water to give 19 mL of -  17% methanol. This solution was again loaded on the 
column followed by a wash with 6  mL of 10% methanol. At this point all the derivatised 
sterols/oxysterols are retained on the column while excess derivatisation reagent is in the 
10% methanol wash. Derivatised sterols/oxysterols were then eluted in three separate 1 mL 
portions of 100% methanol (SPE2-FR1, FR2, FR3) followed by 1 mL of 99.9% ethanol 
(SPE2-FR4). For subsequent analysis of oxysterols the first 2 mL were combined while for 
sterol analysis 3 mL were combined.
2.1.10 LC-MS and MS" analysis
The mass spectral work presented in this thesis was done with two instruments. LTQ 
Orbitrap XL was used for the analysis of neonatal brains and Cyp46al deficient brain. The 
brain tissue from animals with Cyp27al and Cyp7bl deficiencies and were analysed with 
LTQ Orbitrap Velos. The study of macrophages was performed on both systems: LTQ 
Orbitrap XL for the first, preliminary part of the study, while LTQ Orbitrap Velos was used 
for the main body of the macrophage analysis.
LTQ Orbitrap XL or LTQ Orbitrap Velos (Thermo Fisher Scientific, UK) was paired 
with a Dionex Ultimate 3000 LC HPLC system (Dionex, UK). For the data processing and 
analyte quantification was used Thermo-Fisher MS software Xcalibur.
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Liquid chromatography Dionex Ultimate 3000 LC HPLC system consists o f degasser, 
pump unit, flow control module, column compartment and autosampler (Figure 2.3). Sample 
is stored until injection in temperature-controlled tray in the autosampler. The sample is 
withdrawn by the needle and loaded into a sample loop o f defined volume. In the next step 
the analytes are removed from the loop and injected to flowing mobile phase.
Figure 2.3 Thermo Scientific Dionex Ulitmate 3000 HPLC system. Mobile phases from 
reservoirs are passed through degassers (A) propelled by the pumps (B). The separation is 
performed by the HPLC column homed in column compartment (C), the sample is withdrawn 
from vials kept under stable conditions in the sampler (D). Analytes are transferred to the ESI 
probe o f LTQ Orbitrap Velos (E) from Thermo Scientific.
The separation was performed using a Hypersil GOLD reversed-phase column (50 x 2.1 mm,
1.9 pm, Thermo-Scientific) at ambient temperature at flow rate 200 pL/ min.
For the separation o f analytes was used 17 minute long HPLC gradient, however for 
the separation and quantification o f closely eluting compounds was used gradient with altered 
elution profile lasting for 23 minutes.
Mobile phase A consisted o f 0.1% formic acid in 33.3% methanol, 16.7% acetonitrile. 
Mobile phase B consisted o f 0.1% formic acid in 63.3% methanol, 31.7% acetonitrile.
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Figure 2.4. Gradient elution programs used for the separation o f GP-derivatised oxysterols, 
programs were controlled with Chromeleon software. Gradent 1 (“short”) where the change 
between the mobile phases is linear (length o f the run 17 min) and Gradient 2 where applied 
curved mobile phases transition (length o f the run 32 min). Mobile phase A was 33.3% 
methanol, 16.7% acetonitrile and 0.1% formic acid, B was 63.3% methanol, 31.7% 
acetonitrile and 0.1% formic acid. The images were reproduced from the Chromelon 
instrument control program.
In the “short” gradient the elution started with 20% B lasted for 1 min, then the 
proportion o f B was raised to 80% B over the next 7 min and maintained at this level for 
further 5 min, before returning to 20% B in 0.1 min. The column was re-equilibrated for a 
further 3.9 min, giving a total run o f 17 min.
The flow through the ESI probe was maintained at 200 pL/ min, The temperature of 
the capillary was set at 300°C, sheet gas flow was 25 arbitrary units/min, auxiliary gas flow 
was 5 arbitrary units/min. The voltage applied to the probe was 5 kV.
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The LTQ-Orbitrap mass spectrometer was calibrated using Cal Mix (Thermo- 
Finnigan) and mass-tuned using GP charge-tagged 19-hydroxycholesterol prior to each 
analytical run. Subsequent tests of LC, MS and MSn systems were performed by injecting 
GP charge-tagged 19-hydroxycholesterol (1 pg/pL in 60% methanol, 0.1% formic acid) onto 
the reversed-phase column and eluting into the ESI source at a flow-rate of 200 pL/min. The 
analysis of this reference compound was repeated periodically during the analytical batch 
(every 1 0  injections) to assure mass accuracy and monitor chromartographic performance. 
For the analysis of GP charge-tagged sterols/oxysterols, the methanol eluents from the SPE2 
fractions was diluted to give solution of 60% methanol. The volume of injected solution 
ranged between 20pL and 35 pL depending of obtained intensity of analytes.
The LTQ-Orbitap XL or Velos instruments were operated in positive ion mode, using 
three different scan events. For the plain mass spectrum, we utilised a FTMS scan in the 
Orbitrap over the m/z range 400-605 at 30,000 resolution (full width at half-maximum height, 
fwhm, definition) was performed followed by data dependent MS2  ([M]+->) and MS3 
([M]+->[M-79]+->) events in the Linear Quadrupole Ion Trap. These MSn scans in the LTQ 
were performed in parallel to acquisition of the high-resolution MS scan by the Orbitrap. For
9  3the MS and MS scans were performed at the normalised collision energy at 30% and 35% 
(instrument settings) respectively. In order to select monoisotopic ions the precursor-ion 
isolation width was set at 2 (LTQ Orbitral XL) or 1 (LTQ Orbitral Velos). A precursor-ion 
inclusion list was defined according to the m/z of the [M]+ ions of expected sterols/oxysterols 
so that MS2  was preferentially performed on these ions in the LTQ if their intensity exceeded 
a preset minimum (500 counts). If a ffagment-ion corresponding to a neutral loss of 79 Da 
from the precursor-ion was observed in the MS event and was above a minimal signal 
setting (200 counts), MS3 was performed on this fragment (Figure 2.5).
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(A)
(B)
Ci#H„NjO* 
Exact Mass 177 1022
9 9Figure 2.5 Schematic representation o f (A) MS~ and MS performed on ions in inclusion list 
or most abundant ions and (B) M S3 fragmentation o f sterol/oxysterol GP hydrazones. GP- 
tagged 24S-hydroxycholesterol is shown as an example.
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Quantification of sterols/oxysterols
For the quantification of sterols/oxysterol we exploited stable isotope dilution 
methodology. Oxysterols were quantified using 24(S/R)-[ tyhydroxycholesterol, while 
sterols were quantified against [ H7 ]cholesterol. The quantity of sterols/oxysterols in fractions 
(A) represent the sum of sterols/oxysterols oxidised by cholesterol oxidase generating a 3-oxo 
group and those which naturally contain an oxo group. To separate sterols/oxysterols with 
these structures, quantities in fractions (B) are subtracted from fractions (A). The difference 
(A-B) represents the quantity of sterols/oxysterols with a 3 (3-hydroxy group subsequently 
oxidised to the 3-oxo group, while the quantities in (B) represent sterols/oxysterols with a 
natural oxo group. 7 -[2 H7 ]Oxocholesterol was use as the to quantify sterols/oxysterols which 
naturally possess an oxo group and are preserved in fractions (B).
The concentration of analyte of interest was calculated by dividing the analyte peak area 
divided by the peak area of isotopically labelled internal standard and multiplied by the 
known concentration of internal standard.
Aa x  Mf 
~ A  —  = M a
Where:
Ma = concentration of analyte
Mi = concentration of internal standard
Aa = analyte peak area
Aj = internal standard peak area
Karu et al. IT481 shown that various GP-derivatised sterols/oxysterols with a 3-oxo-4- 
ene structure give a similar intensity of response upon analysis by LC-ESI-MS. This allows 
the use of 24(R/S)-[2H6]hydroxycholesterol and [2 H7]cholesterol as internal standards for 
oxysterols and sterols respectively. Once GP tagged 7-oxocholesterol and 24- 
hydroxycholesterol also give similar response in LC-ESI-MS thereby allowing the use of 7- 
[25,26,26,26,27,27,27-2H7]oxocholesterol as the internal standard for (B) fractions.
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Chapter 3
3 Analysis of oxysterols in neonatal mouse brain
3.1 Introduction
Unesterified oxysterols in an adult mouse brain are dominated by a large excess of 
cholesterol (10-20  pg/mg wet weight in most species). This causes an analytical difficulty in 
the study of relatively scarce oxysterols. However, this can be overcome by the analysis of a 
brain isolated from a new bom animal. Mouse belongs to altricial species, which means that a 
new bom mouse is entirely dependant on its mother. Myelination in the neonatal brain has 
not started and cholesterol levels are similar to most other organs ( 2 - 4  fig/mg). The level of 
cholesterol increases rapidly in mouse brain over a three week period during which 
myelination proceeds [8 8 ]. Thus, the newborn mouse offers an opportunity to study the sterol 
content of brain in the absence of masking levels of myelin-derived cholesterol.
Essentially all cholesterol present in the brain is derived from de novo synthesis, this 
is also true of newborn mouse, where at least 90% of cholesterol in the brain has been 
synthesised in the brain [170]. In the developing foetus, after closure of the blood brain 
barrier (BBB), and in the very young animal, desmosterol levels are elevated indicating a 
rapid de novo synthesis of sterols [8 8 , 120. 1701. An active mevalonate pathway in the 
developing foetus is further confirmed by appreciable levels of 24S,25-epoxycholesterol 
[120].
In adult mammals cholesterol levels in brain are maintained at a constant level by the 
equilibrium between cholesterol synthesis via mevalonate pathway and cholesterol removal 
via 24S-hydroxylation reaction. 24S-Hydroxycholesterol is able to cross the BBB and is 
transported by the circulation to the liver for further metabolism IT711. The foetal mouse 
brain is characterised by low expression of cholesterol 24-hydroxylase (Cyp46al), which 
consequently retains newly synthesised cholesterol within the brain [1701. The increase in the 
level of cholesterol is accompanied by upregulated expression of Cyp46al and an increase in 
24S-hydroxycholesterol levels [29, 1721.
24S-Hydroxycholesterol, 24S,25-epoxycholesterol, IT 09. 1731. and 22R-hydroxycholesterol 
are ligands to the liver X receptors (LXRs) in vitro. Moreover, 22R-hydroxycholesterol 
participates as an intermediate in the transformation of cholesterol into pregnenolone by the 
cytochrome P450 (Cyp) side-chain cleavage enzyme (P450SCC, C ypllal). This enzyme first 
hydroxylates cholesterol at 22R position, then at 20R position; resulting 20R,22R- 
dihydroxycholesterol is cleaved forming pregnenolone. Pregnenolone serves a precursor for
70
neurosteroid biosynthesis f 1741. 22R-Hydroxycholesterol has been reported in human brain 
as well as to have neuroprotective effects against amyloid beta toxicity in vitro [175, 1761.
The aim of this work is to present a comprehensive profile of oxysterols and sterols 
present in a new bom mouse brain. Without the masking effect of cholesterol it would be 
possible to evaluate the levels of indigenous oxysterols isolated from the brain. Furthermore, 
this study includes the analysis of oxysterols implicated in neurogenesis found in an 
embryonic brain [120].
3.2 Results
Oxysterols in newborn mouse brain
Monohydroxycholesterols
Cholesterol molecule possessing one additional hydroxyl subjected to derivatisation 
with Girard reagent upon ionisation will produce a molecular ion of m/z 534.4054. The 
reconstructive ion chromatogram (RIC) of this m/z from newborn mouse brain using 
chromatographic Gradient 1 and Gradient 2 (gradient elutions showed in Figure 2.4) is shown 
in Figure 3.1 A and Figure 3.IB, respectively. The analysis of chromatogram for m/z
534.4054 showed two dominating peaks eluting at 7.41 min and 7.72 min. Based on 
comparison with authentic standards these were identified as syn and anti conformers of GP- 
tagged 24S-hydroxycholesterol. The MS3 ([M]+—>[M-79]+—>) spectra of both peaks are 
identical (Figure 3.2B) and show the triad of low mass fragment ions m/z 151 (*bl-12), 163 
(*b3-C2H4) and 177 (*b2) characteristic of the GP-derivatised 3-oxo-4-ene structure (formed 
following cholesterol oxidase treatment), and a distinctive ion at 353 (‘*f), which is 
characteristic of the 24-hydroxy group (Figure 2.5) [148]. 24S-Hydroxycholesterol is 
generated in the Cyp46al catalyzed hydroxylation of cholesterol [291.
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Figure 3.1 M onohydroxycholesterols in newborn mouse brain. (A and B) RIC o f m/z
534.4054 ± 10 ppm utilising gradients 1 (short) and 2 (long), respectively.
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Figure 3.3 Monohydroxycholesterols in newborn mouse brain - cont. MS spectra referring to 
GP-tagged oxysterols. (A) 26-hydroxycholesterol (cholest-(25R)-5-ene-3p,26-diol, 26-HC),
(B) X-hydroxycholesterol (X-HC), and (C) 7a-hydroxycholesterol (7a-HC). Assignment is 
based on a comparison o f retention time, exact mass and MSn spectra with those o f authentic 
standards.
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Figure 3.4 Monohydroxycholesterols in newborn mouse brain - cont. MS^ spectra referring to 
GP-tagged oxysterols. (A) 7 p-Hydroxycholesterol, (B) 6-hydroxycholesterol.
The Cyp46al enzyme is normally expressed in neurons. In newborn mouse brain the level of 
24S-hydroxycholesterol was determined to be 0.510 ± 0.082 ng/mg, (mean ± standard 
deviation, n = 6). This value is considerably lower than that published for the adult mouse (30 
-  60 ng/mg) [172, 177-1791. This is not surprising as expression o f Cyp46al is detected until 
late embryonic development in mouse f 1721. and in human Liitjohann et al have shown that 
CYP46A1 activity is minor in neonates [1801. GP-tagged 24S-, 25- and 26- 
hydroxycholesterols (cholest-(25R)-5-ene-3p,26-diol) give closely eluting peaks but 
characteristically different MS spectra (Figure 3.2B-C and Figure 3.3A). This enables the 
identification o f all three oxysterols. However, in this study the comparatively high level of 
24S-hydroxycholesterol and low levels o f the other two closely eluting oxysterols (<0.010 
ng/mg) made accurate quantification o f the minor oxysterols difficult. This issue was 
mitigated by utilising the extended chromatographic gradient (Gradient 2) which improved
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the resolution of these isomers and make quantitative estimates of oxysterol concentrations 
(Figure 3.1). 25-Hydroxycholesterol is formed from cholesterol either by cholesterol 25- 
hydroxylase (Ch25h) [8] or in Cyp46al catalysed reactions [29, 1071. while 26- 
hydroxycholesterol is formed in Cyp27al catalysed reactions l~1811. Further analysis of the 
RIC of m/z 534.4054 reveals in Figure 3.1 A a minor peak at 8.24 min with retention time and 
MS3 spectrum 13 identical to charge-tagged 24R-hydroxycholesterol. Reference to the 
authentic standard indicates that this compound elutes as syn and anti conformers with the 
earlier eluting component eluting at 7.88 min. These conformers elute at 19.21 and 20.71 min 
with the longer gradient (Figure 3.IB). The level of 24R-hydroxycholesterol was determined 
to be 0.061±0.006 ng/mg. 24R-Hydroxycholesterol has not previously been characterised 
in brain. In mouse Cyp46al accounts for production of 80% of the 24-hydroxycholesterol 
content of plasma and Lund et al suggested the remainder may be formed in a reaction 
catalysed by Cyp27al as earlier studies in pig revealed that the hepatic mitochondrial sterol 
27-hydroxylase has 24-, 25- and (25R),26-hydroxylase activity IT 821. It is uncertain whether 
the 24R-isomer found here in newborn brain is formed as a minor product of Cyp46al 
activity in brain or is an import product hepatically derived from Cyp27al oxidation of 
cholesterol. 24R-Hydroxycholesterol was not detected in young adult female mouse brain. 
Preceding the major peaks in the RIC of m/z 534.4054 is a minor peak eluting at 6.22 min in 
Figure 3.1 A, identified by retention time and its MS3 spectrum (Figure 3.2A) to correspond to 
GP-tagged 22R-hydroxycholesterol (0.010 ± 0.002 ng/mg). The presence of a hydroxy group 
at the C-22 is characterised by an abundant ion at m/z 355 (* f ) resulting from a cleavage of 
the C-20 -  C-22 bond a to the 22-hydroxy group, and at m/z 273 corresponding to the charge- 
tagged ABC rings. 22R-Hydroxycholesterol is formed from cholesterol by P450SCC 
(C yp lla l) as a first step of pregnenolone synthesis via 20R,22R-dihydroxycholesterol. The 
enzyme is expressed in adult rodent brain and also during embryogenesis 11831. Other 
monohydroxycholesterols identified in newborn mouse brain were 7a-, 7P- and 
6-hydroxycholesterols, at levels of 0.048 ± 0.022, 0.039 ± 0.015 and 0.019 ± 0.014 ng/mg 
(Figure 3.3C, Figure 3.4A and B). The hydroxylation of the B ring of the tetracyclic nucleus 
results in an altered pattern of low mass fragment ions in the MS spectra. 7a- or 7P- 
Hydroxylation causes a shift in the *b3-C2H4 ion from m/z 163 to 179. There is an elevated 
abundance of the ion at m/z 151 (*bl-12) in the spectrum of the 7p~isomer compared to the 
7a-isomer, while the peaks at m/z 231 and 394 are more intense in the spectrum of the 7P 
isomer. 7p-Hydroxycholesterol can be formed enzymatically in a Cyp7al catalyzed reaction, 
but Cyp7al is expressed only in liver [1841. Both 7a- and 7p-hydroxycholesterol can be
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produced by autoxidation of cholesterol during sample preparation and storage f 1851. or they 
may be formed endogenously by reaction of cholesterol with reactive oxygen species (ROS) 
[186]. In some, but not all samples, a peak giving MS2 and MS3 spectra identical to those of 
the authentic standard of 6p-hydroxycholesterol was observed (Table 3.1). 6P- 
Hydroxycholesterol can be generated from 5,6-epoxycholesterol by hydrolysis and 
dehydration [126]. The remaining chromatographic peak to be characterised corresponds to a 
14 hydroxycholesterol eluting at 8.91 min in Figure 3.1A and at 22.52 min in Figure 3.IB 
(0.045 ± 0.015 ng/mg). The MSn spectra suggest hydroxylation at a primary or secondary 
carbon on the C17 side-chain (Figure 3.3B). One possibility is cholest-(25S)-5-ene-3p,27- 
diol, however, the retention time does not correspond to that of the authentic standard, which 
elutes just before the 25R isomer (we use the nomenclature suggested by lipid maps where 
26-hydroxycholesterol corresponds to cholest-(25R)-5-ene-3p,26-diol [16]). In summary, the 
pattern in newborn brain is of one dominating monohydroxycholesterol, i.e. 24S- 
hydroxycholesterol (Figure 3.1 A and B), this is similar to what is observed here in the young 
female adult and to published data for adult mouse brain H77. 1791. However, it is 
noteworthy that an array of monohydroxycholesterols isomers are observed in newborn 
mouse brain, and that a similar situation exists in embryonic brain [120].
Oxo and epoxycholesterols and hydroxydesmosterols
Cholesterol modified with additional epoxy- or oxo- groups or possessing a second 
insaturated bond and a hydroxyl group, following GP charge-tagging will give an [M]+ ion at 
m/z 532.3898. RICs for this m/z are shown in Figure 3.6A and Figure 3.6B separated with the 
short and long gradient, respectively. The two peaks eluting at RT 6.80 and 7.01 min in 
Figure 3.6A correspond to the syn and anti conformers of GP-tagged 24S,25- 
epoxycholesterol (0.067 ± 0.012 ng/mg). In Figure 3.6B the corresponding peaks are at 12.47 
and 13.93 min, respectively. The MS spectra are identical to those of the authentic standard, 
giving the characteristic low mass ions at m/z 151, 163 and 177, and side-chain cleavage 
fragment ions at 325 (‘*e), 353 (‘*f) and 367 (‘*g) (Figure 3D). The chromatographic peak 
eluting at 7.79 min in Figure 3.6A was identified as GP-tagged 24-oxocholesterol (0.031 ± 
0.008 ng/mg). The presence of a 24-oxo group rather than the 24,25-epoxide is indicated by 
the elevated abundance of the [M-79-CO]+ ion {m/z 425) compared to the [M-79-H20]+ ion 
(m/z 435) (Figure 3.8B versus Figure 3.7B). 24-Oxocholesterol is an isomerisation product of 
24S,25-epoxycholesterol formed during the derivatisation procedure.
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Figure 3.5 Sterols and oxysterols identified in mouse brain. Charge-tagged with GP- 
hydrazine (A) sterols and (B) oxysterols identified by LC-ESI-MS'1 in newborn brain.
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Figure 3.6 Oxo-, epoxycholesterols and hydroxydesmosterols in newborn mouse brain. RIC 
o f m/z 532.3898 ± 10 ppm acquired using (A) the short and (B) long gradient.
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Figure 3.7 MS3 spectra ([M ]+—»[M-79]+—►) spectra assigned to GP-tagged oxysterols: (A) X- 
hydroxydesmosterol (X-HD), (B) 24S,25-epoxycholesterol (24,25-EC), (C) (24Z),26- 
hydroxydesmosterol (cholesta-5,24Z-diene-3p,26-diol, 26-HD(24Z)).
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Figure 3.8 MS3 spectra ([M]+—>[M-79]+—►) and (F) [M]+—► [M-97]+—► spectra assigned to 
GP-tagged oxysterols. (A) Y-hydroxydesmosterol (Y-HD), (B) 24-oxocholesterol (24-OC), 
(C) 22-oxocholesterol (22-OC).
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The peak with retention time 8.05 min in Figure 3.6A subjected to MS fragmentation gave a 
spectrum characteristic of GP-tagged 22-oxocholesterol (0.060 ± 0.025 ng/mg) (Figure 3.8C). 
Similar to GP-tagged 24-oxocholesterol, the MS3 spectrum of 22-oxocholesterol shows a 
distinctive peak at m/z 425 ([M-79-CO]+), however, the base peak is at m/z 325 (‘*e) with 
additional peaks at m/z 297 (‘*e-CO) and m/z 282 (‘*e-CO-NH) (Figure 3.8). Other intense 
peaks are at 355 (* f) and 312 (*f-CO-NH) in addition to the low mass triad 151, 163 and 
177. The ‘*e ion at m/z 325 results from cleavage of the C-17 -  C-20 bond P to the 22-oxo 
group, probably via a McLafferty-like rearrangement eliminating the side-chain as an enol 
[148]. The * f  fragment ion is generated by a cleavage a to the 22-oxo 15 group with 
elimination of either a ketene or CO and an alkene. Further CO and NH moieties are 
eliminated from the remnants of the derivatising group to give ions at m/z 327 and 312, 
respectively. 22-Oxocholesterol has not previously been reported in the literature regarding 
brain tissue, however the role of side-chain has been discussed in older literature IT 87. 1881. 
The dominant peak in the RIC of m/z 532.3898 is at 7.42 min in Figure 3.6A and 16.25 min 
in Figure 3.6B (0.188 ± 0.046 ng/mg) and is not easy to assign. The MS3 ([M]+—► [M- 
79]+—►) spectrum is completely dominated by the [M-79-18]+ ion at m/z 435. This suggests 
the analyte readily loses H2 O from the [M-79]+ ion, possibly forming a conjugated diene 
derived from a sterol with hydroxy and alkene groups a,p to one another. The presence of 
minor ions at m/z 151, 163, 325 (‘*e) and 353 (‘*f) indicated that the unsaturation and 
hydroxylation are on the side-chain. As the spectrum showed the dominating loss of water, 
we applied a different pattern of MS fragmentation. Only one peak is evident appearing at 
7.42 min, and the corresponding MS spectrum is shown in Figure 3.8A. The spectrum is 
compatible with a GP-tagged sterol unsaturated and hydroxylated in the side-chain, possibly 
23-hydroxydesmosterol. There is a precedent for C-23 hydroxylation is hypothesised as a part 
of bile acid synthesis, however 23-hydroxylation of desmosterol has not been reported [189]. 
Interestingly, cholesterol free mouse has an essentially unaltered pattern of bile acid pattern 
even though desmosterol is the dominant sterol [1901. It should be noted, however, that C-23 
is an allylic site in desmosterol and is thus susceptible to non-enzymatic oxidation. An 
equivalent peak was not observed in the corresponding chromatogram from young adult 
female brain. The partial identification of a hydroxylated desmosterol encouraged us to 
search for further isomers of this molecule. Pikuleva and Javitt demonstrated that desmosterol 
can be 26-hydroxylated in vitro by human recombinant CYP27A1 [1911. while Heverin et al
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have identified this oxysterol in the cholesterol free mouse [190]. Brain-specific Cyp46al is 
known to hydroxylate cholesterol at 24- and 27-positions [107], however desmosterol is not 
recognised by this enzyme as a substrate [172], therefore it is unlikely that Cyp46al can 
contribute to formation of 26-hydroxlated desmosterol. The retention time of authentic 
charge-tagged (24Z),26-hydroxydesmosterol (cholesta-5,24Z-diene-3p,26-diol) run with the 
short gradient is 7.16 min and a peak appearing in the RIC of m/z 532.3898 at this retention 
time (0.048 ± 0.009 ng/mg) gives a spectrum essentially identical to that of the authentic 
standard (Figure 3.7C). By using the longer chromatographic gradient (24Z),26- 
hydroxydesmosterol was completely separated from the second peak of 24S,25- 
epoxycholesterol (Figure 3.6A and Figure 3.6B). Hydroxylation of the terminal carbon of 
desmosterol introduces Z or E stereochemistry about the C-24-25 double bond, and these 
isomers are readily resolved by utilising the extended gradient allowing the identification also 
of (24E),26-hydroxydesmosterol (cholesta-5,24E-16 diene-3p,26-diol) eluting at 16.85 min in 
the chromatogram of newborn brain (0.015 ± 0.004 ng/mg). A minor peak in Figure 3.6A is 
seen at 5.97 min, the MS spectrum (Figure 3.7A) is again compatible with a GP-tagged 
hydroxydesmosterol with an added hydroxy group on the side-chain (0.002 ± 0.002 ng/mg). 
Further scrutinised RIC of m/z 532.3898 (Figure 3.6A) revealed peaks at 8.67 and 9.29 min 
that give MS3 spectra compatible with GP-tagged 7p- and 7a-hydroxydesmosterols, 
respectively (0.020 ± 0.006 and 0.024 ±0.012 ng/mg). The 7a isomer is probably formed, at 
least in part, endogenously in a Cyp catalysed hydroxylation of desmosterol as Cyp7al has 
activity towards desmosterol. MS spectrum of the peak appearing at 9.66 min corresponds to 
a GP-tagged 6-hydroxydesmosterol (0.023 ±0.011 ng/mg), which can be derived from 5,6- 
epoxydesmosterol [1261. The hydroxydesmosterol molecules described here have not 
previously been found in brain, and of the isomers characterised only (24Z),26- 
hydroxydesmosterol is found in the young adult.
Dihydroxycholesterols
Introduction of two hydroxyl groups to a cholesterol molecule and pairing to GP hydrazone 
will produce an ion of m/z 550.4003. Figure 3.9 shows a relevant RIC which reveals two 
major peaks eluting at 3.95 min and 4.62 min corresponding to the syn and anti conformers of 
GP-tagged 24,25-dihydroxycholesterol (0.731 ± 0.439 ng/mg) (Figure 3.11 A). The 
hydroxylation at C-24 and C-25 is indicated by fragment ions m/z 325 (‘*e), 353 (‘*f), 367 
(‘*g) and 381 (‘*h). The presence of hydroxylation at C-25 is further confirmed by the 
dominating ion m/z 453 originating from the loss of water from [M-79]+ ion. 24,25-
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Dihydroxycholesterol can he produced by hydrolysis o f unstable 24S,25-epoxycholesterol. 
24S,25-Epoxycholesterol can be also undergo methanolysis giving
hydroxymethoxycholesterol isomers (0.294 ± 0.177 ng/mg) (Figure 3.10). Analysis o f the 
RIC o f m/z 564 4160 showed a peak doublet with retention times and MS fragmentation 
profiles identical to those obtained during the analysis o f the GP-tagged reference standard 
(Figure 3 .11A). The [M-79-32]+ ion (m/z 453) is formed during the elimination o f a methoxy 
group. The combined concentration o f 24S,25-epoxycholesterol (0.067 ng/mg), 24- 
oxocholesterol (0.031 ng/mg), 24,25-dihydroxycholesterol (0.731 ng/mg) and 
hydroxymethoxycholesterol (0.294 ng/mg) equals 1.123 ± 0.304 ng/mg. 24S,25- 
Epoxycholesterol is a by-product of the mevalonate pathway, so the comparatively high level 
o f this oxysterol is not unexpected for a developing tissue with high rate o f cholesterol 
synthesis.
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Figure 3.9 Dihydroxycholesterols in brain o f newborn mouse. RIC o f m/z 550.4003 ± 10 ppm
recorded using the short gradient.
87
RT: 0 0 0 -1 6  01
100 1
n 60
l  50 
0)
® 40  £
30 
2(H 
10-j 
0 -
Tim e (min)
NL: 1.02E5
m/z= 56 4  4 1 -5 6 4 .4 2  F: 
FTM S + p  E SI Full m s 
[4 0 0 .00 -605 .00 ] MS 
B rain_N +
1 0 0 n g 2 4 o h c d 6 _ 1 0 0 5 0 4  
09
10 11 12 13 14 15 16
Figure 3.10 RIC o f m/z 564.4160 ± 10 ppm obtained using the short gradient.
Figure 3.9 reveals a shoulder (4.48 min) on the leading edge o f the peak at 4.62 min. 
This is partially resolved with the longer gradient. Acquired MS3 spectrum point at the 
presence o f 20R,22R-dihydroxycholesterol (0.020 ± 0.007 ng/mg) (Figure 3.1 IB) providing 
the first direct evidence for the presence o f this cholesterol metabolite in brain. 20R,22R- 
Dihydroxycholesterol is an intermediate in the conversion o f cholesterol to pregnenolone. Its 
presence in newborn brain lends weight to the argument that neurosteroids are formed in 
brain, rather than just passengers from the circulation.
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Figure 3.11 MS3 ([M ]+—> [M-79]+—>) spectra assigned to GP-tagged (A) 24,25- 
dihydroxycholesterol (24,25-DiHC) and (B) 20R,22R-dihydroxycholesterol (20,22-DiHC) 
and 24-hydroxy-25-methoxycholesterol (or the 25-hydroxy-24-methoxy isomer, 24,25-
HMC).
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Sterols in newborn mouse brain
During the SPE fractionation o f the brain extract, cholesterol and its precursor’s desmosterol 
and 7-dehydrocholesterol eluted in fraction 3 (SPE1-FR3). The sterols were derivatised with 
GP reagent and analysed by LC-MS. Obtained eluent contained a high concentration of 
cholesterol. To avoid overloading o f LC-MS system the solution was diluted by a factor of 
10,000 -  20,000 prior to injection. The RIC o f m/z 518.4105 corresponding to GP charge- 
tagged cholesterol is shown in Figure 3.12. The major component elutes at 12.83 min and 
gives an MS3 spectrum identical to that o f GP-tagged cholesterol (Figure 3.13).The 
concentration o f cholesterol in newborn brain was calculated to be 2.221 ± 0.032 pg/mg. 
Similar level was found utilising a GC-MS methodology in work o f  Marcos et al f 1921. These 
values compare with levels in the young female adult determined here of 16.026 ± 0.758 
pg/mg and with literature values for the adult o f 10 -  20 pg/mg (9;21;31;35). Cholest-4-en-3- 
one is also present in newborn brain but at a level o f about 0.1% that o f cholesterol.
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Figure 3.12 Cholesterol in brain o f newborn mouse. RIC o f m/z 518.4105 ± 10 ppm generated
with the short gradient.
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Figure 3.15 MS spectra o f peaks eluting at 11.33, 12.07 and 12.28 min and corresponding to 
GP-tagged desmosterol (A), 7-dehydrocholesterol (B) and cholesta-4,6-dien-3p-ol (C).
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The RIC for m/z 516.3948 corresponding in m/z to GP-tagged desmosterol and 7- 
dehydrocholesterol revealed one major peak with a second appearing as a doublet (Figure 
3.14). The first peak eluting at 11.33 min was identified as GP-tagged desmosterol (493.986 
± 18.062 ng/mg) (Figure 3.15A). This corresponds to about 20% of the total sterol content of 
newborn brain and agrees well with the value determined by Tint et al for 22 day foetus 
[170]. Tint et al also showed a reduced expression of neuronal 24-dehydrocholesterol 
reductase (Dhcr24) in the foetus and newborn animal which accounts for the high level of
-i
desmosterol. The first component of the second peak eluting at 12.07 min gives an MS 
spectrum identical to that of GP-tagged 7-dehydrocholesterol (Figure 3.15B). The second 
component at 12.28 min gives an MS spectrum which we identify as cholesta-4,6-dien-3p~ol 
(Figure 3.15C). This may be an isomerisation product of 7-dehydrocholesterol. Each analyte 
is present at high concentration in newborn brain: i.e. 210.484 ± 8.319 ng/mg, and 46.692 ± 
6.736 ng/mg, respectively.
High concentration of desmosterol and 7-dehydrocholesterol which are cholesterol 
precursors shows a high rate of cholesterol synthesis during neonatal development. These 
also agrees with earlier publications which show that in the developing foetus and suckling 
newborn the rates of sterol accumulation in brain are greatest [94]. Quan et al measured both 
desmosterol and cholesterol levels in the CNS of mice and at their earliest time point of 2 
days-old, desmosterol made up 30% of total sterols, while at day 15 desmosterol had 
“essentially disappeared” [94]. The high levels of desmosterol in the newborn animal are 
particularly interesting in light of recent data indicating that desmosterol can suppress SREBP 
processing and activate LXR target genes IT93. 1941. The precursor of desmosterol is 7- 
dehydrodesmosterol. A component eluting at 10.85 min in the RIC for m/z 514.3792 (Figure 
3.16) gives an MS3 spectrum commensurate with that expected for GP-tagged 7- 
dehydrodesmosterol (41.159 ± 2.503 ng/mg), Figure 3.17A, and a latter eluting peak at 11.59 
min is assigned to cholesta-4,6,24-trien-3P-ol (113.33 ± 7.018) (Figure 3.17B). This may be 
an isomerisation product of 7-dehydrodesmosterol. Again a high level of cholesterol 
precursors in newborn brain can be explained by a low expression of Dhcr24.
93
100^
90
70
8
I  60
■c
I  50-' 
!
1  40  
at
30H
1085I
NL 6.25E3 
m/z= 514.38-514 39 F 
FTMS ♦ p ESI F i i  ms 
[400 00-605 00] MS 
Brain_P+
100ng24ohcd6_100524 
03
Time (min)
Figure 3.16 RIC o f m/z 514.3792 ± 10 ppm corresponding to cholesterol precursors in 
newborn mouse brain.
k  11 M b ♦  c  t:5>i f  uii m s j  5 i4 . j o ( g c i a j u .u u  4 J 3 .5 4 ( g c ia j t ) .u u  i n s . u u - ^ u . u u j
100
90
80
70
|
<
|
tz
60
50
40
30
20
10 284 48 297.57 308 60
m/z
B 100 
9 0; 
80
a  60I Js
1  40 
£T
30
20
10
0 -
120 140
238.37 2 5 2 4 1  ? 7 p ~ ,
268.30 2 7 9  35  295.36 3 2 3  13 33 7  363.33
220 240 260 280 300 320
m/z
420.44-t-
360 380 400 420
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presumptively identified as GP-tagged 7-dehydrodesmosterol (A) and cholesta-4,6,24-trien- 
3p-ol (B), respectively. The presumptive identifications are made due to the absence of 
authentic standards.
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| 3.3 Conclusion
In this work was identified and quantified a high number of oxysterols and cholesterol 
precursors. The most abundant oxysterol found is an “exit” metabolite of cholesterol -  24S- 
hydroxycholesterol. The other monohydroxysterols found were 25-, 26-, 7a, 7P, 6p - 
hydroxycholesterol. 25-Hydroxycholesterol is implicated in the immune response I" 1331. 
however its role in the brain remains unknown. 26- and 7a-hydroxycholesterol are precursors 
of bile acid biosynthesis, although 7a-hydroxylase is a liver specific enzyme and presence of 
this oxysterol is probably derived from the circulation. In this work was detected and 
quantified the C21-neurosteroid progesterone and its biosynthetic precursors 22R- 
hydroxycholesterol and 20R,22R-dihydroxcholesterol in newborn brain. We confirmed the 
presence of major amounts of the LXR and Insig ligand 24S,25-epoxycholesterol in 
developing nervous tissue [120]. Moreover, a number of oxysterols derived from desmosterol 
were identified. This is the first report of the (24Z),26-hydroxydesmosterol isomer in a 
biological system.
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Chapter 4
4 Analysis of oxysterols in Dhcr7D3-5/T93M mouse brain
4.1 Introduction
Deficiency of 3P-hydroxysterol-D7-reductase (7-dehydrocholesterol reductase, 
DHCR7) in humans is associated with Smith-Lemli-Opitz syndrome (SLOS). This 
autosomal recessive disorder is caused by malfunction of enzyme catalysing conversion of 7- 
dehydrocholesterol into cholesterol in the last step of cholesterol biosynthesis via the 
Kandustch-Russell pathway (Figure 1.2) [195]. Increased levels of the cholesterol precursor
7-dehydrocholesterol, and of 8-dehydrocholesterol as a consequence of DHCR7 inefficiency 
accumulate in tissues and in the circulation and serve as a diagnostic marker IT 961. The 
phenotype includes dysmorphia and mental retardation FI97. 1981. SLOS occurs at a 
relatively high incidence rate varying from 1 in 10,000 to 1 in 60,000. For Caucasian 
populations carrier frequency for mutant alleles may be as high as 1 in 30, but it is probable 
that the condition often goes undiagnosed as patients with a mild disorder may have little 
evident phenotype, while early foetal loss may result in the severely affected [197].
In this work were used brain samples derived from heterozygous animals, containing 
one null allele (deletion of coding exons 3,4,5) and one T93M mutation on Dhcr7, i.e. 
Dhcr7D3-5/T93M f!92. 1991. Homozygous animals die shortly after birth f200. 2011. while 
the animals used in this work carry a hypomorfic mutation and present only a mild 
phenotype.
The mechanisms responsible for formation of the phenotype are still not elucidated. It 
is not clear whether the symptoms are developing as a consequence an accumulation of 7- 
dehydrocholesterol or, perhaps, 7-dehydrocholesterol is subjected to further metabolism 
generating abnormal, toxic compounds. In this study will be analysed the sterol content of the 
brain with disrupted mechanism of cholesterol biosynthesis leading to an accumulation of 7- 
dehydrocholesterol. The compensatory mechanism for reduced synthesis of cholesterol will 
be investigated as well as possible downstream metabolites of 7-dehydrocholesterol.
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4.2 Results
In mammalian brain oxysterols are dominated by the excess of cholesterol. In 
Autoxidation of cholesterol can lead to production of artificial oxysterols at levels 
comparable to those found endogenously. 7-Dehydrocholesterol, a hallmark of SLOS, is 
prone to autoxidation at even higher degree than cholesterol [202]. In order to reduce the risk 
of formation of autoxidation products of these sterols they were separated from oxysterols at 
an early stage of sample preparation via SPE methodology.
Cholesterol and dehydrocholesterols
Dehydrocholesterols oxidised with Cholesterol oxidase and GP charge-tagged give an 
[M]+ ion of m/z of 516.3948. The RIC recorded using a short gradient for this m/z from 
newborn SLOS mouse brain is shown in Figure 4.1 A. The MS3 ([M]+->[M-79]+->) spectrum 
of the major peak eluting at 11.07 min (Figure 4.1 C) shows low mass fragment ions at m/z 
137 (*bi-26) and 151 (*bi-12) characteristic of the GP-derivatised 3-oxo-4,7-diene structure 
[3]. Other characteristic ions include m/z 409 formed by loss of CO group from [M-79]+ ion, 
m/z 394 formed by the additional loss of NH, and m/z 365 corresponding to the carbocation 
of the triply unsaturated sterol. The level of 7-dehydrocholesterol in the brain of the SLOS 
mouse was measured to be 316.49 ± 75.61 ng/mg (n = 4, mean ± SE) Levels of oxysterols 
and sterols are detailed in Table 3.1. and Figure 3.1. As is evident in Figure 4.1 A, a later 
eluting component appears as a shoulder to the peak corresponding to 7-dehydrocholesterol. 
This is identified as 8-dehydrocholesterol (cholesta-5,8(9)-dien-3p-ol) (Figure 4.1 D). The 
MS spectrum is quite different to that of the 7-dehydrocholesterol isomer, showing far less 
intense peaks at m/z 365, 151 and 137, but a more prominent one at m/z 231. The level of this 
isomer was estimated to be 133.58 ± 33.75 ng/mg in SLOS animals. As 8-dehydrocholesterol 
is believed to be formed from 7-dehydrocholesterol [203], their combined abundance, 450.06 
ng/mg, is representative of the immediate cholesterol precursors in the Kandutsch-Russell 
pathway.
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Figure 4.3 Sterols (A) and oxysterols (B) identified in SLOS and wild type mouse brains.
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Unsurprisingly, in light of the requirement of the Dhcr7 enzyme to produce desmosterol via 
the Block pathway the desmosterol level is diminished in the SLOS mouse (130.02 ± 30.01 
ng/mg) compared the wild type (439.66 ng/mg [chapter 3]). In the Block pathway the 
precursor of desmosterol is 7-dehydrodesmosterol. This metabolite following GP-tagging has 
an m/z of 514.3792. Two components from SLOS mouse brain elute with this m/z 
(Figure4.2A). The MS3 spectrum of the component eluting at 10.61 min gives a spectrum 
similar to that of 7-dehydrocholesterol, however m/z values for high mass fragments ions 
were reduced down by two mass units (Figure 4.2B vs. Figure 4. IB). The A and B ring 
fragment ions are identical to those characteristic for the MS3 spectrum of 7- 
dehydrocholesterol (i.e. m/z 137, 151) indicating that the extra unsaturation is elsewhere, 
hypothetically at C-24. The latter chromatographic peak eluting at 11.29 min gives an MS3 
spectrum more in line with that predicted for 8-dehydrodesmosterol (cholesta-5,8(9),24-trien- 
3p-ol) (Figure 4.2CC). However, authentic standards are not available for 7- and 8- 
dehydrodesmosterols to confirm these presumptions. The levels of these two putatively 
identified molecules in the SLOS mouse are 135.75 ± 30.99 ng/mg and 79.04.76 ± 34.31 
ng/mg, respectively. The combined level of 7-dehydrodesmosterol and 8-dehydrodesmosterol 
is 327.51 ng/mg in the SLOS mouse compared to 143.70 ng/mg in the wild type. As was the 
case with immediate precursors of cholesterol in the Kandutsch-Rusell pathway, there is an 
elevation in the level of the immediate precursors of desmosterol in the Block pathway. The 
SLOS mouse is viable, hence retains some Dhcr7 enzymatic activity allowing the formation 
of cholesterol. Its level in the SLOS mouse is 1531.48 ± 240.93 ng/mg compared to 2350.69 
ng/mg in the wild type mouse.
24S,2 5-Epoxy cholesterol and cholesterol and desmosterol derived oxysterols
The availability of cholesterol in the SLOS mouse brain suggests that a normal profile 
of cholesterol derived oxysterols may be observed, but at lower levels than in the wild type 
animal. Similar to the wild type mouse, the pattern of monohydroxycholesterols in the brain 
of the newborn SLOS mouse is dominated by 24S-hydroxycholesterol (Figure 4.4). The 
chromatogram (short gradient) of GP-tagged monohydroxycholesterols (RIC m/z 534.4054) 
shows two closely eluting peaks at 7.36 and 7.67 min identified as syn and anti conformers of 
GP-derivatised 24S-hydroxycholesterol. Both peaks give an identical MS3 ([M]+->[M- 
79]+->) spectrum showing a characteristic triad of low mass fragment ions at m/z 151 (*bi- 
12), 163 (*b3-C2H4 ) and 177 (*b2), and a distinctive ion at 353 (Figure 4.5A). The enzyme 
responsible for the formation of 24S-hydroxycholesterol from cholesterol is cytochrome P450
104
(Cyp in mouse, CYP in human) 46a 1 and is expressed in normal brain exclusively in neurons 
[204]. In the SLOS newborn mouse the concentration o f 24S-hydroxycholesterol in brain was 
determined to be 0.346 ± 0.041 ng/mg. This value is about 70% that found in the wild type 
newborn animal (0.510 ± 0.034 ng/mg \ 1191). This lower level o f  24S-hydroxycholesterol in 
SLOS brain is a reflection o f a lower cholesterol concentration in the SLOS mouse brain than 
in the wild type. Application o f the short chromatographic gradient as utilised in
Figure 4.4A does not fully separate 24S-hydroxycholesterol, 25-hydroxycholesterol 
and 26-hydroxycholesterol making quantification o f the latter two compounds unreliable. To 
resolve this issue we developed a longer chromatographic gradient giving better separation o f 
these isomers (Figure 4.4B).
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Figure 4.5 M S3 spectra o f peaks eluting in long gradient: (A) 17.41 min corresponding to 
24S-hydroxycholesterol (cholest-5-ene-3b,24S-diol); (B) 17.41 min corresponding to 25- 
hydroxycholesterol (cholest-5-ene-3b,25-diol); (C) 19.69 min corresponding to 26-
hydroxycholesterol (cholest-5-ene-3b,26-diol).
A great advantage o f utilising the GP-tag with M S3 fragmentation is that the resulting spectra 
allow isomer differentiation. For example, the M S3 spectrum o f 25-hydroxycholesterol (
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Figure 4.5B) is completely dominated by the fragment ion at m/z 437 resulting from facile 
dehydration o f the [M-79] ion and is quite different from MS spectra o f the other isomers. 
25-Hydroxycholesterol is formed from cholesterol either in a reaction catalysed by 
cholesterol 25-hydroxylase (Ch25h) [8 , 29] or as a side-product o f Cyp46al or Cyp27al 
catalysed hydroxylation o f cholesterol [4 0 7 , 2051. The level o f 25-hydroxycholesterol in the 
SLOS mouse brain was at about the detection limit o f our methodology (0.006 ± 0.002 
ng/mg). 26-Hydroxycholesterol is formed in a Cvp27al catalysed reaction 1471, and in SLOS 
mouse brain the level o f this oxysterol was determined to be 0.025 ± 0 .017  ng/mg (
Figure 4.5C).
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Figure 4.6 MS spectra o f  peaks eluting in long gradient presented in
Figure 4.4B: (A) 17.41 min corresponding to 24R-hydroxycholesterol (cholest-5-ene-
3b,24R-diol) and in short gradient (B) 6.06 min corresponding to 22R-hydroxycholesterol
(cholest-5-ene-3b,22R-diol)
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Figure 4.7 MS3 spectra o f peaks eluting in the short gradient presented in 
Figure 4.4A: (A) 9.59 min corresponding to 7P-hydroxycholesterol (cholest-5-ene-3 p,7p- 
diol), 7a-hydroxycholesterol (cholest-5-ene-3 p,7a-diol) and (C) 10.51 min corresponding to 
6 p-hydroxycholesterol (cholest-5-ene-3 p,6 p-diol)
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As well as finding 24S-hydroxycholesterol in brain, we also find low levels of the 24R- 
isomer (0.048 ± 0.008 ng/mg) (Figure 4.6A). We also identified low levels of 22R- 
hydroxycholesterol (0.010 ± 0.002 ng/mg) giving a peak eluting at 6.06 min in the short 
gradient (Figure 4.6B). This is generated from cholesterol via oxidation by C ypllal 
(P450scc) [206]. The combined levels of the side-chain hydroxycholesterols in the SLOS 
mouse is 0.435 ng/mg, this compares with 0.594 ng/mg in the wide type mouse [13] i.e. 
about 70%.
We also identified monohydroxysterols with hydroxylation in the B-ring at positions 7p-, 7a- 
and 6p (0.244 ± 0.078, 0.132 ± 0.051 and 0.129 ± 0.045 ng/mg respectively, Figure 4.7 A, B 
and C). These are autoxidation products of cholesterol, formed during sample storage or they 
may be formed endogenously by reaction of cholesterol with reactive oxygen species (ROS), 
or alternatively they may be formed extra-cerebrally and cross the BBB from the circulation 
into brain. 6p-Hydroxycholesterol is a formed from 5,6-epoxycholesterol following acid 
hydrolysis and is a subsequent dehydration product [207]. The level of 7-oxocholesterol was 
below the limit of detection and no evidence of 4a- or 4P-hydroxycholesterols was found.
24S,25-Epoxycholesterol is formed in parallel to cholesterol via a shunt of the 
mevalonate pathway. The RIC of m/z 532.3898, the appropriate m/z of the GP-tagged 24S,25- 
epoxycholesterol, from SLOS mouse brain samples revealed two peaks eluting at 6.70 and 
6.96 min corresponding to the syn and anti conformers of GP-tagged 24S,25- 
epoxycholesterol (0.024 ± 0.004 ng/mg) (Figure 4.8A). The MS spectra are shown in Figure 
4.8B. The peak eluting at 7.74 min was identified as GP-tagged 24-oxocholesterol (0.035 ± 
0.006 ng/mg). The presence of a 24-oxo group is characterised by an abundant [M-79-CO]+ 
ion (m/z 425) in the MS3 spectrum (Figure 4.8C). 24-Oxocholesterol is formed from 24S,25- 
epoxycholesterol during derivatisation. Analysis of the newborn SLOS mouse brain also 
revealed a peak with retention time 7.99 min which gave an MS spectrum corresponding to 
GP-tagged 22-oxocholesterol (0.118 ± 0.028 ng/mg) (Figure 4.8D). The peak in the RIC of 
m/z 532.3898 eluting at 7.37 min (0.062 ±0.011 ng/mg) presumptively identified as to GP- 
tagged 23-hydroxydesmosterol f 1191. The MS3 ([M]+-^[M-79]+->) spectrum being is 
completely dominated by the [M-79-H20]+ ion at m/z 435 (Figure4.8A) and an [M]+->[M- 
97]+-> MS3 spectrum indicating that the facile hydroxyl group is located a to the side-chain 
double bond in desmosterol.
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Other compounds identified in the SLOS new bom mouse brain include (24Z)26- 
hydroxydesmosterol eluting at 7.11 min (0.016 ± 0.003 ng/mg (Figure4.8B). Close inspection 
of the RIC m/z 532.3898 reveals further peaks at 8.62 and 9.34 min that give MS3 spectra 
compatible with GP-tagged 70- and 7a-hydroxydesmosterols, respectively (0.024 ± 0.005 
ng/mg and 0.027 ± 0.013 ng/mg), although authentic standards are not available to confirm 
the identification. These oxysterols could possibly be formed in Cyp7al catalysed reactions 
with desmosterol as the substrate, or via ROS or autoxidation [190].
24S,25-Epoxycholesterol is unstable in acid solution and is susceptible to both 
hydrolysis and methanolysis during the derivatisation process [120]. The RIC of m/z 
550.4003 (Figure 4.10A), appropriate for the hydrolysis product, revealed two peaks eluting 
at 3.84 min and 4.51 min identified as the syn and anti conformers of GP-tagged 24,25- 
dihydroxycholesterol (0.598 ± 0.128 ng/mg). The MS3 spectra are presented in Figure 4.10B. 
Close inspection of the RIC for m/z 550.4003 shown in Figure 4 .10C reveals a shoulder on 
the leading edge of the peak at 4.51 min.
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Figure 4.8 RIC for m/z 532.3898 from newborn SLOS mouse brain following GP charge-
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tagging using the short gradient. MS spectra o f peaks eluting in (A) 6.70 min corresponding 
to 24S,25-epoxycholesterol (24S,25-epoxycholest-5-ene-3(3-ol), (B) 7.74 min corresponding 
to 24-oxocholesterol (24-oxocholest-5-ene-3p-ol), (B) 7.99 min corresponding to 22- 
oxocholesterol (22-oxocholest-5-ene-3p-ol).
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Figure 4.9 MS3 spectra o f peaks eluting in the short gradient presented in Figure 4.8A: (A) 
7.37 min corresponding to 23-dehydrocholesterol (cholest-5,24-diene-3p,23-diol), (B) 7.11 
min corresponding to (24Z)26-hydroxydesmosterol ( c h o l e s t - 5 , 2 4 - d i e n e - 3 p , ( 2 4 Z ) 2 6 - d i o l ) ,  (C) 
8.62 min corresponding to 7p-hydroxydesmosterols (cholest-5,24-diene-3p,7P-diol) and (D) 
9.34 min corresponding to 7a-hydroxydesmosterols (cholest-5,24-diene-3p,7a-diol).
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Figure 4.10 RIC for m/z 550.4005 from newborn SLOS mouse brain following GP charge- 
tagging using the short gradient (A). M S 3 spectra o f a doublet eluting in (B) 3.84 min and 
4.57 min corresponding to 24,25-dihydroxycholesterol (cholest-5-ene-3p,24,25-triol) and (C) 
M S 3 spectrum corresponding to 20R,22R -dihydroxycholesterol (cholest-5-ene-3p,20R,22R- 
triol)
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The MS spectrum suggests the presence of 20,22-dihydroxycholesterol (0.024 ± 0.007 
ng/mg).
Analysis of the RIC of m/z 564.4160 showed two peaks with retention times and MS 
fragmentation characteristic for the methanolysis product of 24S,25-epoxycholesterol. The 
level of the methanolysis product in SLOS brain was determined to be 0.297 ±0.103 ng/mg. 
The combined concentration of native 24S,25-epoxycholesterol, its isomer 24-oxocholesterol, 
its hydrolysis product 24,25-dihydroxycholesterol and its methanolysis product 24-hydroxy- 
25-methoxycholesterol equals to 0.920 ng/mg. Considering that the level of cholesterol in the 
newborn SLOS mouse is only about 60% that of the wild type, it was expected that the
24S,25-epoxycholesterol ratio between the mice would give a similar percentage. In fact, the 
level in the SLOS mouse is about 80% of that in the wild type. One plausible explanation for 
the higher than expected level of 24S,25-epoxycholesterol in the SLOS mouse is the down 
regulation of Cyp7bl, the enzyme responsible for 24S,25-epoxycholesterol metabolism. 
Bjorkhem et al have noted down regulation of CYP7B1 in human SLOS patients [2].
7-Dehydrocholesterol derived oxysterols
Studies of developing mouse embryos from another SLOS mouse model, the Dhcr-7-KO 
reported presence of three novel monohydroxydehydrocholesterol isomers [31;32]. These 
were identified by high performance (HPLC) purification and NMR analysis as 4a-, 4p- and
24-hydroxy-7-dehydrocholesterols [32]. In our SLOS mouse model these three novel 
metabolites may account for the late eluting peaks in the of RIC m/z 532.3898 (Figure 4.8A). 
The components eluting at 9.66 and 10.12 min both give MS3 ([M]+-^[M-79]+->) spectra 
compatible with an A/B ring system containing two double bonds, and an extra alcohol group 
(besides that at C-3 oxidised here by cholesterol oxidase to a 3-oxo group), possibly the 4a- 
and 4p-hydroxy-7-dehydrocholesterol isomers reported by Xu et al (0.168 ± 0.039 ng/mg 
Figure 4.11 A and B. No authentic standard is available for these isomers. The latest eluting 
peak (10.49 min) gives a spectrum indicative of GP-tagged cholest-4-ene-3,6-dione (0.040 ± 
0.012 ng/mg, Figure 4.11C). No evidence was found for a metabolite giving MSn spectra 
appropriate to 24-hydroxy-7-dehydrocholesterol.
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Figure 4.11 M S3 spectra o f peaks eluting in the short gradient presented in Figure 4.8A: (A) 
9.66 min corresponding to 4a-hydroxy-7-dehydrocholesterol (cholest-5,7-diene-3p,4a-diol), 
10.12 min corresponding to 4[3-hydroxy-7-dehydrocholesterol (cholest-5,7-diene-3p,4p-diol), 
10.49 min corresponding to cholest-4-ene-3,6-dione
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Figure 4.12 RIC for m/z 548.3847 from newborn SLOS mouse brain following GP charge- 
tagging using the short gradient (A). M S 3 spectra o f peaks eluting at (B) 8.41 min and (C) 
9.07 min possibly both corresponding to 3b,5a-dihydroxycholest-7-en-6-one and (D) 10.12
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min probably corresponding to an additional dihydroxycholestenoneisomer. In the absence of 
authentic standards these identifications are presumptive.
Xu et al also identified 3p,5a-dihydroxycholest-7-en-6-one in the brain extract 
from embryonic Dhcr-7-KO mouse and suggested its formation was through 5a,6a- 
epoxycholest-7-en-3p-ol and subsequently cholest-7-en-3p,5a,6p-triol [32]. Oxidation by 
cholesterol oxidase and GP tagging 3p,5a-dihydroxycholest-7-en-6-one will give an [M]+ ion 
at m/z 548.3847.
The RIC for this mass from brain extracts of our Dhcr7 A3*5/T93M SLOS mouse is 
shown in Figure 4.12A. The chromatogram shows a large number of late eluting analytes. 
The MS3 spectra of three distinct compounds are shown in Figure 4.12B-D. The components 
eluting at 8.41 (in Figure 4.12B) and 9.22 min give a similar pattern of MS3 fragment ions 
dominated by successive losses of 18 Da (H2 O), 28 Da (CO) and 46 Da (H2 O+CO) from the 
[M-79]+ ion. The pattern indicates the presence of a free hydroxy and a carbonyl group 
attached to the sterol skeleton. The spectra are compatible with that predicted for GP tagged 
3p,5a-dihydroxycholest-7-en-6-one following treatment with cholesterol oxidase where the 
GP-tag is on C-6, with the two chromatographic peals corresponding to the syn and anti 
isomers (0.299 ± 0.042 ng/mg). Likewise, the components eluting at 9.07 (in Figure 4.12C) 
and 9.59 min give similar MS3 spectra, this time dominated by the loss of 18 Da (H2 O) and 
46 Da (H2 O+CO) from the [M-79]+ ion, with only a minor loss of 28 Da (CO). Following 
treatment with cholesterol oxidase 3p,5a-dihydroxycholest-7-en-6-one is converted to 5a- 
hydroxycholest-7-ene-3,6-dione and this latter pair of peaks probably correspond to syn and 
anti confirmers of the molecules with the derivatising group at C-3 (1.343 ± 0.368 ng/mg). 
The final major peak at m/z 10.10 min gives a different MS3 spectrum to that of the earlier 
isomers, but the parent structure is not immediately obvious (0.602 ± 0.266 ng/mg, in Figure 
4.12D).
4.3 Discussion
Cholesterol and desmosterol levels were reduced in the SLOS mouse compared to the 
wild type, while their respective precursors 7-dehydrocholesterol (and 8-dehydrocholesterol) 
and 7-dehydrodesmosterol (and 8-dehydrodesmosterol) were increased. This findings are in a 
good agreement with studies by Marcos et al and Correa-Cerro et al who also observed a 
reduction in cholesterol and an elevation in DHC in one day old SLOS mouse brain [9; 10].
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It is not clear how the mutation in DHCR7 results in the characteristic SLOS 
phenotype. A lack of cholesterol (or desmosterol) during development may account for the 
features like dysmorphia and mental retardation. It is also feasible that a decreased level of 
cholesterol metabolites required for normal development or a build up of toxic metabolites of 
7-dehydrocholesterol (and/or 7-dehydrodesmosterol) is responsible for the formation of 
SLOS symptoms.
The analysis of sterolome of SLOS mouse showed a decreased the level of essentially 
all cholesterol-derived, enzymatically-formed oxysterols, in particular the dominating brain 
oxysterol 24S-hydroxycholesterol (reduced to about 70% of the wild type) (Fig. 7). This is 
not surprising as 24S-hydroxylation is an “exit” route for the cholesterol, and in reduced 
supply of this sterol its metabolism is also diminished [34]. In the SLOS mouse total amount 
of 24S,25-epoxycholesterol was also reduced compared to the wild type, although not to 
significance.
A C /T O lX y f
In conclusion, in newborn brain from the Dhcr7 ' mouse model of SLOS there is a 
reduced level of cholesterol and desmosterol and elevated level of 7-dehydrocholesterol and 
7-DHD. In concert to the reduction in cholesterol there is also a reduction of cholesterol 
derived oxysterols, but an elevation in 7-dehydrocholesterol derived oxysterols. It is not clear 
at present whether these latter oxysterols are formed by autoxidation, via ROS, or 
enzymatically.
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Chapter 5
5 Profiling of sterol content of Cyp46al -/- mouse brain
5.1 Introduction
Cholesterol accounts for the 2% of the mass of mouse brain f851 making the brain the 
most cholesterol-rich organ in the body. Although only a fraction of this pool is 
physiologically active, it still requires an efficient turnover mechanism. Cholesterol cannot 
cross blood brain barrier, but its 24S-hydroxylated derivative is membrane permeable and 
readily passes to the blood stream. This hydroxylation is mainly provided by cholesterol 
hydroxylase Cyp46al, an endoplasmatic enzyme which belongs to the family of cytochrome 
P450 monooxygenases [208]. In mouse the enzyme is predominantly expressed in the brain, 
and to a lesser extent, in the testis and liver [29]. Cyp46al preferably hydroxylase 24S 
position of cholesterol, but 25-hydroxylase activity is also detected [2081. In the circulation, 
24S-hydroxycholesterol is a substrate for hepatic enzyme Cyp7bl, which initiates conversion 
of this oxysterol into bile acid, which is excreted from the body.
Apart from serving as an exit routE for cholesterol, 24S-hydoxycholesterol is 
involved in cell signalling as a potent ligand to Liver X Receptors (LXR) [173. 209. 2101. 
LXRs, both isoforms a  and (3, are expressed in the brain where they regulate cholesterol 
metabolism and trafficking f211. 2121.
Transgenic mice with knockout mutation were created in the Me Donald’s laboratory 
by replacing a fragment of the first exon of Cyp46al with a terminal sequence of bovine tau 
protein coupled to bacterial P-galactosidase gene IT 061. Obtained mutants did not present 
phenotype, moreover, the weight of main organs such as liver, brain and adrenal gland was 
not differing from the wild type mice. Although there were no physical symptoms, the 
deficiency of Cyp46al adversely affected spatial, associative and motor learning as well as 
long term potential (LTP) of hippocampal neurons [2131.
Basic biochemical analysis showed the absence of 24S-hydroxycholesterol with 
normal levels of cholesterol. The inhibition of cholesterol metabolism was compensated by 
decreased cholesterol synthesis reflected by reduced levels of its precursor, desmosterol.
In this work we present more comprehensive profile of cholesterol derivatives aiming 
to get a better understanding of the effect of the Cyp46al knockout on the lipidome.
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5.2 Results
Cholesterol has a relatively low polarity, therefore it elutes from the first SPE column 
in fraction SPE1-Fr3 and from the second column in fractions SPE2-Frl,2,3. Upon ionisation, 
GP-derivatised generated a molecular ion o f m/z 518.4105. Figure 5.1 presents chromatogram 
for GP-derivatised cholesterol extracted from Cyp46al-/~ mouse brain, the M S 3 
fragmentation pattern is shown in Figure 5.2. Analysis o f these sterol fractions unsurprisingly 
revealed a high level o f cholesterol (-16  pg/mg), similar in knockout and wild type animals.
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Figure 5.2. MS spectrum o f peak eluting at 12.85 min identified as GP-tagged cholesterol
The quantification o f cholesterol precursor - desmosterol showed a variation between 
Cyp46al +/+  and Cyp46al-/~, where knockout mice had reduced level by 50% (0.104 pg/mg 
and 0.057±0.004 pg/mg) (RIC and MS3 spectrum showed in Figure 5.4 and Figure 5.5). The 
detailed levels o f sterols are shown in Table 5.1.
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Figure 5.3 Sterols (A ) and oxysterols (B) identified in C yp46al /_ and wild type m ouse brains.
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Figure 5.5. MS spectrum o f compound eluting at 11.33 min identified as GP-tagged 
desmosterol
The wild type mouse chromatogram is completely dominated by GP-tagged 24S- 
hydroxycholesterol (27.9069±0.7322 ng/mg, Table 5.2) which, following derivatisation, 
gives two peaks corresponding to the syn and anti conformers of the GP-derivative, RT 7.49 
min and 7.80 min. The MS3 chromatogram is showed in Figure 5.7. In the Cyp46al-/~ mouse 
the deletion o f Cyp46al gene results in a great reduction in the level o f 24S- 
hydroxycholesterol in brain (Table 5.2). The almost complete depletion o f the sample from 
this major oxysterol allows the injection o f greater amounts of material on-column without 
risking column overloading. As a consequence, the sensitivity o f the analytical method 
increases from 50 pg/mg to 5 pg/mg. Interestingly, low levels o f 24S-hydroxycholesterol
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(0.0173±0.0025 ng/mg) are still observed in brain of the Cyp46al-/~ mouse as revealed in the 
RIC of 534.4054 for the GP-tagged hydroxycholesterols . The origin of this oxysterol may be 
from extracerebral synthesis or from other cholesterol hydroxylases present in brain e.g. 
cholesterol 27-hydroxylase, Cyp27al IT 06. 177. 1821.
Murine brain also contains another isomer of 24-hydroxylated cholesterol, 24R- 
hydroxycholesterol (MS spectrum presented in Figure 5.8 ). In brain of the Cyp46al-/~ 
mouse present at the level 0.1598±0.0228 ng/mg, while in wild type animal, putative 24R- 
hydroxycholesterol was dominated by its 24S isomer and, therefore, not reliably quantifiable. 
24R-Hydroxycholesterol could conceivably be formed from desmosterol in a hydration 
reaction catalysed by D-bifunctional protein (DBP), a multifunctional enzyme expressed in 
brain, although the hydratase domain of this stereospecific enzyme usually forms (R)- 
hydroxy-acyl-CoA intermediates from trans-2-enoyl-CoAs [45]. Alternatively, a mouse 
microsomal Cyp3a enzyme has be shown to be a hepatic 24R-hydroxylase to 5p-cholestane- 
3a,7a,12a,25-tetrol and could have some activity towards cholesterol [214], or the source of 
24R-hydroxycholesterol may be some other cholesterol hydroxylases present in brain e.g. 
Cyp27al f 1771. In knockout mouse it may be expected that some other oxysterol would 
compensate the absence of Cyp46al from brain, however, in agreement with earlier studies 
f 1061 there was no matching increases in the abundance of any other oxysterol.
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Figure 5.6. Monohydroxylated GP derivatives o f cholesterol in brain o f Cyp46al + /+  (A) and 
Cyp46al-/~ (B) mouse brain.
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Figure 5.7. MS3 spectrum o f peak eluting at 7.49 min identified as GP-tagged 24S- 
hydroxycholesterol
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Figure 5.8. MS spectrum of peak eluting at 7.49 min identified as GP-tagged 24R- 
hydroxycholesterol
GP-Tagged 26-hydroxycholesterol (Figure 5.9) was identified at relatively low levels 
of in wild type mice 0.3342±0.1327 ng/mg, while in the knockout mice these were 
0.1485±0.0060 ng/mg. In the chromatogram o f wild type mouse brain 27-hydroxycholesterol 
is eluted closely to 24S- and 24R-hydroxycholesterol, therefore the integration and 
quantification o f 27-hydroxycholesterol peak is biased.
bram_ko1_s1 *100ng24ohcd6_ 100602_05 21/09/2010 13.38:50 (Fr1a/Fr1 ♦Fr2)6O%M0OH. 0.1 %FA (3pg/ii 24ohcd6)
brain k0 1 s i  ♦I00ng24ohcd6 100602 05#467  RT: 8 04 AV. 1 NL 1 09E2 
F: 1TMS * c ESI Full ms3 534 41@ cid30 00 455 36@ cid35.00 (125.00-550.00]
297.21 
2802 7 309.50 380.30L
140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460
Figure 5.9. MS spectrum o f GP-tagged 26-hydroxycholesterol eluting as a peak o f RT 8.04 
min
Also trace amounts o f 25-hydroxycholesterol was detected at very low level in 
knockout type mice: 0.0502±0.0094 ng/mg while in the wild type these were quantified at 10-
128
fold higher levels (0.7696±0.1029ng/mg), MS' spectrum presented in Figure 5.10. In the 
knockout chromatogram the absence o f major analyte 24S-hydroxycholesterol reveals peaks 
belonging to the other compounds, therefore its quantification is more reliable. Cholesterol
25-hydroxylse (ch25h) and Cyp27al are both expressed in rodent brain and will generate 25- 
and 26-hydroxycholesterols respectively [ 108, 1771.
1 00
95
90
85
80
75
70
65
sc 60
■oc 55
■O
< 50
4b
a . 40
35
30
25
2 0
15
10
5
0
187 28  205  17 217 14 240 16
' 'I '
285  35 311 .29  3 2 5  5 5 3 8 1 2 0  3 9 4  2 5
400
Figure 5.10. MS3 spectrum of peak eluting at 7.63 min identified as GP-tagged 25- 
hydroxycholesterol
Ring-hydroxylated sterols such as 7a- and 7(3-hydroxycholesterol (MS spetra 
presented in Figure 5.11 and Figure 5.12, respectively) were detected in some analytical runs 
o f Cyp46al-/~ (<0.050 ng/mg), in wild type animals the levels of 7a- and 7p- 
hydroxycholesterols were significantly higher (0.0401 ±0.0525 and 0.1834±0.2425 ng/mg, 
respectively). It is likely that 7a- and 7p-hydroxycholesterols are imported into brain from the 
bloodstream as C yp7al, the cholesterol 7a-hydroxylase, is liver specific, while 7P- 
hydroxycholesterol can be of a non-enzymatic source arising from cholesterol autoxidation 
[185, 215]-
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Figure 5.11. MS3 spectrum of peak eluting at 10.18 min identified as GP-tagged 7a- 
hydroxycholesterol.
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Figure 5.12. MS3 spectrum of peak eluting at 9.59 min identified as GP-tagged 70- 
hydroxycholesterol.
The final eluting oxysterol from the RIC o f 534.4054 corresponds to 6(3- 
hydroxycholesterol (M S3 spectrum in Figure 5.13); in wild type these were below the 
detection level, while in Cyp46al-/~ animal were quantified as 0.0527±0.0690 ng/mg. This is 
derived from either cholestane-3[3,5a,6P-triol or a 5,6-epoxycholesterol during the charge- 
tagging process.
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Figure 5.13. M S 3 spectrum o f peak eluting at 10.53 min identified as GP-tagged 60- 
hydroxycholesterol.
There are also low levels o f a side-chain hydroxylated sterol, probably the 25S isomer 
o f 26-hydroxycholesterol (0.0283±0.0048 and 0.0302±0.0353 ng/mg) present in the wild type 
and C y p 4 6 a l '  brain. There is evidence that cholest-(25S)-5-en-30,27-diol is formed from 
cholesterol by a microsomal enzyme in contrast to the mitochondrial Cyp27al enzyme which 
gives the 25R isomer [2161.
Table 5.2 lists the levels o f detected metabolites. The identification o f oxysterols was 
confirmed by comparison o f accurate mass, retention time and MSn spectra with authentic 
standards (Figure 5.14).
24S,25-Epoxycholesterol is produced as a side product o f the cholesterol biosynthesis 
pathway. During the GP-tagging reactions the 24S,25-epoxide isomerises to the 24-ketone, is 
hydrolysed to the 24,25-diol and undergoes methanolysis to the 24-ol-25-methoxide and/or
24-methoxide-25-ol (Figure 5.14-Figure 5.18). Each of this products was quantified 
separately, the total sum of the compounds is considered as a final concentration o f 24S,25- 
epoxycholesterol, which was higher in wild type mice (0.6411±0.0155 ng/mg and 
0.1235±0.0435 ng/mg; in wild type and Cyp46al-/~, respectively).
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Figure 5.15. M S3 spectrum of peak eluting at 7.97 min identified as GP-tagged 24S,25- 
epoxycholesterol.
132
R
el
at
iv
e 
A
bu
nd
an
ce
100
95
90
85
80
75
70
65
60
55
50 1 51.1  163.1
45
40
4 1 0 .4
35
30
25
4 0 8 .3
15
10 2 2 3 .0186 .3 32 5 .4 3 8 2 .8133 .2 4 3 5 .22 3 7 .2  2 5 5 .5 3 5 5 .32 8 9 .6  308 .82 1 3 .3 3 9 2  1
3 5 0 .3
4 5 0 5 5035 0 4 0 0 5001 50 200 2 5 0 3 00
Figure 5.16. MS3 spectrum of GP-tagged 24-ketocholesteroleluting at 7.92 min.
RT: 0 0 0 -  15 99 
100- 
95 
90 
85 
80 
7 5 ;
70-3 
65
s 60;
•5 55
1 5 0  
|  45 
©
x  40 
35H  
30 
25 
20 } 
15 
"0  -
Time (min)
NL: 3 .88E 3
m/z= 550  3948-550  4058  F 
FTMS + p ESI Full m s 
[400.00-605.00] MS CIS 
B rain_W T1_S1 + 
100ng24ohcd6+ 
100ug-cd7_100511_07
Figure 5.17. RIC o f m/z 550.4005 showing GP derivatives o f 24,25-dihydroxycholesterol in 
Cyp46al + /+  mouse brain.
133
453 5
©
-S
-C
55
a  40
35
30
443.5
25
20
15
425 510 454.24 1 0 4233.31 6 3 2
151 3 1 7 7 2  1 9 5 4  2 1 7 .,
367 3 4 0 7 3  
3 78  6  396 5
2 9 7 5
325 5 339 32 5 7 3
500350 450 550150 200 250 300 400
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Cytochrome P450 l l a l ,  also known as P450scc, is expressed in rodent brain f 174, 
1831. In the first step this enzyme hydroxylates cholesterol at C-22R, and then at C-20R to 
give the diol, followed by the cleavage o f the C-20 -  C-22 bond to reveal pregnenolone. Low 
levels o f both 22R-hydroxycholesterol (1 pg/mg±0.49pg/mg) RT6.80min and 20R,22- 
dihydroxycholesterol (29 pg/mg) are evident in the Cyp46al-/~ animals. As in the wild type 
animal low levels o f 24S,25-epoxycholesterol are found in brain from the Cyp46al-/- animal 
appearing as the GP-tagged epoxide, its 24-oxo isomer and methanolysis and hydrolysis 
products (127 pg/mg) (Figure 5.16- Figure 5.18).
Despite the absence o f appreciable amounts o f 24S-hydroxycholesterol or of a major 
replacement oxysterol in the brain o f Cyp46al-/- mouse, the level o f cholesterol is essentially 
identical to that o f the wild-type mouse (Table 5.1, Figure 5.2). This is in agreement with 
earlier studies which showed that knockout o f the Cyp46al gene in mice does not reduce the 
brain cholesterol level only its rate o f synthesis f 1061. This hypothesis is further supported in 
the present study where reduction o f desmosterol levels are noted in the Cyp46al mouse 
(Figure 5.4).
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5.3 Discussion
24S-Hydroxylation is the main enzyme involved in metabolism of cholesterol in the 
brain and in mouse accounts for about 70% of cholesterol turnover F1051. Unexpectedly, a 
consequence of deletion of the Cyp46al gene in the cholesterol 24-hydroxylase knockout 
mouse was a reduction in the rate of cholesterol biosynthesis rather than an its accumulation 
in the brain [106]. The deletion of cholesterol 24S-hydroxylase results in removal of the most 
abundant metabolite unveiling less pronounced compounds which in wild type animal would 
be obscured by 24S-hydroxycholesterol. This aim of this study was to unveil an alternative 
routes of cholesterol removal in the absence of Cyp46al. However, the sterols extracted form 
the brain of Cyp46al deficient animal did not exhibit the increase in its level which would 
compensate for the loss of cholesterol 24S-hydroxylase. The steady level of cholesterol is 
maintained via reduction of its production rather than an alternative route of exertion.
In the lipid extracts of brain Cyp46al-/~ mouse low levels of both 24S- and 24R- 
hydroxycholesterols were found (Table 5.2). The origin of these oxysterols are not defined as 
there are few references to the presence of 24R-hydroxycholesterol in mammals. Work of 
Spencer and colleagues have shown that this isomer can be formed enzymatically from 
24R,25-epoxycholesterol by Dede cells and by rat liver homogenate [2J_7]. However, 24R,25- 
epoxycholesterol is not the natural 24,25-epoxide formed via the shunt of the mevalonate 
pathway in mammals F2181. In the brain of the Cyp46al-/~ mouse we also detected a small 
quantities of (25R),26-hydroxycholesterol and of an isomer which is probably (25S),27- 
hydroxycholesterol. While Cyp27al, the microsomal (25R),26-hydroxylase, is expressed in 
brain [177], a microsomal (25S),27-hydroxylase is expressed in mammalian liver [208]. 25- 
hydroxycholesterol in chromatograms acquired from the wild type brain is almost entirely 
dominated by closely eluting 24S-hydroxycholesterol [123, 1481. However, in the absence of 
the Cyp46al gene the presence of 25-hydroxycholesterol (50 pg/mg) in brain is evident.
25-Hydroxycholesterol has been recently intensively studied for its function in the 
immune system [44, 1301. A number of reports show that it is produced and secreted by 
macrophages in response to TLR activation U29. 130, 1351.
Cyp7al is a liver specific enzyme catalyzing a reaction of 7a-hydroxylation of 
cholesterol [245], so detected 7a-hydroxycholesterol in brain is probably a consequence of 
diffusion of this oxysterol across the blood brain barrier from the circulation. Cholesterol can 
become also oxidized on its tetracycling core forming analytes such as 7a- and 7p- 
hydroxycholesterols IT 861. This may be arise from oxidative stress [2191, or can be generated
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during sample preparation f 1851 Similarly, the 5a and 5p isomers of 5,6-epoxycholesterol are 
formed from cholesterol non-enzymatically [1861.
Unlike Cyp7al, Cyp7bl, the oxysterol 7a-hydroxylase, is expressed in the brain [220, 
221]. Here we obtain evidence for the presence of this enzyme in brain with the identification 
of 7a,26-dihydroxycholesterol, the 7a-hydroxylation product of 26-hydroxycholesterol.
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Chapter 6
6 Analysis of oxysterols and sterols from Cyp27al -/- mouse brain
6.1 Introduction
Cerebrotendinous Xanthomatosis (CTX) is an inborn error of cholesterol metabolism 
resulting in an impaired synthesis of bile acids. Clinical symptoms of the disorder include 
accumulation of sterols in tendons and brain (xanthomas), atherosclerosis, mental retardation, 
ataxia and cataracts [222], CTX was first described by van Bogaert in 1937 [2] while the 
genetic defect underlying the disease was identified in 1991 by Cali [223].
CTX is caused by a recessive mutation in the gene coding the mitochondrial 
cytochrome P450 enzyme sterol 27-hydroxylase (CYP27A1). This hydroxylase catalyses the 
initial step in the “alternate” bile acids biosynthesis pathway where cholesterol is 
hydroxylated at the C-26 position and subsequently transformed into chenodeoxycholic acid. 
The “classical” bile acid pathway also requires 26-hydroxylation of the intermediates to 
produce cholic acid. CYP27A1 is also involved in the hydroxylation of a number of other 
substrates such as vitamin D3 f224-2261.
The CYP27A1 gene is located on the long arm of human chromosome 2 [223]. The 
genetic alterations underlying CTX include deletions, insertions, mis-sense and non-sense 
mutations that affect various regions of the CYP27A1 gene [227. 2281.
There is a significant variation between clinical symptoms of CTX which do not correlate 
with the genotypes of the patients. This implies the possible role of other factors in the 
development of CTX [229].
Biochemical analysis of samples from CTX patients show that the general pool of bile 
acids is reduced in particular chenodeoxycholic acid is almost completely absent. 
Furthermore their blood has an increased concentration of cholestanol and normal to 
increased level of cholesterol f2301 and altered ratios of cholesterol precursors [231]. 
Analysis of urine and shows abnormal multihydroxylated alcohols [232, 2331.
A murine model of CTX has been constructed by replacing the 71 bp fragment of 
Cyp27al that encodes the heme-binding region of the hydroxylase with a neomycin 
resistance gene cassette. This region is believed to be essential for the catalytic activity of the 
enzyme [2341.
Unlike patients affected by CTX, the knock-out (Cyp27ar/_) mice, do not show the 
features characteristic for CTX such as xanthomas. Despite missing the main phenotypical 
features of human CTX, the knockout mice still develop abnormal levels of cholesterol 
precursors and metabolites f214. 235-2371.
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The deletion of Cyp27al causes a compensatory increase in the expression of Cyp7al 
catalyzing the first step of the classical pathway of bile acid synthesis and Cyp3a which is 
responsible for side-hydroxylation of oxysterols [214]. Upregulated expression of enzymes is 
followed by an increase in the level of their products detected in blood and plasma. Analysis 
of the tissues shows a high content of 7a-hydroxycholesterol and side-chain hydroxylated 
sterols.
In this study we focused on a detailed analysis of the oxysterols extracted from the 
brains of Cyp27ar/_ homozygous mice. A study carried out by Ogundare et al IT 671 showed 
the presence of bile acid precursors in human cerebrospinal fluid, here is further investigated 
a possibility that brain has autonomous bile acid synthesis pathways. This analysis of the 
mouse brain lipidome aims to identify the disturbances in the oxysterol formation that may 
affect the formation of bile acids in this organ.
6.2 Results 
Sterols
Cholesterol treated with cholesterol oxidase and subjected to GP-derivatisation yields 
an [M]+ ion of m/z of 518.4105. A chromatogram obtained for the analysis of fraction 3a at 
m/z 518.4105 showed a single peak with a RT of 11.75 min (Figure 6.1 A and B); this was 
identified as cholesterol by the comparison with the authentic standard. The deletion of 27- 
hydroxylase does not affect the level of cholesterol in the brain (16.90±0.29ug/mg in wild 
type and 16.98±0.96ug/mg in knockout, as per Table 6.1).
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Figure 6.1 Cholesterol in brain of Cyp27al-/- mouse.
(A) RIC o f m/z 5 18.4105±5 ppm
(B) MS3 spectrum o f peak eluting at 11.75min identified as GP-tagged cholesterol
Cholesterol can be synthesised by two pathways that use different unsaturated sterols in the 
finals step: either desmosterol or 7-dehydrocholesterol. Sterols with two C-C double bonds 
derivatised with GP give a molecular ion m/z 516.3948.
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Figure 6.2 Desmosterol in brain o f Cyp27al mouse.
(A) RIC o f m/z 516.3948±5 ppm
(B) MS3 spectrum o f peak eluting at 10.82min identified as GP-tagged desmosterol
Analysis o f  RIC at m/z 516.3948 shows two peaks with RT 10.82min and 11.41 min. Based 
on the comparison with an authentic GP-tagged standard, the peak at 10.82 min was 
identified as desmosterol (Figure 6.2). Level in C y p 2 7 a l"  animals was established as 
0.0377±0.0012 ug/mg, in comparison, more was detected in wild type 0.0630±0.0048ug/mg.
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Figure 6.3 Oxysterols identified in fraction la  o f Cyp27al and C yp27aT /+ mice brains 
extracts. Charge-tagged with GP-hydrazine oxysterols identified by LC-ESI-MS0.
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Figure 6.4 Oxysterols identified in fraction lb  o f C y p 2 7 a f ' and C yp27al+/+ mice brains 
extracts..
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Figure 6.5 8(9)-Dehydrocholesterol in brain o f C yp27al' mouse.
(A) RIC o f m/z 5 16.3948±5 ppm
(B) M S3 spectrum o f peak eluting at 11.41 min identified as GP-tagged 8(9)- 
dehydrocholesterol
The second peak in the chromatogram of m/z 516 eluted at RT 11.41 min (Figure 6.5). 
Analysis o f the spectrum and comparison with an authentic standard identified this compound 
as 8(9)-dehydrocholesterol. In KO mice the concentration is 0.0543±0.0011 pg/mg, while in 
WT 0.0116=1=0.0012 pg/mg.
Conversely to sterols with 3p-hydroxy-5-en group which can be only detected after 
the treatment with Cholesterol oxidase, sterols naturally possessing an oxo group can be 
derivatisation in the absence o f the enzyme. We analysed fraction 3b where the derivatisation 
was carried out without the enzymatic oxidation; RIC o f m/z 518 showed a peak at RT 11.98 
min (Figure 6.6), which we identified as cholest-4-en-3-one at concentration 1.3013±0.8154 
pg/mg in the knockout and 0.1722±0.0587 pg/mg in the wild type mice. The slight retention 
time shift in comparison with Figure 6.1 was a consequence o f analysis being performed in 
different analytical batches.
Sterols possessing an oxo group and two unsaturated bonds, after derivatisation with 
GP reagent are detected at m/z ratio o f 516.3948. The RIC showed a peak at 11.65 min
T /  •present only in Cyp27al deficient animals. The MS spectrum of m/z 516 contains 
dom inating ions o f m/z 409 and m/z 394 and low intensities ions o f m/z 137, m/z 231, m/z 247 
m/z 325 and m/z 365. Comparison o f MS3 spectrum with authentic standards o f cholesta-4,6-
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dien-3-one and cholesta-4,8(9)-dien-3-one suggests that the analyte is a mixture o f the above 
substances. Fragment ions o f m/z 409 and m/z 394 dominate the spectra o f both standards. 
Ions o f m/z 247 and 365 are present in the M S3 spectrum o f cholesta-4,6-dien-3-one, while 
ions m/z 137, m/z 231, m/z 325 and m/z 365 are in MS3 spectrum o f cholesta-4,8(9)-dien-3- 
one. The standards elutes at very similar times (relative retention times 0.975 and 0.974, 
respectively) therefore this method is not sufficient to separate these analytes.
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Figure 6.6 Cholestadien-3-one mixture in brain o f Cyp27aF ‘mouse.
(A) RIC o f m/z 5 16.3948±5 ppm
(B) MS3 spectrum of peak eluting at 11.41 min identified as a mixture o f GP-tagged 7- and 
8(9)-dehydrocholesterols
Oxysterols
245.25-Epoxycholesterol is produced by the shunt pathway o f cholesterol biosynthesis [2181. 
This oxysterol is present at a high concentration in the developing nervous tissues f 1201 and 
has been implicated the development o f the brain[J_2JJ.
GP derivatised 24S,25-epoxycholesterol has a m/z ratio 532.3898. However, due to chemical 
labiality this oxysterol is degraded during sample preparation and can be transformed into
24.25-dihydrocholesterol (m/z o f GP derivatised 550.4003), 24-methoxy,25- 
hydroxycholesterol or 24S-hydroxy,25-methoxycholesterol (m/z o f GP derivatised 564.4106) 
or 24-oxocholesterol (m/z o f GP derivatised 532.3898) f 1201. The total level o f this oxysterol
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was determined to be 1.2624±0.0711 ng/mg in the wild type mouse and 0.9466±0.491 ng/mg 
in the knockout mice (Table 6.1). RIC chromatograms and MSn spectra are shown in Figure 
6.9 -Figure 6.10.
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Figure 6.7 24S,25-Epoxycholesterol in brain o f Cyp27aF mouse.
(A) RIC o f m/z 532.3898±5 ppm of C yp27al' " mouse
(B) MS3 spectrum of peak eluting at 6.59min identified as GP-tagged 24S,25- 
epoxycholesterol
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Figure 6.8. 24-Oxocholesterol from brain o f C y p 2 7 a l"  mouse.
(A) RIC o f m/z 532.3898±5 ppm o f Cyp27al" ‘
(B) MS spectrum o f peak eluting at 7.64 min identified as GP-tagged 24-oxocholesterol
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Figure 6.9 24,25-Dihydroxycholesterol from brain of C yp27al"‘mouse.
(A) RIC o f m/z 550.4003±5 ppm from Cyp27al " mouse
(B) M S3 spectrum o f peak eluting at 3.29 min identified as GP-tagged 24,25- 
dihydroxycholesterol
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Figure 6.10 3p,24(or25)-dihydroxycholest-5-ene-25(or24)-methoxide from brain of Cyp27al' 
‘ mouse.
(A) RIC o f m/z 564.4160±5 ppm o f C yp27aF ' mouse
(B) M S3 spectrum of peak eluting at 5.96 min identified as GP-tagged 3p,24(or25)- 
dihydroxycholest-5-ene-25(or24)-methoxide.
Further analysis o f peaks present in RIC at m/z 532.3898 reveals a compound eluting 
at 9.20 min with an MS fragmentation pattern resembling that o f 7a-hydroxycholesterol but 
with an extra-unsaturation (Figure 6.11). The spectrum contains low mass ions m/z 151, m/z 
179 and m/z 231, while higher mass ions have their m/z ratios reduced by two units compared 
to the 7a-hydroxycholesterol spectrum i.e. m/z m/z 392 cf. 394, 407 cf. 409, 425 cf. 427 and 
435 c f 437. Based on the fragmentation profile that shows the same features as 7a- 
hydroxycholesterol on the level o f tetracyclic core we putatively identified this compound as 
7a-hydroxydesmosterol. The concentration is calculated to be 0.0078±0.0010 ng/mg in wild 
type and 0.0270±0.0030 ng/mg in C yp27al‘ ‘ littermates which gives almost 3.5 fold increase 
in knockout mice.
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The studies on the “cholesterol-free mouse” which lack 24-dehydrocholesterol 
reductase (Ch24r) showed that 7a-hydroxydesmosterol can be formed by the action of 
C yp7al, and in vitro at a rate similar to hydroxylation o f cholesterol (5% and 6% o f the total 
amount o f substrate) [ 1901.
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Figure 6.11 7a-Hydroxydesmosterol brain of C yp 2 7 aF ‘mouse.
(A) RIC o f m/z 532.3898±5 ppm from C yp27aF ".
(B) M S3 spectrum of the peak eluting at 9.20 min identified as GP-tagged 7a- 
hydroxydesmosterol.
We can hypothesise that 7a-hydroxydesmosterol can be further hydroxylated at 
position 12a by C yp8bl, yielding 7a,12a-dihydroxydesmosterol. This oxysterol when 
subjected to oxidation and derivatisation will produce a molecular ion o f m/z 548.3847. We 
analysed the relevant RIC and analysed the MS spectra. The peak eluting at RT 7.77 min 
(Figure 6.12) has a M S3 fragmentation pattern similar to that o f 7a,12a-dihydroxycholesterol 
with the high mass fragments reduced by two mass units. Low mass fragments consist o f ions
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m/z 151 and m/z 179 and 279 present in the spectrum of 7a,12a-dihydroxycholesterol. The 
concentration has been calculated as 0.0107±0.016 ng/mg in Cyp27al"" and 0.0002±0.00004 
ng/mg in wild type littermates.
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Figure 6.12 7a,12a-Dihydroxydesmosterol in brain o f C y p 2 7 a l'm o u se .
(A) RIC o f m/z 548.3847±5 ppm from Cyp27al ‘ mouse
(B) MS spectrum o f peak eluting at 7.77 min identified as GP-tagged 7a, 12a- 
dihydroxydesmosterol
In fraction lb o f the knockout mice we also found a small amount o f 7a,12a-dihydroxy- 
cholesta-4,24-dien-3-one at a level o f 0.0024±0.0005ng/mg. This indicates that 7a, 12a- 
dihydroxylated desmosterol may exist in two forms: 3p-hydroxy-5-ene and 3-oxo-4-ene,
154
w h ^ e  the metabolic conversion is catalysed by 3(3-hydroxy-A5-C27-steroid 
dehydrogenase/isomerise.
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Figure 6.13 7a,12a-Dihydroxycholesta-4,24-dien-3-one in brain o f C yp27aF mouse.
(A) RIC o f m/z 548.3847±5 ppm from Cyp27al "" mouse
(B) M S3 spectrum of peak eluting at 7.82min identified as GP-tagged 7a, 12a- 
dihydroxycholesta-4,24-dien-3-one.
Further analysis o f m/z 532.2898 RIC revealed peak eluting at 8.25min (Figure 6.11). The 
MSn spectrum and retention time corresponds with GP-derivatised 22-oxocholesterol. The 
level o f this analyte is elevated in knockout mice (0.0098±0.0007 ng/mg in KO and 
0 .007l±0.0009ng/m g in WT).
At 10.29 min elutes another compound with m/z 532.3898 (Figure 5.13). The fragmentation 
profile o f the MSn spectrum fits the characteristics o f GP-derivatised cholest-4-en-3,6-dione. 
The levels were evaluated as 0.0494±0.0143 ng/mg in knockout mice, in wild type were
155
below the detection limit. Cholest-4-en-3,6-dione is usually considered to be a product of 
cholesterol autoxidation.
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Figure 6.14 Cholest-4-en-3,6-dione in brain o f C yp27al‘ mouse.
(A) RIC o f m/z 532.3898+5 ppm from C yp27al"' mouse
(B) M S3 spectrum of peak eluting at 10.29 min identified as GP-tagged cholest-4-en-3,6- 
dione
The compound o f m/z 532.3898 eluting at RT 9.76 does not have the features characteristic 
for any o f the reference standards. The MSn spectrum is dominated by fragment ion 435, 
which shows that the molecule easily undergoes dehydration, which occurs when a hydroxyl 
group is attached to the tertiary carbon atom such as C-25 or is allyl to a double bond. Low 
mass fragments do not exhibit the triad characteristic for the derivatised 3(3-hydroxy-5-ene 
group, therefore the tetracyclic structure may contain a double bond at C-7 or C-8(9) position 
(Figure 5.14).
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Figure 6.15 X-Hydroxydehydrocholesterol in brain o f C yp27al" ' mouse.
(A) RIC o f m/z 532.3898±5 ppm o f C y p 2 7 af + and C y p 2 7 a f ' (B) mouse
(C) M S3 spectrum of peak eluting at 9.76min
The chromatogram of monohydroxylated cholesterols o f m/z 534.4054 is dominated 
by 24S-hydroxycholesterol in both knockout and wild type mice which elutes in the 
chromatogram in two peaks (RT 7.35 min and 7.66 min), identified as syn- and anti- GP 
modified conformers (Fig. 14). 24S-FIydroxycholesterol is a product o f catalytic activity o f 
neuron-specific enzyme Cyp46al. The total concentration o f 24S-hydroxycholesterol in KO 
mice was determined to be 25.9209±1.7289 ng/mg and in WT mice at 25.9209±1.7289 
ng/mg, respectively.
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Figure 6.16 24S-Hydroxycholesterol in brain o f C yp27al" ' mouse.
(A) RIC o f m/z 534.4054±5 ppm o f Cyp27a 1' mouse.
(B) MS3 spectrum of peak eluting at 7.36 min identified as GP-tagged 24S- 
hydroxycholesterol
24S-Hydroxycholesterol can be metabolised by the action o f Cyp39al which 
introduces the hydroxyl group at the 7a position. The same reaction was reported to be 
catalysed by cholesterol 7a-hydroxylase Cyp7al present in the liver, but not by oxysterol 7a- 
hydroxylase Cyp7bl [238], which is expressed in the brain [239]. 7a,24S-
Dihydroxycholesterol was identified by comparison with the standard and the level was 
calculated as 0.0311 ±0.0053 ng/mg and 0.0131±0.0037 ng/mg in the knockout and the wild 
type mice, respectively. Spectra are presented in Figure 6.17.
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Figure 6.17 7a,24R-Dihydroxycholesterol in brain of C y p 2 7 a l '' mouse.
(A) RIC of m/z 550.4003±5 ppm of C yp27al4 + and C yp27al' ‘ (B) mouse (C) MS3 spectrum 
of peak eluting at 5.81 min identified as GP-tagged 7a,24R-dihydroxycholesterol
24R-hydroxycholesterol is the second stereoisomer o f 24-hydroxylated cholesterol we 
identified in this study (Figure 6.18). This oxysterol elutes closely to the next compound - 27- 
hydroxycholesterol. To separate the above analytes we developed a different LC gradient 
method. The concentration o f the 24R-hydroxycholesterol in the KO mice was reduced by 
50% compared to the WT littermates (0.310±0.055 ug/g and 0.642±0.023 ug/g).
Figure 6.18 24R-Hydroxyocholesterol in brain o f  C yp27al‘ ‘ mouse.
(A) RIC o f m/z 534.4054±5 ppm from C yp27al‘ mouse (B) M S3 spectrum o f peak eluting at 
17.96min identified as GP-tagged 24R-hydroxycholesterol
The amounts o f 27-hydroxycholesterol in wild type mice were at level o f 
0.0904±0.0069 ng/mg while in knockout littermates the concentration was reduced by 90% 
(0.0111±0.0019 ng/mg). The residual amounts o f 27-hydroxycholesterol present in Cyp27al 
deficient mice can be attributed to the activity o f  other enzymes with the capability o f 27- 
hydroxylation such as Cyp46al. The RIC chromatogram and the M Sn spectrum are shown of
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Figure 6.19 26-Hydroxydehydrocholesterol in brain of C yp27al"'m ouse.
(A) RIC o f m/z 534.4054±5 ppm of C yp27al+ + and (B) Cyp27al *" mouse. (C) M S3 spectrum 
o f peak eluting at 18.18 min identified as GP-tagged 27-hydroxydehydrocholesterol
In Cyp27al"" mice the alternative pathway o f bile acid formation is disabled, causing 
a compensatory up-regulation o f the classical pathway [2141. In this pathway, Cyp7al 
catalyses the initial step where cholesterol is hydroxylated at the C-7 position, yielding 7a- 
hydroxycholesterol. Cyp7al is a liver specific enzyme [ 1841, thus it is likely, that an elevated 
level o f 7a-hydroxycholesterol is due to the influx o f this oxysterol from peripheral 
circulation. 7a-Hydroxycholesterol was identified eluting in two peaks at 10.03 min and 
10.41 min (Figure 6.20). The level was 60-fold higher in the knockout mouse than in the wild 
type (2.4936±0.3520ng/mg and 0.0358±0.0065ng/mg).
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Figure 6.20 7a-Hydroxycholesterol in brain o f Cyp27al mouse.
(A) RIC o f m/z 534.4054±5 ppm of Cyp27al mouse
(B) M S3 spectrum o f peak eluting at 10.03 min and 10.41 min identified as GP-tagged 7a- 
hydroxycholesterol
We also quantified 7P-hydroxylated cholesterol which is usually considered as an 
autoxidation product o f cholesterol. The total concentration in the knockout mice is almost 10 
fold higher than in the wild type (0.3382±0.0308 ng/mg and 0.0348±0.0069 ng/mg). 7a- 
Hydroxycholesterol can be converted to 7-oxocholesterol by 7a-hydroxycholesterol 
dehydrogenase at least in hamster [240]. 7-Oxocholesterol can be quantified from fraction 
lb.. The level o f 7-oxocholesterol was calculated as 0.0548±0.0272 ng/mg in Cyp27a" mice 
while in the wild type the amounts were below the detection limit. Significantly, in mouse 
11 P-hydroxysteroid dehydrogenase 1 ( l ip H S D l)  catalyses the conversion of 7- 
oxocholesterol to 7p-hydroxycholesterol [24JJ- 7-Oxocholesterol itself can be formed from 7-
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dehydrocholesterol via a reaction catalysed by Cyp7bl. 8,9-Dehydrocholesterol an isomer of 
7-dehydrocholesterol is present at elevated concentrations in the Cyp27al-/- brain.
Another monohydroxycholesterol found in this study was 6 p-hydroxycholesterol. The 
level in the knockout mice was 20-fold higher than in wild type (0.7092±0.1737 ng/mg and 
0.0356±0.0031 ng/mg). This oxysterol is formed by hydrolysis of 5,6-epoxycholesterol 
[126], however we cannot rule out the possibility that 6 P-hydroxycholesterol is the product of 
an autoxidation of 7- and 8(9)-dehydrocholesterols. These are elevated in the knockout mice 
and have been shown to be prone to autooxidation [242].
In the second step of the neutral pathway of bile acid synthesis 7a-hydroxycholesterol is 
oxidised at the C-3 position by an ER enzyme, 3p-hydroxy-A5-steroid oxidoreductase 
(Hsd3b7) f243-2451 with the shift of double bond from C-5-C-6 to C-4-C-5 forming 7a- 
hydroxycholest-4-en-3-one. It is possible that this reaction occurs in the brain as Hsd3b7 is 
present in the nervous tissue fl08, 2361. 7a-Hydroxycholest-4-en-3-one can be also imported 
from periphery as this compound has been shown to be able to transverse the blood brain 
barrier [236]-
In our method, we use cholesterol oxidise to transform a hydroxyl group at 3p 
position into an oxo group. As a consequence, the processed sample solution becomes a 
mixture of oxidised and indigenous sterols possessing the 3-oxo moiety. To distinguish 
between the levels of naturally occurring 3-oxo sterols from transformed compounds, we 
divided each of the SPE1 fractions in two aliquots and treated only one with the enzyme 
(fraction a). In the aliquot which was not enzymatically oxidised (fraction b), only the 
endogenous sterols possessing an oxo group will be derivatised with GP reagent.
The analysis of RIC at m/z 534.4054 in fraction b (Figure 6.21) established level of 7 a- 
hydroxy-cholest-4-en-3-one as 0.0572±0.0070 ng/mg in knockout mice, while in wild type 
the levels were below the limit of detection.
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Figure 6.21 7a-Hydroxycholest-4-en-3-one in brain o f C y p 2 7 a l"  mouse in fraction lb.
(A) RIC o f m/z 534.4054±5 ppm from C y p 2 7 a f ' mouse.
(B) MS3 spectrum of peak eluting at 10.07 min identified as GP-tagged 7a-hydroxycholest-4- 
en-3-one.
In wild type mice, 7a-hydroxycholest-4-en-3-one during bile acid biosynthesis is 
subjected to further hydroxylation by Cyp27al at the C-27 position. The disruption o f this 
pathway results in up-regulation o f alternative routes such as C-12 hydroxylation catalysed 
by Cyp8bl or dehydroxylation at C-7, reduction a C-3 and reduction o f the C-4 double bond 
leading to formation o f 5p-cholestan-3p-ol. In the neutral pathway 27-hydroxylation is 
required for bile acid formation after ring modifications and the malfunction o f this enzyme 
results in accumulation o f the down-stream substrates. 7a-hydroxycholest-4-en-3-one is not 
cleaed at a normal rate in the absence of C yp27al, which leads to an accumulation o f  this 
compound detected by analysis o f fractions b in the knockout mice.
Double bound in 7a-hydroxycholest-4-en-3-one can be reduced forming 7a- 
hydroxycholestan-3-one. This oxysterol has a naturally occurring oxo moiety, therefore, it 
would be expected to be present in fraction la  as well as in lb. We were not able to identify 
any analytes with m/z ratio fitting GP derivatised 7a-hydroxycholestan-3-one in fraction lb 
neither in the knockout nor in wild type mice. There is a possibility that C-3 oxo group is 
instantly reduced to hydroxyl moiety forming cholestan-3,7a-diol. Sterols with 3a-hydroxy or 
-5p-H function cannot be oxidised by the action o f cholesterol oxidase and, in consequence, 
detected using our technique.
In fraction la (but not in lb) we found a peak of m/z 536.4211 eluting at RT of 10.59 min 
(Figure 6.22). The exclusive presence of this compound in the fraction treated with 
cholesterol oxidase indicates that the compound possess a 3p-hydroxy-5a-hydrogen structure, 
which upon oxidation is converted into 3-oxo-5a-hydrogen structure and is therefore, a 
substrate for GP derivatisation. The m/z value of the compound of interest corresponds to a 
dihydroxylated cholestane molecule. Unfortunately at the time of writing this report the 
relevant standard was not available to confirm the identity of this analyte. However, in the 
study by DeBarber et al. f246. 2471 7a-hydroxy-5P-cholestan-3-one has been analysed by 
LC-MS following GP-derivatisation in the manner similar to our methodology. The MSn 
spectrum presented in that work is consistent with the spectrum of the compound which we 
putatively identified as 5a-cholestane-3P,7a-diol. The concentration of this analyte was 
determined as 0.2051±0.2016 ng/mg in Cyp27al-/- mice; conversely, in wild type this 
compound was below the detection limit.
The exact origin of this novel oxysterol is not known. One of the candidates is 
Cyp7al with the ability of 7a-hydroxylation, however there is no data showing cholestanol is 
a substrate for Cyp7al.
There are studies reporting the presence of 7a-hydroxy-5P-cholestan-3-one in the plasma 
derived from Cyp27ar/_ mice [247]. However, we were not able to identify this substance in 
the brain extracts. This may be due to the reduction of peripheral 7a-hydroxy-5P-cholest-3- 
one f236] to 5p-cholestane-3a,7a-diol.
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Figure 6.22. 5a-Cholestane-3p,7a-diol in brain o f C yp27al‘ ' mouse.
(A) RIC o f m/z 536.4211±5 ppm of Cyp27al " mouse
(B) MS spectrum of peak eluting at 10.02 min identified as GP-tagged 5a-Cholestane-3p,7a- 
diol
Other routes o f the neutral pathway employs Cyp8bl catalyzed hydroxylation at the 
12a position o f 7a-hydroxycholesterol and 7a-hydroxycholest-4-en-3-one. This generates 
7a,12a-dihydroxycholesterol and 7a,12a-dihydroxycholest-4-en-3-one, respectively. 7a, 12a- 
Dihydroxycholest-4-en-3-one posses an oxo moiety, therefore, it is possible to quantify this 
compound in fraction lb. The analysis o f RIC at m/z 550 in fraction b reveals a double peak 
(RT 8.75 min and 8.95 min), which we identified as 7a,12a-dihydroxycholest-4-en-3-one. 
The MS spectrum (Figure 6.23) is dominated by an ion m/z 453 formed by the loss o f water 
from product ion o f MS m/z 471. The ion o f m/z 443 is a result o f removal o f CO group from 
m/z 471, the loss o f two water molecules gives an ion of m/z 435. The loss o f one water 
molecule and CO from the GP molecule will yield an ion o f m/z425. Simultaneous double
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dehydratation combined with loss of the carbonyl and NH+ groups gives an intense ion at m/z 
392. The complete removal of GP moiety and migration of double bond to the adjacent 
steroid ring of the dehydrated oxysterol molecule produces ion of m/z 365. The loss of the 
side-chain from dehydrated MS -parent ion generates ion of m/z 323 and combined with the 
loss of GP molecule, results in the formation of a product ion with the m/z 279. The doublet 
of ions of m/z 151 and 179 are the hallmark of C-7 hydroxylation and are formed during the 
cleavage of rings A and B of the tetracyclic steroid structure. By comparison with the internal 
standard we determined the level of 7a,12a-dihydroxycholest-4-en-3-one in Frlb of the 
knockout mice to be 0.1409±0.0235 ng/mg, while in wild type the level was below the 
detection limit.
We also measured the level of 7a,12a-dihydroxycholesterol in fraction a, 
(chromatogram and spectrum presented in Figure 6.23) where the levels were markedly 
higher (0.4971±0.1658 ng/mg) in the Cyp27al-/- mouse than the wild type (0.0002±0.0001 
ng/mg). The actual amount of 7a,12a-dihydroxycholesterol in fraction a (after subtracting the 
amount detected in fraction b) was 0.3562 ng/mg, while in wild type the levels were 
evaluated as 0.0002±0.0001 ng/mg, this gives a 2500-fold difference between Cyp27ar;' and 
control mice. This shows a major accumulation of 7a,12a-dihydroxylated 
cholesterol/cholestenone in the nervous tissue. Cyp27al utilises also 7a, 12a- 
dihydroxycholesterol and 7a,12a-dihydroxycholest-4-en-3-one and its deletion will cause the 
accumulation of these oxysterols.
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Figure 6.23. 7a,12a-Dihydroxycholesterol in brain o f C yp 2 7 aF ‘mouse.
(A) RIC o f m/z 550.4005±5 ppm o f C yp27al+ +
(B) MS3 spectrum of peak eluting at 8.75min identified as GP-tagged 7a, 12a- 
dihydroxycholesterol
The next step o f bile acid biosynthesis from 7a,12a-dihydroxycholest-4-en-3-one is 
reduction to 7a,12a-dihydroxy-5p-cholestan-3-one. This compound also possesses a readily 
derivatiseable oxo group allowing for its detection in the fraction b. GP modification o f this 
compound should yield a derivative o f m/z 552.4160, the analysis o f relevant RIC o f fraction 
b showed two major peaks which we identified as a doublet belonging to one analyte.
The peak exhibits a very “low” profile o f fragments which is usually characteristic for 
oxysterols hydroxylated at the C-25 position (Figure 6.24). This compound was only detected 
in knockout mice at the levels o f 0.1260±0.0036 ng/mg.
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Figure 6.24. Unidentified sterol in brain o f C yp27al‘ mouse in fraction lb.
(A) RIC o f m/z 552.4160±5 ppm of C yp27al+ +
(B) MS3 spectrum of peak eluting at 8.52 min
However, the above spectrum does not agree with the MS spectrum of 7a, 12a- 
dihydroxy-5P-cholestan-3-one presented in the study published by DeBarber et al. [247].
We analysed the RIC o f m/z 552.4160 o f metabolites obtained in the fraction la; the 
spectrum shows a number o f analytes, which are present exclusively in knockout mice. The 
dominating peak is eluted at RT 8.52 min. The M S3 spectrum presents a prominent ion m/z 
445, produced by the loss o f CO group from [M-79]+ ion o f m/z 473. The ion of m/z 365 is 
formed by the loss o f GP moiety combined with removal o f both hydroxyl groups. This 
analyte was absent in wild type mice; in the Cyp27al " mice its concentration equals to 
0.0870±0.0571 ng/mg.
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Figure 6.25. Unidentified sterol in brain o f C yp27al' mouse in fraction la.
(A) RIC o f m/z 552.4160±5 ppm from Cyp27al + +
(B) M S3 spectrum o f peak eluting at 9.14min
The presence o f doubly-hydroxylated derivatives o f cholesterol is not limited to 
7a,12a-hydroxylated compounds. The RIC obtained at m/z 550.4003 shows a large number of 
compounds (Figure 6.23). We identified 7a,25-hydroxycholesterol at concentration markedly 
increased in knockout mice as opposed to wild type (0 .1183±0.0095 ng/mg and 
0.0285±0.0026 ng/mg) and 7a,25-hydroxycholest-4-en-3-one (0.0392±0.0022 ng/mg and 
0.0022±0.0005 ng/mg). Increased concentration in the knockout mice is not surprising as 
both enzymes responsible for 7a- and 25 hydroxylation are up-regulated in C yp27al' ‘ mice. 
The other compounds we putatively identified are: 6,24S-dihydroxycholesterol
(0.1477±0.0094ng/mg in KO and 0.1237±0.0245 ng/mg in WT), present only in the 
knockouts: 6p,12a-dihydroxycholesterol (0.0894±0.0223ng/mg) and 6p,12a-
Dihydroxycholest-4-en-3-one (0.0066±0.0012 ng/mg).
7a,12a-Dihydroxylated analogues o f cholesterol, that contain functions o f 3-oxo or 33- 
hydroxy-5a-cholestan may be subjected to further hydroxylation. It was showed that 
microsomal enzyme CYP3A4 has the catalytic activity o f 25- and 27-hydroxylase towards 
3a,7a,12a-trihydroxy-5P-cholestane [2141. After derivatisation, such a compound would have 
m/z ratio o f 566.3952 (for analytes containing unsaturated bond by 4 or 5 position) or 
568.4106 (for cholestanol based sterols). The chromatograms o f  m/z 566.3952 and m/z 
568.4109 from knockout mice showed an accumulation o f analytes, which were absent in the 
wild type extracts (Figure 6.26 and Figure 6.27).
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Figure 6.26. 7a,12a,X-Trihydroxycholesterol in brain o f Cyp27al'~ mouse in fraction la.
(A) RIC o f m/z 566.3952±5 ppm o f Cyp27al + +
(B) M S3 spectrum o f peak eluting at 3.62min
RIC of m/z 566.3952 shows a major peak at RT 3.65min (Figure 6.26). The M S3 
spectrum has features characteristic for cholesterol hydroxylated at 7a and 12a positions. 7a 
Hydroxylation gives ions o f m/z 151 and 179, while high mass fragments give similar profile 
to 7a,12a-dihydroxycholesterol with the masses increased by 18 units o f hydroxyl group. It is
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n o t clear where the third hydroxyl group is positioned, the fact that the fragmentation has not 
ailtered low mass fragments suggest that it was hydroxylated the side chain. According to 
H onda et al. [2J_4], CYP3A4 can hydroxylate 5P-cholestane-3a,7a,12a-triol at positions 25 
amd 26, with the preference towards C25 hydroxylation. The concentration o f this compound 
w as calculated in the knockout mice as 0.1018ng/mg in a fraction la  and 0.1336±0.0154 
ng/m g in fraction lb. The presence o f this oxysterol in both fractions a and b suggest that it 
i;s present in two forms - 3p-hydroxy and 3-oxo containing function groups.
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Figure 6.27. Trihydroxycholesterols in brain o f C yp27al""mouse in fraction la.
(A ) RIC of m/z 568.4109±5 ppm and Cyp27al" (B) mouse
RIC o f m/z 566.3952 shows a number o f analytes unique for knockout mice (Figure 
6.27), which suggest multihydroxylation o f sterols with 3p-hydroxylate-5a-cholestane group. 
This is consistent with the observations o f multi-hydroxylations o f the sterol side chain 
reported by Flonda et al [214],
6.3 Discussion
The deletion o f Cyp27al resulted in an elevated activity o f a neutral bile acid 
pathway, which is initiated by 7a-hydroxylation provided by Cyp7al. This enzyme catalyses 
the formation o f 7a-hydroxycholesterol, which in C yp27al-/- mice is largely accumulated. 
The increased activity o f this enzyme is presumably responsible for 7a-hydroxylation o f 
desmosterol, the presence o f 7a-hydroxydesmosterol has been already reported in 
“cholesterol-free” mouse f 1901. Contrary to C yp27al, C yp7al, is specific found in liver 
[2_j_5], so presumably the presence o f its 7a-hydroxylated products in brain is possible due to
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diffusion of this oxysterols across the blood brain barrier from the circulation. The 
mechanism by which 7a-hydroxycholestrol could pass BBB and enter the brain is not entirely 
clear. It is widely accepted that oxysterols can transverse the barrier in passive diffusion [30, 
2481 which requires the gradient of compounds, however there are reports showing active 
transport aiding oxysterols efflux [249]. In healthy human brain the flux of two main 
oxysterols from and into the brain occurs at levels 6-7mg for 24-hydroxycholesterol IT711 
and 5mg for 27-hydroxycholesterol [2501. respectively. It is possible that in the absence of 
27-hydroxycholesterol, 7a-hydroxycholesterol passes thought the BBB at increased rate 
which leads to its accumulation in the CNS.
Accumulated 7a-hydroxydesmosterol is probably further hydroxylated at 12a position 
yielding 7a,12a-dihydroxydesmosterol, which was detected in biological system for the first 
time. These two reaction of 7a- and 12a-hydroxylations in regard to desmosterol can 
implicate the existence of new metabolic pathway.
Cyp27al catalyses two reactions involving cholesterol. One is hydroxylation at C-26 
position of cholesterol, and the second one involves the cleavage and further oxidation of the 
sterol side chain leading to formation of bile acids l~1811. Unsurprisingly, the deficiency of 
this changes the oxysterol profile with an accumulation of compounds with multiple 
hydroxylations of the side chain. Cyp27al-/- mouse has a largely elevated level of di- and 
trihydroxycholesterols. Among these oxysterols is 7a,25-dihydroxycholesterol largely studied 
for its function in modulation of cellular immune response. Enhanced 25-hydroxylation is not 
surprising as increased activity of Cyp3a, which can introduce a hydroxyl group at C-25 
position, was reported [26].
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Chapter 7
7 Sterol profiling of brain of the Cyp7bl-/- mouse
7.1 Introduction
In the course of the “acidic” bile acid biosynthesis pathway hydroxylation of the 
cholesterol side-chain at the 26 position is followed by hydroxylation of the ring structure at 
position 7a. This reaction is catalysed by the microsomal monooxygense Cytochrome P450 
(Cyp) 7bl.
Cyp7bl is widely distributed in various tissues; the highest expression is reported in 
brain, however, this enzyme is also present in liver, kidneys, ovaries, testis and the adrenal 
glands. In rat brain it is mainly detected in the hippocampus [220]. The analysis of mice 
adrenal glands showed a sexual dimorphism for the presence of Cyp7bl, with the higher level 
found in the males [251J. In humans the mRNA transcripts of CYP7B1 are most abundant in 
kidneys and brain [252]. Cyp7bl participates in bile acid biosynthesis via the “acidic” 
pathway by 7a-hydroxylation of 27-hydroxycholesterol. Deficiency of this enzyme leads to 
accumulation of 27-hydroxycholesterol and a compensatory up-regulation of the classical 
pathway resulting in an increased level of cholic acid.
Another substrate of Cyp7bl is 25-hydroxycholesterol. This oxysterol recently emerged as a 
part of the body’s defence system as it is produced by stimulated murine macrophages. The 
product of 7a-hydroxylation of 25-hydroxycholesterol has been reported as a chemotactic 
factor directing B-cells in the lymphoid tissue required during the immunological response 
[132].
Oxysterol 7a-hydroxylase in also implicated in neuroprotection as its metabolites 7a- 
hydroxy-dehydroepiandrogene and 7a-hydroxyepiandrosterone prevent neuronal damage 
[253,254].
The mutations of CYP7B1 in humans are associated with two disorders: liver failure 
in children [23, 25] and hereditary spastic paraplegia type 5 in adults [24]. The first disorder 
has been described in four infants. The main symptoms included cholestasis, cirrhosis and 
elevated level of bile acid precursors in the urine. MS analysis of the patient’s urine showed a 
large increase in the concentration of monohydroxycholenoates conjugated with sulphuric 
acid, glycine and taurine; hydrolysis of the sample revealed that major cholenoate was 30- 
hydroxychol-5-enoic acid. The bile profile of the serum was remarkably similar to that of 
urine, the main compounds were identified as 3 0-hydroxychol-5-enoic acid and its 27 carbon
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atom analogue. Analysis of neutral sterols showed an accumulation of 27- and 24- 
hydroxycholesterol in the urine and serum.
The neurological importance of CYP7B1 has been revealed by analysis of the genome 
of patients suffering from hereditary impairment of motor functions. Hereditary spastic 
paraplegia type 5 (HSP5) is a neurological disorder characterised by spasticity and weakness 
of lower limbs. There are also reported white matter lesions in affected individuals [255]. The 
deficiency of CYP7B1 has been directly linked to HSP5, a number of mutations have been 
identified including missense and nonsense [24]. The exact dependency between the gene 
deficiency and the neurological symptoms are not known.
To gain a better understanding of these disorders, an animal model was constructed 
using a mouse with disrupted Cyp7bl locus. Cyp7bl deficient mice have no physical 
phenotype, however, analysis of the lipidome showed alteration in the steroid profile. The 
most striking feature of the chemical phenotype was an accumulation of 25- and 27- 
hydroxycholesterol which led to the conclusion that these oxysterols are main substrates of 
murine Cyp7bl. on the contrary, the level of cholesterol and triglycerides was not affected in 
these animals. In our work we focus for the first time on the analysis of brain of Cyp7bl 
knockout animals.
7.2 Results 
Sterols
Cholesterol upon oxidation with cholesterol oxidase and GP-derivatisation produces 
an [M]+ ion of m/z of 518.4105. We quantified a compound which presented as a single peak 
in the RIC of m/z 518.4105 with the RT 11.47 min (Figure 7.2A and Figure 7.2B) whose MS3 
spectrum was identical to the authentic standard of cholesterol. Data was obtained by the 
analysis four wild type and four knockout animals of 13 months and, three wild type and 
three knockout of 23 months. The levels of sterols are presented in Table 7.1. The levels of 
brain cholesterol were not affected by the presence of the Cyp7bl mutation. The 
concentration was measured as 10.60±1.43 pg/mg in the wild type and 10.33±2.02 pg/mg in 
the knockout mice of 13 months and 15.81±0.65 pg/mg 16.85±0.59 pg/mg in 23 month mice 
(Table 7.1).
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Figure 7.2. Cholesterol in mouse brain. (A) RIC o f m/z 518.4105±5 ppm o f C yp7bl“  mouse.
(B) MS spectrum of peak eluting at 11.75 min identified as GP-tagged cholesterol from the 
the C yp7bl+ +mouse.
Cholesterol precursors include sterols containing an additional double bond either in the side 
chain (desmosterol) on within the cyclic core. Both dehydrocholesterol molecules upon 
oxidation and GP-derivatisation will be detected as ions of m/z 516.3948. The analysis o f 
brain samples carried out under routine analytical conditions did not provide a MS signal 
sufficient for the quantification o f cholesterol precursors. To get an insight into the levels o f 
the precursors we analysed one knockout and one wild type brain from 13 month animals by 
injecting much higher amounts o f brain extract in to the LC-MS system than under routine
conditions. The chromatogram of both the wild type and knockout mouse shows three peaks 
with RT: 10.66 min, 10.90 min and 11.17 min (Figure 7.4A and Figure 7.4B). The MS" 
spectra of these analytes are shown in Figure 7.4C, Figure 7.4D and Figure 7.4E.
Based on the information obtained from the analysis o f authentic standards we identified the 
first peak as desmosterol and the peak with RT 11.17 min as 8(9)-dehydrocholesterol. The 
identity of the peak with RT 10.90 min is unknown. The level o f desmosterol was lower in 
the knock out brain compared to the wild type (0.0060 pg/mg and 0.0688 pg/mg, 
respectively). The amount o f 8(9)-dehydrocholesterol was also reduced in the knockout 
animals (0.0021 pg/mg in the knockout and 0.0089 pg/mg in the wild type). The third, 
unidentified, compound is present in the knockout brain also at reduced concentration 
(0.0013 pg/mg in the knockout and 0.0116 pg/mg in the wild type).
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Figure 7.3 Cholesterol precursors in mouse brain. RIC o f m/z 516.3948±5 ppm in brain o f the 
Cyp7bl + + (A) a n d C y p 7 b l‘ (B)
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Figure 7.4 Cholesterol precursors in mouse brain.
RIC o f m/z 516.3948±5 ppm in brain o f the C yp7b l“ and respective spectra
(A) MS spectrum of GP-tagged desmosterol eluting at 10.67 min
(B) MS spectrum of unidentified compound eluting at 10.82 min
(C) MS spectrum o f peak eluting at 11.21 min identified as GP-tagged 8(9)- 
dehydrocholesterol
The level o f precursors is reduced although the amount o f cholesterol is maintained which 
suggest that the rate o f the cholesterol biosynthesis has been diminished. The unchanged level 
o f cholesterol is agrees with the findings o f Li-Hawkins et al. where cholesterol was assessed 
in a wide array o f murine tissues.
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Oxysterols
Cholesterol with an epoxy function between the 24S and 25 positions is a side-product of the 
mevalonate pathway f2181. It is implicated in neurogenesis f!2 11 and high levels were 
identified in developing brain [120]. GP modified 24S,25-epoxycholesterol produces a 
molecular ion of a m/z ratio 532.3898. Chemical instability is responsible for transformation 
of this compound into its isomer (24-ketocholesterol, GP derivatised m/z 532.3898), a 
hydrated (24S,25-dihydroxycholesterol, GP derivatised m/z 550.4003) and methanol- 
modified (24-hydroxy-25-methoxycholesterol or the 24-hydroxy-25-methoxy isomers, GP 
derivatised m/z 564.4160) form [120]. The levels of these analytes were combined to give 
the total concentration of 24S,25-epoxycholesterol, which is significantly higher in the 
knockout mice. In 13 months old mice the levels were 0.9593±0.2390 ng/mg and 
3.6109±0.2160 ng/mg for wild type and knockout animals respectively, and for the 23 month 
old animals 1.5063±0.3006ng/mg and 2.5765±0.1460ng/mg, respectively. RIC 
chromatograms and MSn spectra are shown in Figure 7.5-
Figure 7.7. As the level of cholesterol precursors decreased implying a reduced cholesterol 
biosyntesis, the elevated level of 24S,25-epoxycholesterol can be a consequence of the 
absence of Cyp7bl. This also suggests that 24S,25-epoxycholesterol can be a substrate for 
Cyp7b (data in the Table 7.1).
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Figure 7.5. 24S,25-Epoxycholesterol and 24-ketocholesterol in brain o f 23 month old 
C yp7baT + and Cyp7bal " ‘mice. The spectrum comes from the short HPLC elution.
(A) RIC o f m/z 532.3898±5 ppm of C yp7bal+ + and Cyp7bal " mice
(B) M S3 spectrum of peak eluting at 6.68 min identified as GP-tagged 24S,25- 
epoxycholesterol
(C) MS spectrum o f peak eluting at 7.74 min identified as GP-tagged 24-ketocholesterol
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Figure 7.6. 24,25-Dihydroxycholesterol in brain o f 23 month old C yp7bal+ f and C yp7bal'/' 
mice. The spectrum received from the short HPLC gradient.
(A) RIC o f m/z 550.4003±5 ppm of C yp7bal+ + and Cyp7baF 'm ice
(B) MS3 spectrum o f peak eluting at 3.48 min identified as GP-tagged 24,25- 
dihydroxycholesterol
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Figure 7.7. 24-hydroxy-25-methoxy- or 24-hydroxy-25-methoxycholesterol from brain o f 23 
month old C yp7bal‘ mice. The spectrum recorded from the short HPLC gradient.
(A) RIC o f m/z 564.4160±5 ppm o f C yp7bar "mice
(B) M S3 spectrum of peak eluting at 6.07 min identified as GP-tagged 24-hydroxy-25- 
methoxy- or 24-hydroxy-25-m ethoxycholesterol.
Further peaks in RIC o f m/z 532.3898 eluting at RT 7.11 min and 7.50 min were identified as 
(24Z) and (24E) isomers o f 26-hydroxydesmosterol. The levels o f both o f these oxysterols 
were markedly higher in the Cyp7bl deficient animals. MSn spectra are illustrated in Figure 
7.8. (24Z)-26-Hydroxydesmosterol concentrations in 13 months old mice were 
0.0029±0.0008 ng/mg in the wild type and 0.0096±0.0040 ng/mg in the knockout, for 23 
month-old mice the levels were 0.0094±0.0016 ng/mg and 0.0252±0.0009 ng/mg. The 
amounts o f  (24E)-26-hydroxydesmosterol in 13 months old mice were estimated as
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0.0028±0.0004 ng/mg and 0 .0187±0.0064 ng/mg in the wild type and knockout, respectively; 
in 23 months old mice this analyte was found at the levels o f 0.0089±0.0034 ng/mg and 
0.0383±0.0037 ng/mg.
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Figure 7.8 (24Z)-26-Hydroxydesmosterol and (24E)-26-hydroxydesmosterol from brain 23 
month old Cyp7bal" "mice. The spectrum from the short HPLC elution.
(A) MS spectrum o f peak eluting at 7.11 min identified as GP-tagged (24Z)-26- 
hydroxydesmosterol.
(B) M S3 spectrum o f peak eluting at 7.50 min identified as GP-tagged (24E)-26- 
hydroxydesmosterol.
At 10.45 min elutes another compound with m/z 532.3898 (Figure 7.9). The fragmentation 
profile o f the MSn spectrum fits the characteristics o f GP-derivatised cholest-4-en-3,6-dione. 
The levels were evaluated as 0.0494±0.0143 ng/mg in knockout mice, but in wild type mice 
were below the detection limit. The origin o f cholest-4-en-3,6-dione is not known, it could be 
generated during an autoxidation o f cholesterol.
186
(A) 762E4 
flCF:irfc6+cE3RJ 
m&3 532 39@cd30.00 
45335@c<fl5.00 
[120 00-550.00] MS 
am to 619 120707 03
£ :
i* 
“ »] 
20
1.55 1.86 2.32 2.74 3.11 357
! f" H " f ' 1 ' I 'I '
428 4.89 5.16 5.79 6.06
6.67 7.10 ; 8.39 8.81 9.22 9.64 9.95 1052 11.16 12.09 12.62 13.48 1427 14,49 15.01 15.68 16.16 16.85
Sf
210 43 224 40 238 32 254 24 268
320 380 420 440120 140 160 180 200 220 240 260 300 340 360 400
Figure 7.9 Cholest-4-en-3,6-dione in brain o f 23 months old Cyp7bF mouse. The spectrum 
received from the short HPLC gradient.
(A) RIC o f m/z 532.3898±5 ppm from Cyp7b 1"' mouse
(B) M S3 spectrum of peak eluting at 10.45 min identified as GP-tagged cholest-4-en-3,6- 
dione.
The most abundant monohydroxylated sterol in brain is 24S-hydroxycholesterol 
[256]. 24S-Hydroxylation provides as an exit route for brain-derived cholesterol in a reaction 
catalysed by the brain-specific enzyme Cyp46al. GP-modified 24S-hydroxycholesterol has 
m/z ratio 534.4054 and in our LC method syn- and anti- isomers elute separately at RT 7.48 
min and 7.79 min. RIC and MSn spectra are shown in Figure 7.10.
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Figure 7.10 24S-Hydroxycholesterol in brain of C yp7b l+ + and C yp7bT ' 23months old mice. 
The spectrum recorded using an extended HPLC gradient, described in detail in Chapter 3.
(A) RIC o f m/z 534.4054±5 ppm o f Cyp7bl + + and C y p 7 b l '2 3  months old mice.
(B) M S3 spectrum of peak eluting at 14.86 min identified as GP-tagged 24S- 
hydroxycholesterol.
(C) M S3 spectrum of peak eluting at 15.87 min identified as GP-tagged 25- 
hydroxycholesterol
The total concentration o f 24S-hydroxycholesterol in wild type 13 months old mice was 
determined to be 16.8211±2.5529 ng/mg and in knockout mice at 18.2565±4.2880 ng/mg, in 
23 months old animals the levels were 25.9581±3.0040 and 25.3367±1.4027, respectively. 
There was no statistical difference in the amount o f 24S-hydroxycholesterol between the wild
type and knockout mice which suggests that Cyp7bl is not involved in the metabolism of 
24S-hydroxylated cholesterol. On the contrary, the deletion o f Cyp7bl caused a substantial 
accumulation o f both 25- and 26-hydroxycholesterol, as also reported by Li-Hawkins [ 1031 
for other tissues. In our work both oxysterols were quantified using chromatograms 
developed in the long gradient LC analysis, where these compounds elutes at RT 15.87 min 
and 18.33 min, respectively. 25-Hydroxycholesterol is a catalytic product o f the enzyme 
cholesterol 25-hydroxylase, however it can be also generated by Cyp3a [26], Cyp27al [ 182, 
2571 and Cyp46al [291. While in wild type animals 25-hydroxycholesterol was not detected, 
in the knockout animals this compound was easily integrated and quantified as 
0 .8892±0.1422 ng/mg in 13 months old and 2.0906±0.4461 ng/mg in 23 months old mice 
(Figure 7.10). 25-Hydroxycholesterol is subject to 7a-hydroxylation catalysed by C yp7bl; 
therefore we also measured the level o f its products. 7a,25-Dihydroxycholesterol in the 
knockout mice had markedly reduced level (0.0009±0.0001 ng/mg 0.0131 ±0.0026 ng/mg in 
13 and 23-month old mice, respectively) compared to the wild type, 0 .0114±0.0050 ng/mg 
0 .0 197±0.0037 ng/mg.
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Figure 7.11 26-Hydroxycholesterol in brain o f Cyp7bl " 23months old mouse. M S3 spectrum 
o f peak eluting at 18.33 min identified as GP-tagged 25-hydroxycholesterol. The spectrum 
recorded for a long HPLC gradient.
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We also quantified the product of 7a-hydroxylation of 27-hydroxycholesterol. 
Surprisingly, the amounts of 7a,27-dihydroxycholesterol in the wild type and knockout mice 
did not show a statistical difference. In the wild type mice these were 0.0206±0.0105 ng/mg 
and 0.0339±0.0099 ng/mg in 13 and 23 month-old mice, while in its knockout counterparts 
were 0.0124±0.0024 ng/mg and 0.0451±0.0056 ng/mg.
A variant of the acidic pathway of bile acid biosynthesis is initiated by 27-hydroxylation of 
cholesterol followed by 27-carbonylation and ultimately carboxylation all catalysed by 
Cyp27al, this is followed by 7a-hydroxylation by Cyp7bl. In the wild type animals the 
levels of 27-hydroxycholesterol are relatively low and were established as 0.2766±0.1340 
ng/mg and 0.2976±0.1204 ng/mg in 13 and 23 month-old animals, while in the knockouts the 
amounts were increased roughly 15-fold (3.0686±0.8612 ng/mg and 3.7181±0.3911 ng/mg, 
respectively). The MS3 spectrum from Cyp7bl-/- animal is presented in 
Figure 7.11. 27-Hydroxycholesterol is a substrate for 7a-hydroxylation catalysed by Cyp7bl 
f245. 251. 2581 and in mice the deletion of Cyp7bl causes a major accumulation of 27- 
hydroxycholesterol.
Carboxylation of cholesterol at C-27 position yields 3P-hydroxycholest-5-enoic acid, which 
upon GP derivatisation produces an ion of m/z 548.3847 (Figure 7.12). In the “acidic” 
pathway 3p-hydroxycholest-5-enoic acid is further hydroxylated at the 7a position by 
Cyp7bl, thus dysfunction of this enzyme leads to an accumulation of its substrate. In the wild 
type mice the concentration of this compound was low (0.0089±0.0023 ng/mg in 13 month 
old and 0.0145±0.0047 ng/mg in 23 month old) while in the knockouts these were 10 to 13- 
fold increased (0.1175±0.0250 ng/mg in 13 month old and 0.1509±0.0081 ng/mg in 23 month 
old).
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Figure 7.12 3p-Hydroxycholest-5-enoic acid in brain o f C y p 7 b l" 'an d  C yp7b l+ + 23months 
old mouse. The spectrum recorded for a SHORT HPLC gradient.
(A) RIC o f m/z 548.3849±5 ppm o f C y p 7 b f ' and C yp7b l+ + mouse.
(B) M S3 spectrum o f peak eluting at 7.58 min identified as GP-tagged 3(3-Hydroxycholest-5- 
enoic acid
24R-Hydroxycholesterol is a diastereoisomer o f 24S-hydroxycholesterol eluting later 
than its S isomer. With this long LC gradient method 24R-hydroxycholesterol appears as 
shoulders to 26-hydroxycholesterol, with retention times 17.72 min and 19.74 min (Figure 
7.10), and the MS fragmentation profile resembles that o f 24S- isomer (Figure 7.12). The 
concentration o f the 24R-hydroxycholesterol in the wild type and the knockout mice did not 
differ significantly in both age groups (13 months: WT 0.1995±0.0890 ug/g and KO 
0.1356±0.0222 ng/mg 23 months: WT 0.3020±0.0306 ug/g and KO 0.3590±0.0660 ug/g).
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Figure 7.13 24R-Hydroxyocholesterol in brain o f C yp7bl+ " 23months old mouse. MS3 
spectrum of peak eluting on the shoulder o f a dominating peak at 17.72 min) identified as 
GP-tagged 24R-hydroxycholesterol. The spectrum recorded for a long HPLC gradient.
The late eluting compounds on the in the chromatogram o f m/z 534.4054 are products 
o f cholesterol ring hydroxylations: 7a, 7p- and 6(3-hydroxycholesterol. The amounts o f these 
compounds in 13-month old group do not differ between Cyp7bl deficient and wild type 
mice, for elder group there is a marked increase in the levels of all three compounds in the 
Cyp7bl-/- animals (Table 7.1). 7a-Hydroxycholesterol is the first intermediate in the 
“classical” bile acid biosynthesis pathway, where is synthesised by Cyp7al, however it can 
be also a product o f cholesterol autoxidation. The concentration o f this compound in the 
mature 23 month wild type was established as 0.0095±0.0046 ng/mg while in the knockouts 
this was 0 .0192±0.0035 ng/mg. This result is consistent with Li-Hawkins et all (44) who 
reported a 30-40% increase in the level of Cyp7al protein in Cyp 7 b IT  mouse liver. This 
pattern was not observed in younger animals, however this may be due to insufficient 
accumulation o f metabolites.
The origin o f 6p- and 7P-hydroxycholesterol is not clear, they are mainly considered as a 
cholesterol autoxidation products. Both compounds are significantly more concentrated in 23 
months old knockouts.
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7.3 Discussion
In humans dysfunction of CYP7B1 is implicated in two different disorders: spastic 
paraplegia type 5 and lethal neonatal liver disease [221], [259], The mechanisms behind the 
development of two separate syndromes arising from the mutations in the same gene remain 
unknown.
In this study we analysed sterol content of Cyp7bl deficient mice. Although the 
absence of this enzyme in mice does not have the deleterious effect observed in humans 
IT 031. it still provide an insight into metabolic pathways affected by the absence of Cyp7bl 
the analysis of oxysterols and sterols form Cyp7bl-/- brain allowed to target the putative 
substrates of this enzyme. Cyp7bl is expressed in the brain tissue brain oxysterol hydroxylase 
1~220. 221] well characterised as 7a-hydroxylase for 25- and 26-hydroxycholesterols. The 
current study confirmed this activity of Cyp7bl by showing a major accumulation of these 
two oxysterols. The Cyp7bl-/- mice had also an elevated level of cholesterol biosynthesis by­
product: 24S,25-epoxycholesterol. In the light of reduced levels of cholesterol precursors, the 
increased level of 24S,25-epoxycholesterol suggests that this oxysterol can be metabolised by 
Cyp7bl under normal physiological conditions. In the light of neurodegenerative disorder 
spastic paraplegia type 5 arising form mutation in CYP7B1, this finding is particularly 
interesting. 24S,25-Epoxycholesterol is important for neuronal development and disruption 
of its metabolism may be implicated in the neuronal impairment.
Analysis of hydroxylated desmosterols identified two compounds, namely (24Z),26- 
hydroxydesmosterol and (24E),26-hydroxydesmosterol. Biological origins of these 
compounds are not defined, however it has been reported that human recombinant of 
CYP27A1 used desmosterol as a substrate [1911. Increased level of (24Z),26- and (24E),26- 
hydroxydesmosterols in mutated mice points at possible mechanism of metabolism of this 
oxysterols by the catalytical activity of Cyp7bl. The biological activity of these sterols 
remains to be assessed. Neither of hydroxydesmosterols is a ligand to Liver X Receptor a or 
p, as opposed to desmosterol -  a potent activator of LXRs f 1191.
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Chapter 8
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8 Macrophages
8.1 Introduction
25-Hydroxycholesterol was initially considered as a product of cholesterol 
autoxidation generated during sample processing [260, 2611. however later studies reported 
the enzymatic origin of 25-hydroxycholesterol, catalysed by an enzyme cholesterol 25- 
hydroxylase [8 ]. The role of 25-hydroxycholesterol in cholesterol homeostasis emerged for 
the first time in 1975. The work of Kandutsch and others l~262. 2631 showed that 25- 
hydroxycholesterol, among other oxygenated derivatives of cholesterol, can suppress activity 
of the mevalonate pathway. Oxysterols reduced the activity of HMG CoA reductase - the 
rate-limiting enzyme in cholesterol biosynthesis pathway. Since then numerous studies 
characterised 25-hydroxycholesterol as a potent regulatory agent capable to moderate many 
aspects of cholesterol metabolism IT 04. 264. 2651.
Cholesterol 25-hydroxylase is a microsomal glycoprotein [8 ], which does not belong to the 
cytochrom P450 family of cholesterol hydroxylases. It is detected across the whole body [8 ], 
however, challenge with TLR ligands such as LPS selectively induces the gene in the heart, 
brain, muscle, kidney, lung and liver [130].
Inhibition of the mevalonate pathway is through the regulatory protein INSIG (insulin 
induced gene), which upon binding to 25-hydroxycholesterol binds to SCAP (SREBP 
cleavage-activating protein) and prevents SREBP (sterol regulatory element binding protein) 
being transported to the Golgi for processing to its active form which regulates cholesterol 
biosynthesis [6 8 ]. Moreover, this oxysterol is also a potent ligand of LXR, which is involved 
in cholesterol metabolism and cellular trafficking [51, 209. 2101.
The last five years have brought important findings regarding the role of 25- 
hydroxycholesterol in immunity. Microarray data showed upregulation of the cholesterol 25- 
hydroxylase gene upon treatment with LPS in vitro, moreover the level of 25- 
hydroxycholesterol increased in blood of human volunteers who received an injection of LPS 
[1291. In 2010 Park et al showed that the induction of cholesterol 25-hydroxylase is also 
possible by type I interferons and that upregulation involved the STAT1 signalling pathway 
[266].
25-Hydroxycholesterol can by further hydroxylated by Cyp7bl forming 7a,25- 
dihydroxycholesterol. In 2011 two groups reported the role of this oxysterol in directing B 
cells required for humoral response. 7a,25-Dihydroxycholesterol has been defined as a
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ligand for a chemotactic receptor EBI2, directing B cells for the maturation in lymphoid 
tissue [132,137, 2671.
In the following study we investigated the impact o f interferon P (IFNP), interferon y (IFNy) 
and murine cytomegalovirus (mCMV) on the synthesis o f 25-hydroxycholesterol in bone 
marrow derived murine macrophages (BMDM).
8.2 Results
Bone derived murine macrophages were cultured in full media, and subjected to the 
following treatments for 12 hours: interferon P, interferon y, murine cytomegalovirus and 
control. Interferon challenge was performed at concentration 25 U/ml. Each experiment was 
performed in triplicate in Edinburgh University and then biological material was shipped to 
Swansea.
25-Hydroxycholesteroi
In the first round o f experiments we focused exclusively on 25-hydroxycholesterol 
and its dependency on interferon or virus treatment. The chromatogram o f GP derivatised 25- 
hydroxycholesterol derived from treated BMDM consists o f one peak eluting at 7.59 min and 
is showed in Figure 8.1, the identity o f the compound was confirmed by the M S3 spectrum 
presented in Figure 8.2.
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Figure 8.1. RIC o f m/z 534.4054±5 ppm corresponding to 25-hydroxycholesterol extracted 
frommurine bone marrow derived macrophages.
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Figure 8.2. MS spectrum of peak eluting at 7.59 min identified as GP-tagged 25- 
hydroxycholesterol.
In untreated cells the level of 25-hydroxycholesterol was evaluated as 11.20±2.57 ng/plate, in 
samples treated with interferon y and mCMV the concentrations were 64.27±0.72 ng/plate 
and 58.98±9.05 ng/plate which gives 5.5-fold increase. Cells challenged with interferon [3 
also had an elevated concentration of this oxysterol which was quantified as 19.68±1.74 
ng/plate (Figure 8.3A). The levels of 25-hydroxycholesterol measured in the cell media 
(Figure 8.3B) closely reassemble the pattern established in the cells, where the highest 
increase was found in samples treated with interferon y and MCMV. In the media of 
untreated cells the level equals 54.39±1.44 ng/ml while in interferon y and mCMV these were 
195.19±12.71 ng/ml 202.54±2.68 ng/ml, in interferon p treated sample the concentration was 
only moderately increased to 87.83±6.47 ng/ml. The fold-difference between the untreated 
cell media and interferon y or mCMV treated cell media was about 3 fold. The reduced 
relative increase in the concentration of 25-hydroxycholesterol in media compared to cells 
can be attributed to the relatively short incubation time, where the cell may require more than 
12 hours to excrete the oxysterol to the external matrix. The results are presented in .
25-Hydroxycholesterol in MBMD cells
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Figure 8.3. Concentrations o f 25-hydroxycholesterol extracted from BMDM cells expressed 
as ng/plate (A) or cell media expressed as ng/ml (B) following mCMV infection, IFNp (25 
U/ml), IFNy (25 U/ml) stimulation for 12 hours. Error bars show SE for data obtained from 3 
independent biological replicates.
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Cholesterol and desmosterol
To assess the impact of 25-hydroxycholesterol on the mevalonate pathway we measured the 
concentration of cholesterol and its precursor desmosterol. As 25-hydroxycholesterol is a 
potent INSIG ligand we expect that an increased level of this oxysterol would adversely 
affect the synthesis of cholesterol. Surprisingly the concentration of cholesterol is higher in 
interferon y and mCMV treated macrophages. The increase in interferon p treated samples is 
smaller but still statistically significant (p<0.01,Figure 8.4). This trend applies only to 
cholesterol analysed in the cells, in the media the level is steady as cholesterol in present in 
the bovine serum supplementing the media. The increased concentration of cholesterol may 
reflect either an import from extracellular matrix or enhanced rate of synthesis. To investigate 
the origin of the cellular cholesterol we measured the level of its precursor desmosterol. The 
level of this compound is around 1 0 0  times lower than cholesterol therefore the quantification 
is less robust. We recorded the statistically significant increase in the level of desmosterol in 
mCMV treated samples (Figure 8.5), which suggest that the viral treatment in this experiment 
encouraged the synthesis of cholesterol.
Unlike the situation with 25-hydroxycholesterol where there were fold changes between 
treated and untreated samples, the changes in levels of cholesterol and desmosterol were 
much less drastic. These changes may be a consequence in small changes in the number of 
cells per plate.
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Figure 8.4. Concentrations of cholesterol extracted from BMDM expressed as pg/plate (A) or 
cell media expressed as fig/ml (B) following IFNP (25 U/ml), IFNy (25 U/ml) stimulation 
and mCMV infection for 12 hours. Data are the mean o f 3 biological replicates, error bars 
represent SD, ***P<0.001, **p<0.01
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Figure 8.5 Concentrations o f desmosterol extracted from BMDM media expressed as pg/plate 
(A) or cell media expressed as pg/ml (B) following IFNp (25 U/ml), IFNy (25 U/ml) 
stimulation and mCMV infection for 12 hours. Data are the mean o f 3 biological replicates, 
error bars represent SD, **p<0.01
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Sterol depleted medium
In the following experiments we investigated the time-dependant change in the concentration 
o f  sterols produced in response to the interferon or virus stimuli. In this study the 
macrophages were incubated during the treatments in a sterol-depleted medium to avoid the 
bias provided by cholesterol and oxysterols present in the medium.
25-Hydroxycholesterol in BMDM cells
250
2 0 0
***
«  150 ***
* * *
“  1 0 0  _  ■ ***
"  ■
^  *** *** ***
50 "  .  ■  ■
Mock Mock Mock Mock mCMV mCMV mCMV IFNp IFNp IFNp IFNy IFNy IFNy 
Oh 8h 16h 24 h 8h 16h 24h 8h 16h 24h 8h 16h 24h
Figure 8.6. Concentrations o f intra-cellular 25-hydroxycholesterol expressed as ng/plate in 
BMDM following MCMV infection, IFNp (10 U/ml), IFNy (10 U/ml) stimulation for 8, 16 
and 24 hours. Error bars show SE for data obtained from 3 independent biological replicates, 
*** pO .001 .
The increase in the concentration of 25-hydroxycholesterol was triggered by interferon P and 
interferon y. Treatment with interferon p increased the concentration 2-fold, while with 
interferon y almost 3-fold. The elongated time o f incubation did not affect the level o f 25- 
hydroxycholesterol in a statistically significant degree, suggesting that the activation occurs 
within the first 8 hours o f treatment and is maintained for at least another 16 hours (Figure 
8 .6 ).
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Surprisingly, in this experiment the treatment with MCMV did not alter the concentration of 
25-hydroxycholesterol. The study by Haspot et al. [268] points at the depletion o f cholesterol 
as the factor inhibiting viral entry into a host cell, therefore it is feasible that culturing the 
macrophages in serum free media abolished the antiviral response.
1 0 0
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25-Hydroxycholesterol in BMDM media
f
Mock Mock Mock Mock CMV CMV CMV Inf B Inf B Inf B InfG Inf G InfG
Oh 8h 16h 24h 8h 16h 24h 8h 16h 24h 8h 16h 24h
Figure 8.7. Concentrations o f 25-hydroxycholesterol extracted from BMDM media expressed 
as ng/ml following MCMV infection, IFNp (10 U/ml), IFNy (10 U/ml) treatment for 8, 16 
and 24 hours. Error bars show SE for data obtained from 3 independent biological replicates; 
* <0.001p<0.05,**0.01<p<0.01,*** pO.OOl.
Even more pronounced trend was observed in the levels o f 25-hydroxycholesterol measured 
in the cell media [Figure 8.7]. The stimulation with mCMV did not increase the concentration 
o f 25-hydroxycholesterol, confirming the results in the cells. The media o f the cells treated 
with interferon P contained on average 2 times more 25-hydroxycholesterol, while in the 
interferon y challenged samples the level o f this oxysterol rose 3-fold on average. The 
analysis o f the levels at 8, 16 and 24 hours shows a time wise rise in the levels o f the 
oxysterol. An increase o f the metabolite is a result o f an accumulation o f 25- 
hydroxycholesterol in the cellular media.
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Other oxysterols
We also quantified other monohydroxylated derivatives o f cholesterol in cells and secreted to 
the medium: 7p-hydroxycholesterol, 7-ketocholesterol, 7a-hydroxycholesterol and 6- 
hydroxycholesterol. The levels o f these oxysterols do not show a dependence on the applied 
treatments and are no more than a few o f percent o f the abundance o f 25-hydroxycholesterol.
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Figure 8.8. Doubly hydroxylated cholesterol derivatives in murine bone marrow derived 
macrophages. RIC o f m/z 550.4003±5 ppm obtained from the analysis o f from IFNy treated 
cells (A) and cell media (B).
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6
We analysed the products o f a double hydroxylation o f cholesterol, which, 
following the derivatisation, produce a molecular ion o f m/z 550.4003. The RICs o f 
m/z 550.4003 obtained from IFNy treated macrophages and relevant media are shown 
in Figure 8.8B and Figure 8.8B. The first eluting compound, with retention time 3.10 
min was identified as 7p,25-dihydroxycholesterol, the MS spectrum is presented in 
Figure 8.9. An authentic standard o f 7p,25-dihydroxycholesterol elutes as a 
doublet, with the second peak eluting about 1.2 min later than the first one. In our 
analysis we identified the second peak o f 7p,25-dihydroxycholesterol as a shoulder 
to a dominating peak and eluting at 4.35 min (Figure 8.8a). The quantification of 
7p,25-dihydroxycholesterol was based on the combined area o f  its two peaks which 
showed a significantly increased concentration in interferon treated samples. As there 
was no statistical difference between the different time points, the data presented 
below were averaged concentrations calculated for replicates in each o f 8, 16 and 24 
hour treatments. The average level in the control samples was assessed as 
0.5369±0.1611 ng/plate and in MCMV treated 0.4369±0.1460 ng/plate. In interferon 
treated macrophages the level o f 7p,25-dihydroxycholesterol was significantly 
elevated: in interferon p challenged samples the concentration was
1.1933±0.3757ng/plate and in interferon y 1.9902±0.5096ng/plate (Table 8.1).
F ITMS ♦ c ESI FJI ms3 550 40@cid30 00 471 36@cid35 00 [125.00-560 00]
425.45 435.50327.28 341.54 355.39178.16 197.36 211 44 227.22 243.16 271.34 283.35 295.30
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Figure 8.9. MS spectrum of peak eluting at 3.10 min identified as GP-tagged 7p,25- 
dihydroxycholesterol from IFNy treated cells.
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In the media retained after incubation of the macrophages a similar trend was 
observed, however, it was only possible to integrate the first peak belonging to 7p,25- 
dihydroxycholesterol, as the second part of the doublet was dominated by unknown 
eluent. Due to this underestimation of the peak area, the result can be only used as 
indication of the fold difference between control and treated samples, rather than an 
absolute quantification. The level of 7P,25-dihydroxycholesterol in media retained 
after incubation of control samples and MCMV treated cells was estimated 
0.6309±0.2845 ng/ml and 0.5085±0.2537 ng/ml, while in samples where the 
interferon was applied, the levels were markedly increased 4- and 5-fold for 
interferons p and y, respectively.
The pattern of changes in the levels of 7p,25-dihydroxycholesterol closely follows 
those of 25-hydroxycholesterol. It is established that 7P-hydroxylation of cholesterol 
occurs in an autoxidation process f 1851. it is likely that a similar transformation 
applies to 25-hydroxycholesterol, resulting in generation of 7p,25- 
dihydroxycholesterol.
25-Hydroxycholesterol can be also hydroxylated at the 7a-position by the catalytic 
action of ER enzyme oxysterol 7a-hydroxylase, Cyp7bl. By the comparison of the 
cell extract RIC of m/z 550.4003 with the authentic standard we identified the peak 
eluting at RT 5.91 min ( Figure 8 .8 A) as 7a,25-dihydroxycholesterol, however for the 
evaluation of the levels we used MS TIC due to high baseline interferences in the 
mass RIC, the MS spectrum is shown in Figure 8.10. The levels of this oxysterol 
were similar in control and MCMV treated macrophages (0.0306±0.0242 ng/plate and 
0.0545±0.0227 ng/plate, Table 4), while the treatment of the macrophages with 
interferon P and y resulted in an increase in these levels 3- and 5-fold (0.1012±0.0701 
ng/plate and 0.1660±0.0639ng/plate) respectively. 7a,25-Dihydroxycholesterol was 
also identified in the cell media separated from the macrophages (Table 8.2). In the 
untreated and MCMV treated cell media the levels were 0.0131±0.0112 ng/ml and 
0.0055±0.0067 ng/ml, while in the interferon p and y treated macrophages media 
these were increased to 0.1214±0.0674 ng/ml and 0.1848±0.0819 ng/ml. It is worth 
noting that both hydroxylations: at position C-7 and C-25 were reported as an 
autoxidation process .
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Figure 8.10. MS3 spectrum of peak eluting at 5.91 min identified as GP-tagged 
7a,25-dihydroxycholesterol from IFNy treated cells.
Further analysis o f the cell extract chromatogram revealed the peak eluting at 
RT 3.36 min, which we identified as 24S,25-dihydroxycholesterol (M S3 spectrum 
presented in Figure 8.11). This oxysterol can be produced as a result o f hydrolysis of
24S,25-epoxycholesterol, however this process is usually accompanied by other 
products generated during the derivatisation reaction such as 24-ketocholesterol and 
24-hydroxy,25-methoxy (or 24-methoxy,25-hydroxy)cholesterol. As we could not 
identify these products, it is viable that this doubly hydroxylated cholesterol is an 
authentic product present in the cells. The standard of 24S,25-dihydroxycholesterol is 
eluted as a doublet, in our sample the second peak is masked by a closely eluting 
large peak o f an unidentified compound, causing integration o f the second peak 
unreliable. The level o f 24S,25-dihydroxycholesterol (only the first peak used for 
quantification) was steady across all the treatments: in control and MCMV treated 
samples was evaluated as 0.5462±0.2630 ng/plate and 0 .5418±0.2525 ng/plate, and in 
interferon (3 and y treated samples these were 0 .5120±0.2258 ng/plate and 
0.6175±0.3415 ng/plate, respectively. In the cell media we could not integrate the 
peak belonging to 24S,25-dihydroxycholesterol due to the presence o f the dominating 
peak o f 7P,25-dihydroxycholesterol.
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Figure 8.11. MS3 spectrum of peak eluting at 3.36 min identified as GP-tagged
24S,25-dihydroxycholesterol from IFNy treated cells.
The dominating peak o f RIC 550.4003 appears in the chromatogram o f cells is at 4.24 
min. The analysis of the MS3 spectrum (Figure 12) showed a number o f similar 
fragments to those observed in the spectrum o f 6,24S-hydroxycholesterol [ 1481. The 
main difference between the spectra is the ratio between fragment ions m/z 453 (M- 
7 9 -H 2O) and m/z 443 (M-79-CO). This is possibly because hydroxylation at the 25 
instead o f 24S position, as a hydroxyl group at 25 carbon atom tends to produce a 
more prominent ion 453 in the MS3 spectra o f GP-derivatised dihydroxycholesterols. 
The quantification of this substance showed a differences between untreated or 
MCMV infected cells and interferon activated macrophages. In control samples the 
concentration was assessed as 1,3934±0.4565 ng/plate, in MCMV these were 
significantly decreased to 0.2032±.00954 ng/plate. In interferon (3 and y treated 
samples the level were 2.5904±1.0507 ng/plate and 3.9206=1= 1.2911 ng/plate, 
respectively. In the cell media these levels showed a similar dependency with the 
concentrations in untreated and MCMV treated macrophage media evaluated as 
0.3025 ng/ml and 0.2278 ng/ml in controls and MCMV treated samples, while the 
incubation with the interferons lead to an increase in the levels: 0.7468ng/ml and 
1.1882 ng/ml in interferon (3 and y, respectively.
The changes in the levels o f this analyte were similar to those o f 25- 
hydroxycholesterol, suggesting that this compound either the product o f autoxidation 
o f 25-hydroxycholesterol or unknown product o f metabolism, supporting the 
hypothesis that this is 6,25-dihydroxycholesterol. It worth mentioning that 6p-
hydroxylation o f bile acid precursors is catalysed by C y p 3 a ll. This enzyme 
hydroxylases C-6 position o f litocholic and taurochenodeoxycholic acids, 
transforming it into less toxic bile acids. It is not known whether this enzyme is 
capable o f 6-hydroxylation o f 25-hydroxycholesterol molecule.
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3Figure 8.12. MS spectrum of peak eluting at 4.24 min identified as GP-tagged 6,25- 
hydroxycholesterol from IFNy treated cells.
The peak eluting at 4.98 min was not identified, however the quantification o f this 
compound showed the increased level in the interferon treated macrophages. In 
untreated and MCMV incubated macrophages the levels were 0.3910 ng/plate and 
0.2796 ng/plate, in interferon p and y treated cell the concentrations were 0.6859 
ng/plate and 0.9687 ng/plate, respectively.
The levels evaluated in the media showed the same pattern with the concentrations: 
0.3620 ng/ml and 0.2313 ng/ml in control and MCMV treated cells, while in 
interferon p and y incubations the levels were 0.7749 ng/ml and 0.9421 ng/ml, 
respectively.
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Figure 8.13. M S3 spectrum of an unknown compound o f m/z 550.4003 eluting at 4.98 
min from IFNy treated macrophages.
We also analysed the RIC o f m/z value 532.3898, presenting a single dominating peak 
eluting at 6.63 min (Figure 14). Although M S3 spectrum does not resemble any 
known standard (Figure 15), we noticed that the same compound appearing during 
the analysis o f synthetic standards o f 7a,25-dihydroxycholesterol and 7p,25- 
dihydroxycholesterol at an approximate level of 2% of the synthetic standards. 
Interestingly, this peak is absent in the analogous standards where the 25-hydroxyl is 
replaced by 27-hydroxyl group. A molecular ion o f m/z 532.3898 can be produced 
from GP-derivatised monohydroxylated cholesterol molecule possessing one, 
additional unsaturated bond. 25-Hydroxy-7-dehydrocholesterol is a molecule with 
this structure, although in the absence o f a standard it is not possible to reliably 
identify the analyte.
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Figure 8.14. Hypothesised monohydroxylated unsaturated cholesterol derivatives in 
murine bone marrow derived macrophages. RIC of m/z 532.3898±5 ppm obtained 
from IFNy treated cells.
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Figure 8.16. RIC o f m/z 548.3847±5 ppm obtained from the analysis o f IFNy treated 
cells.
>. ootyjoiuoo.oo Hua.JHty/uiuou oo i i^o.oo-ooo.ooj
145.03 16428
i 11'i t'U i
188.10 200 48 229.34 252.42 264 19 283 29J
313.49 337.29
I lf i * ,■ d t  I
397.57
395.20
424.37 
i 427.48
ifIII, .i, l|ll
Figure 8.17. M S3 spectrum of unknown eluent o f m/z 548.3847 eluting at 4.79 min 
from IFNy treated cells.
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Figure 8.18. MS spectrum of unknown eluent o f m/z 548.3847 eluting at 4.79 min
The analysis o f the cell extract in chromatograms acquired at m/z 548.3847 revealed 
two peaks (Figure 16, 17 and 18), whose intensities following the changes observed 
in 25-hydroxycholesterol. Due to low intensities, the estimation o f the concentration 
was carried out based on the M S3 chromatogram, therefore it was only used as a 
comparison o f the folds change between the experiments. The difference between the 
control samples and interferon (3 and y treated cell shows a strong statistical 
significance (p<0.001). The M S3 spectra did not match any o f these seen in the 
authentic standards; therefore the identity of these compounds is yet to be revealed. 
RIC obtained at m/z ratio 564.3796 presented a number of compounds in the cell 
media (Table 5), the analytes eluting with retention times 3.41 min, 4.43 min, 4.62 
min, 5.19 min, 5.24 min and 6.01 min were o f a particular interest as their 
concentration was in a statistically significant manner lower in the interferon treated 
cell media than in controls (Table 8.2). This may indicate that the change in 
metabolism initiated by incubation with the interferons leads either to reduced 
synthesis or an increased uptake from the media. In the cell extract these compounds 
were below the level o f detection.
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As 25-hydroxycholesterol is a ligand to INSIG, we would be expected that alterations 
in the level of this oxysterol should be followed by the alterations in the levels of 
mevalonate pathway intermediates and its final product - cholesterol.
Sterols
Cholesterol is less polar compared to oxysterols, and is eluted from the first 
Sep-Pak in 100% ethanol in fraction 3. The molecular ion formed following oxidation 
and derivatisation steps has an m/z 518.4105. The RIC of m/z 518.4105 showed a 
single peak eluting at 11.66 ( Figure 8.19 ) min with MS3 characteristics matching the 
authentic standard of cholesterol ( Figure 8.20 ). The levels of cholesterol were the 
highest in control and MCMV infected samples (34.84±2.64 pg/plate and 35.17±3.59 
jig/plate), while in the interferon p and y treated macrophages the concentration of 
cholesterol was lowered by 6% and 9% (31.64±3.99 pg/plate 32.77±3.46 pg/plate), 
respectively (Figure 8.21).
Desmosterol (RIC in Figure 8.22 and MS3 in Figure 8.23), one of the 
cholesterol precursors, shows an analogous trend to cholesterol with a reduction of 
desmosterol levels by 11% and 13% in the interferon treated samples, however not to 
statistical significance (Figure 8.24). Although the changes in average concentrations 
of cholesterol and its precursors mirror in a inverse manner the concentrations of 25- 
hydroxycholesterol, these changes do no reach the statistical significance. However, 
for this evaluation we used a T Student Test, which is designed for a large 
representation groups and may not be sensitive enough to detect small differences 
between the cohorts of nine replicates.
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Figure 8.19. Cholesterol in murine bone marrow derived macrophages. RIC o f m/z 
518.4105±5 ppm obtained from the analysis o f IFNy treated macrophages.
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Figure 8.20. M S3 spectrum o f cholesterol, m/z 518.4105 eluting at 11.67 min from 
macrophages incubated with mCMV.
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Figure 8.21. Concentrations of intra-cellular cholesterol calculated as ng/plate in 
BMDM control and treated by MCMV, IFNp (10 U/ml), IFNy (lOU/ml). The bars 
representing an average concentration from data obtained from 3 replicates in each 
time point (8,16 and 24 hours). Error bars show SE 9 biological replicates.
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Figure 8.22. Desmosterol in murine bone marrow derived macrophages. RIC o f m/z 
516.3948±5 ppm obtained from macrophages incubated with mCMV.
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Figure 8.23. MS spectrum o f desmosterol, m/z 516.3948 eluting at 10.56 min. 
Chromatogram recorded from cells treated with mCMV.
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Figure 8.24. Concentrations o f intra-cellular desmosterol calculated as ng/plate in 
BMDM control and treated by MCMV, IFNp (10 U/ml), IFNy (lOU/ml). The bars 
representing an average concentration from data obtained from 3 replicates in each 
time point (8,16 and 24 hours). Error bars show SE 9 biological replicates.
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The impact of interferon treatment on the mevalonate pathway is particularly 
interesting in regards to conflicting results from the first and second experiment. In 
the initial study the treatment increased the level of cholesterol, while in the second 
work this increase is not observed, moreover, averaged levels point at a decrease in 
the concentrations of the sterols. In the first experiment the cells were cultured in full 
media, therefore the sterols might have been imported into the cell, leading to an 
increased cellular level which was detected. In the second investigation the media 
used to culture the cells were not enriched with cholesterol containing serum. In this 
case an uptake of sterols was not possible; therefore the level of cholesterol was 
solely regulated by intra-cellular mechanisms. A modest down-regulation of 
cholesterol synthesis in interferon p and interferon y treated samples can be attributed 
to an inhibition of mevalonate pathway by 25-hydroxycholesterol.
8.3 Discussion
This study showed that 25-hydroxycholesterol is excreted by macrophages in 
response to pathogens. Incubation with interferon type I (interferon p) as well as 
interferon y were acting as inducers of cholesterol 25-hydroxylase. The level of 25- 
hydroxycholesterol increases both intracellulary and in the cell media.
25-Hydroxycholesterol is a potent regulator of cell metabolism as LXR ligand 
and as SREBP activator. SREBP regulates the synthesis of cholesterol by 
transcriptional control of the key enzyme in mevalonate pathway -  HMG-CoA 
reductase. The removal of cholesterol from the cell is regulated by proteins belonging 
to the family of ABC transporters , expressed under control of LXR. Blanc et al 
showed that reduction in the activity of cholesterol biosynthetic pathway can be a part 
of cellular antiviral response[133]. Increased concentration of 25-hydroxycholesterol 
adversely affects viral growth f 1351. It is not defined how this oxysterol inhibits viral 
propagation. Apart from decreasing the cholesterol level, 25-hydroxycholesterol can 
hypothetically interfere with viral cell entry by altering the properties of the 
membranes such as fluidity.
The cell signalling study reported by Blanc and colleagues shows that 
activation of cholesterol 25-hydroxylase by interferons in transduced by STAT1 
protein f 1351. Interferon P and Interferon y activates respectively receptors INFAR1 
and INFGR which induce its target proteins STAT 1 and 2. STAT 1 directly binds to 
cholesterol 25-hydroxylase promoter, thus controlling its transcriptional activity.
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Chapter 9
9 Conclusions
9.1 Summary
Mass spectrometry serves as a highly sensitive and accurate tool for analysis of 
metabolites. The detection of compounds is based on accurate mass and structural 
features such as distribution of functional groups. The limitation of mass 
spectrometry defined by the requirement of electrical charge carried by the analyte 
can be solved by introduction of the derivatisation technique. With this approach even 
molecules with weak ionisation capacity can be subjected to mass spectroscopic 
analysis. This is of a particular importance for electrically neutral oxysterols.
Oxysterols exert a broad range of cellular functions, for example enable the 
trafficing of cholesterol, and they are precursors to steroid hormones and bile acids. 
Oxysterols were also recognised as ligands to “orphan” receptors such Liver X 
Receptor.
In our methodology oxysterols possessing 3P-hydroxy-5-ene or 3p-hydroxy-5a 
-hydrogen moieties are oxidised by the bacterial enzyme Cholesterol oxidase to form 
3-oxo-4-ene and 3-oxo groups, respectively. The formation of an oxo group is crucial 
for the derivatisation step as Girard P reagent can form hydrazones with sterols 
possessing an oxo function. The introduction of the Girard P tag to the oxysterol 
provides a quaternary nitrogen carrying a positive charge. This “charge-tagging” 
procedure improves the MS detection by a factor of up to 10 .
Derivatised molecules analysed by mass spectrometer can be subjected to 
collision with an inert gas, resulting in formation fragments ions. This was used for 
the determination of the structure of the analysed sterols. We applied a multistage 
fragmentation technique where the ions were fragmented in two steps. In the first one 
analytes derivatised with Girard P gave a neutral loss of 79 Da corresponding to the 
loss of the pyridine ring from the Girard reagent. The second collision cycle was 
applied only to these ions giving a neutral loss of 79 Da from the first step. This 
approach increased the selectivity of the method as only derivatised compounds were 
selected in the second cycle.
Oxysterols are generated by oxidation of cholesterol and some of the resulting 
molecules may be structural isomers with identical molecular mass. These can be 
separated prior to MS analysis by a Liquid Chromatography system. Dissolved
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analytes were passed under high pressure through a Cjg column. To improve 
chromatographic separation we modified an existing gradient into a curved transition 
between the mobile phases. This enhanced the separation of oxysterols present in 
nervous tissue.
In brain oxysterols are dominated by a high background of cholesterol (10 - 
106 more abundant). Such a wide range of concentrations cannot be analysed in a 
single analytical run due to a limited dynamic range of the instrument. Besides, 
cholesterol is vulnerable to autoxidation and sterols generated in this process can 
obscure the analysis of endogenous metabolites. This was avoided by separating 
cholesterol from oxysterols at the earliest possible stage of sample preparation. We 
used a SPE cartridge and exploited the difference in polarities between sterols and 
oxysterols.
In chapter 3 we describe the analysis of sterols and oxysterols derived from 
newborn mouse brain. Brain is unique in the isolation of its mevalonate pathway from 
the peripheral organs. The blood brain barrier is impermeable to cholesterol which 
can not be neither imported in or exported from the brain per se. 24S-Hydroxylation 
of cholesterol provides an exit rout for brain cholesterol and 24S-hydroxycholesterol 
is the main oxysterol in the brain.
Due to incompleted myelination of neurons in neonatal brain, the cholesterol 
content is relatively low, consequently the amounts of cholesterol’s main metabolite, 
24S-hydroxycholesterol, is also reduced compared to an adult brain. This facilitates 
the analysis of other monohydroxycholesterols, otherwise obscured by 24S- 
hydroxycholesterol. Thus, we quantified 22R-, 25-, 26-, 7a, 7p, 6p-
hydroxycholesterols. 25-Hydroxycholesterol is synthesised by the widely expressed 
cholesterol 25-hydroxylse, and is particularly important for an antiviral immune 
response. 26- and 7a-hydroxycholesterol initiate two different pathways of bile acid 
biosynthesis. This is interesting as bile acids can be ligands to LXRp which has been 
implicated in neurogenesis. We also quantified 24S,25-epoxycholesterol, another 
LXR and Insig ligand. The level of desmosterol, a cholesterol precursor, in 
developing brain is relatively high which reflects a high rate of cholesterol synthesis. 
Desmosterol can become hydroxylated and we quantified 7a- and 26- 
hydroxydesmosterols. This is the first study reporting the presence of hydroxylated 
desmosterols in the brain.
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Smith-Lemli-Opitz syndrome (SLOS) arises from the malfunction of 
dehydrocholesterol reductase converting 7-dehydrocholesterol into cholesterol. We 
analysed the lipidome of a mouse model of SLOS to evaluate whether the dysfunction 
of cholesterol biosynthesis is accompanied by formation of other compounds which 
could account for neuronal symptoms of SLOS. The sterol profile showed an altered 
level of cholesterol precursors with increased concentration of 7- and 8- 
dehydrocholesterols accompanied by reduced levels of desmosterol and cholesterol. 
The general level of oxysterols was reduced, which is a probable consequence of 
lower availability of cholesterol.
Next we moved to analysis of an adult brain derived from Cyp46al deficient 
mice. Cyp46al is almost exclusively expressed in brain where it catalyses 24S- 
hydroxylation of cholesterol. In this project we investigated if disabling of Cyp46al 
will reveal any other mechanisms of cholesterol removal form brain. The analysis of 
sterols showed a reduction in cholesterol synthesis reflected by a diminished amount 
of cholesterol precursors, while the concentration of cholesterol remained unaltered. 
The oxysterol profile remained generally unaltered, however an absence of 24S- 
hydroxycholesterol allowed the observation a number oxysterols allowing for their 
precise quantification.
In chapter 6 we profiled the sterol content of Cyp27arA mouse brain. In 
humans this deficiency results in CTX, which main diagnostic features include 
accumulation of sterols in tendons and brain and unusual bile alcohols present in 
body fluids. The knock out of Cyp27al disables the “acetic” pathway of bile acid 
synthesis. The oxysterol profile revealed a high concentration of 7a-hydroxylated 
cholesterol and desmosterol, as well as the products of further 12a-hydroxylation of 
these analytes accompanied by unusually high ratio of its 3-oxo analogues. The 
Cyp27al-/- brain had a high number of tri- and tetra-hydroxycholesterol isomers not 
observed in wild type. This may be a consequence of upregulation of Cyp3a, 
responsible for hydroxylation of the cholesterol side chain.
In chapter 7 we analysed sterols and oxysterols isolated from Cyp7bl'/’ 
mouse brain, people affected by mutations in this gene can suffer from two different 
disorders: neonatal liver disease and spastic paraplegia. The levels of 25- and 26- 
hydroxycholesterols were largely increased due to the absence of Cyp7bl 
metabolising these oxysterol under normal conditions. Concentrations of 24S,25-
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epoxycholesterol, (24Z) and (24E)26-hydroxydesmosterols was also increased 
suggesting that this analytes can be also metabolised by Cyp7bl.
The last experimentalal chapter was concentrates on the analysis of oxysterols 
in challenged murine macrophages. The incubation of bone derived murine 
macrophages with interferon p and interferon y led to increased production and 
excretion of 25-hydroxycholesterol. We also observed a rise in putative products of 
25-hydroxycholesterol metabolism such as 7a,25-dihydroxycholesterol. Both are 
strongly involved in mechanisms of immune response.
In this work we provided a comprehensive study of oxysterols and sterols 
present in murine brain. W analysed brains at an early stage of development in pursuit 
of compounds associated with neurogenesis. We also looked into brains derived form 
animals carrying mutations in enzymes involved in cholesterol and sterol metabolism, 
in order to delve into sterol metabolic pathways subjected to constraints imposed by 
the mutations.
9.2 Future directions
The analysis of brain tissue and macrophages revealed an array of 
compounds, a number of which have been identified in vivo for the first time. The 
biological significance of these analytes still remains to be understood and more work 
is required to unveil their physiological roles.
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